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Metastasis is the major burden for colon cancer patients as it reduces their five-year 
survival chances to less than 10%. Efforts made to identify the molecular players in 
metastasis formation revealed the calcium binding protein S100A4. S100A4 is a Wnt/β-
catenin target gene which promotes migration, invasion and angiogenesis. Its 
overexpression leads to aggressive tumor growth and metastasis formation in colon 
cancer. Consequently, inhibition of S100A4 expression is a promising strategy for anti-
metastatic treatment of colon cancer patients. Moreover, knowledge on the gene 
regulations that occur upon S100A4 overexpression helps to further understand its 
metastasis promoting function.  
In this vein, the present study characterizes the small molecules niclosamide and 
calcimycin as transcriptional inhibitors of S100A4 which reduced S100A4 expression 
concentration- and time-dependently. Niclosamide and calcimycin treatment restricted 
cell migration, invasion and wound healing capabilities in a S100A4-specific manner, 
and inhibited cell proliferation and colony formation of colon cancer cells. 
Both small molecule inhibitors interfere with the constitutively active Wnt pathway. 
Targeting β-catenin expression by calcimycin or interfering with the β-catenin/TCF 
transcription activating complex by niclosamide resulted in reduced Wnt target gene 
transcription, among them S100A4. 
The study further presents a human colon cancer xenograft mouse model for 
monitoring S100A4-induced metastasis formation via non-invasive bioluminescence 
imaging. Treatment of xenograft mice with niclosamide resulted in a significant 
reduction of the S100A4 mRNA level in the tumor accompanied by inhibition of 
metastasis formation.  
Moreover, this study presents evidence that S100A4 is an inhibitor of DKK-1 
expression. In colon cancer cells DKK-1 and S100A4 expression was negatively 
correlated. Ectopic S100A4 overexpression inhibited DKK-1 expression. Targeting 
S100A4 via shRNA recovered the repressed DKK-1 expression and vice versa.  
In summary, the study describes a novel positive feedback loop in the Wnt pathway 
regulation formed by S100A4 repressing its antagonist DKK-1. This novel mechanism 
further strengthens the need for S100A4 inhibitors such as niclosamide or calcimycin. 
Consequently, such small molecules provide immense potential for the treatment of 






Dickdarmkrebs wird zu einer lebensbedrohlichen Krankheit wenn sich Metastasen 
bilden. Daher ist die Erforschung der molekularen Mechanismen, die der 
Metastasierung zu Grunde liegen für die Entwicklung neuer Therapien für das 
Kolonkarzinom wichtig. Ein zentraler molekularer Beschleuniger für die Metastasierung 
ist das Protein S100A4. Die S100A4 Expression in Kolonzellen wird durch den Wnt 
Pathway reguliert, der in 90% der Kolontumore konstitutiv aktiv ist. Eine 
Überexpression von S100A4 erhört die Zellmotilität und fördert damit die 
Metastasierung von Kolonkarzinomen. Um dies therapeutisch unterbinden zu können, 
ist die Hemmung der S100A4 Expression ein vielversprechender Ansatz. Des Weiteren 
ist bekannt, dass S100A4 im Zellkern vorkommt. Jedoch ist wenig darüber bekannt, 
welche transkriptionellen Konsequenzen aus der S100A4 Überexpression folgen. 
 
Die vorliegende Arbeit präsentiert die beiden Small Molecules Niklosamid und 
Calcimycin als neue Inhibitoren der S100A4 Transkription. In Kolonkarzinomzellen, die 
mit einem der beiden Inhibitoren behandelt wurden, wurde die S100A4 Expression 
konzentrations- und zeitabhängig unterdrückt. Des Weiteren war die Zellmigration und 
-invasion in Abhängigkeit von S100A4 in behandelten Zellen vermindert. Niklosamid 
und Calcimycin Behandlung verhinderten die Zellproliferation und die Koloniebildung 
von Kolonkarzinomzellen. 
Beide Inhibitoren hemmten den konstitutiv aktiven Wnt Pathway von 
Kolonkarzinomzellen. Calcimycin Behandlung verminderte die Expression von β-
catenin. Niklosamid hemmte die Bildung des β-catenin/TCF Komplexes und unterband 
damit die Expression von Wnt Pathway Genen, wie z.B. S100A4.  
Im Rahmen dieser Arbeit wurde ein in vivo Tiermodell entwickelt mit dem die S100A4-
induzierte Metastasierung mit Hilfe von nicht-invasivem Biolumineszenz Imaging 
visualisiert werden konnte. In diesem Model konnte gezeigt werden, dass Niklosamid 
signifikant die S100A4 Expression im Tumor vermindert und damit die Metastasierung 
hemmt.  
Des Weiteren zeigt diese Arbeit, dass eine S100A4 Überexpression die 
Expressionshemmung des Wnt Pathway Antagonisten DKK-1 in Kolonkarzinomzellen 
induziert. Die Expression von S100A4 und DKK-1 in Kolonkarzinomzelllinien korrelierte 
signifikant negativ. S100A4 Überexpression verminderte die DKK-1 Expression und die 
Hemmung der S100A4 Expression mit shRNA führte zur vermehrten DKK-1 




ein Anstieg in der S100A4 Expression. Letztere konnte durch die Behandlung mit 
rekombinantem DKK-1 vermindert werden. 
Zusammenfassend beschreibt die vorliegende Arbeit einen neuen regulativen 
Mechanismus im Wnt Pathway, der die S100A4 Expression im Kolonkarzinom fördert. 
Diese Beobachtung verdeutlicht die Notwendigkeit für wirksame S100A4 Inhibitoren, 
wie Niklosamid und Calcimycin. Solche Inhibitoren haben das Potenzial in einer 
klinischen Anwendung die Metastasierung von Kolonkarzinompatienten mit einer 
erhöhten S100A4 Expression zu hemmen und damit deren Überlebenschance 




1. INTRODUCTION  
 
1.1. Colon cancer  
1.1.1. Colon cancer epidemiology 
According to the World Health Organization, colon cancer is the third most common 
cancer worldwide and even the second most frequent type of cancer concerning men 
and women in developed countries. In the Western world colon cancer occurs with a 
lifetime incidence of 5% (1). Thus, colon cancer is a leading cause of cancer death 
worldwide. 
Intensive health programs comprising novel screening methods for early diagnosis of 
colon cancer induced a declining trend of colon cancer cases and deaths in the 
developed countries. The decline further correlated with the access to specialists and 
the availability of modern drug therapy (1, 2). Nonetheless, colon cancer still represents 
13% of all diagnosed neoplasms in Europe (2). In Germany, 16% of all cancers are 
situated in the colon, rectum or anus. The latest German cancer report states that there 
are yearly about 70,000 new colon cancer cases diagnosed and each year 28,000 
colon cancer patients die (3). 
The overall five year survival rate for colon cancer lies between 53 and 63%. However, 
survival is highly dependent on the tumor stage at the time of diagnosis. For instance, 
the five year survival rate for patients with a local tumor in its early stages is 90%. 
However, less than 40% of early stage tumors are detected. The majority of colon 
tumors are diagnosed at a more progressed stage, when regional lymph node or even 
distant metastases have already been formed. Diagnosis of colon cancer with regional 
lymph node metastases decreases the five year survival rate to about 65%. Drastically, 
only 10% of colon cancer patients will survive the five years post diagnosis when their 
tumor has spread to distant organs. Thus, metastatic dissemination of primary colon 
tumors accounts for 90% of all colon cancer deaths rendering metastasis formation one 
central process to be inhibited in colon cancer therapy (4).  
 
1.1.2. Risk factors and causes for colon cancer 
The major cause for the development of colon cancer lies in the personal genetic 
predisposition. 20 to 30% of colon cancer patients present a personal familial history of 
colon tumors implicating that a certain genetic background increases the risk for colon 
cancer (5). Only 5 to 10% of those patients present well-characterized hereditary 
cancer syndromes, such as familial adenomatous polyposis (FAP), hereditary non-
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polyposis colon cancer (HNPCC) and MUTYH-associated polyposis (MAP). These 
autosomal-dominant (FAP, HNPCC) or autosomal-recessive (MAP) inherited diseases 
are caused by a highly penetrant mutation leading to the development of colon cancer 
early in lifetime (6). For instance, FAP is caused by a germline mutation of the 
adenopolyposis coli (APC) protein which is the gatekeeper protein of the canonical 
Wnt/β-catenin pathway. The resulting constitutively active Wnt pathway causes the 
formation of hundreds to thousands polyps during childhood which further develop into 
carcinoma at the age of about 45 (7). HNPCC, also referred to as the Lynch syndrome, 
is caused by a mutation in the MLH1 gene coding for a mismatch repair protein. Loss 
of MLH1 leads to increased accumulation of mutations in the DNA and a characteristic 
microsatellite instability (8).  
In contrast, 90 to 95% of all colon cancers are sporadic and the genetic causes for 
cancer development are manifold and multivariable. Moreover, risk factors such as 
age, sex and dietary aspects can promote the development of sporadic colon 
cancer (5). For instance, with each decade of age the colon cancer incidences in 
women and men increase rapidly. In Germany, less than 10 out of 100,000 women and 
men at the age of 40 are diagnosed with colon cancer. However, at the age of 70 this 
incidence increases to 400 men and 200 women, respectively (3). Furthermore, a diet 
which is poor in red meat and fat and rich in fiber, folate and calcium can decrease the 
risk to develop colon cancer. Increased uptake of fiber stimulates butyrate production, 
which in turn was found to inhibit histone deacetylation and thereby restricts 
carcinogenesis (9). Besides age and dietary aspects, co-morbidities such as ulcerative 
colitis or Crohn’s colitis often increase the risk of developing colon cancer.  
 
 
1.2. The development of metastatic colon cancer 
The development of colon cancer and its metastases is thought to be a progressive 
process which is mediated by a sequence of certain mutations. The following sections 
deal with the histology of the normal colon crypt, the tumor initiation and the 
progression towards metastasis formation as well as the molecular processes 
underlying colon cancer.  
 
1.2.1. The normal colon crypt 
Together with the rectum and the anus, the colon constitutes the final part of the 
gastrointestinal tract. It is composed by the endoderm-derived layer of colon epithelium 
and the two mesoderm-derived layers containing smooth muscle cells needed for 
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peristalsis and stroma cells as connective tissue (10). The epithelial layer presents the 
characteristic crypts of Lieberkühn (Fig 1.1), which are separated into two functional 
compartments: the proliferative compartment at the lower part of the crypt and the 
differentiated compartment at the luminal side of the crypt.  
The proliferative compartment contains slowly dividing multipotent stem cells which 
give rise to transit amplifying cells. These progenitor cells divide twice as fast as the 
stem cells and migrate to the apex of the crypt in coherent bands. During migration 
these cells differentiate into one of the four major epithelial cell types: the absorptive 
enterocyte and the secretory Goblet, as well as the enteroendocrine and Paneth 
cells (11).  
 
Fig. 1.1 Histology of the colon crypt. The scheme represents one crypt of 
Lieberkühn which is divided into the compartments of proliferation and 
differentiation. At the bottom of the crypt, multipotent stem cells give rise to 
transit amplifying cells. Those rapid dividing cells migrate in coherent bands 
towards the luminal side of the crypt. Along their way to the crypt apex these 
progenitor cells differentiate into absorptive enterocytes, Goblet cells, 
enteroendocrine and Paneth cells. Differentiated cells at the apex of the colon 
crypt are mechanically shedded or undergo apoptosis. Their loss is permanently 
compensated by new stem-cell derived cells from the crypt bottom. Modified 
after Radtke and Clevers (12).  
 
In the differentiated compartment of colon crypts, enterocytes and Goblet cells are the 
most prominent cell types. Absorptive enterocytes reabsorb water and electrolytes from 
the chime. Goblet cells produce mucus to protect the colon epithelium against chear 
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stress and chemical damage. Enteroendocrine cells secrete hormones such as 
secretin, serotonin, substance P and somatostatin. Paneth cells are sometimes present 
in the ascending colon and in inflammatory states. These cells reside at the bottom of 
the crypt where they secrete anti-microbial peptides such as cryptins, defectins, 
lysozyme and phospholipase A2 (13). Differentiated cells migrate towards the crypt 
apex were they are either mechanically shedded or enter apoptosis. Lost cells are 
permanently replaced by new stem-cell derived upcoming cells from the bottom of the 
crypt. The lifespan of differentiated epithelial cells ranges over 3 to 5 days, except for 
Paneth cells, which have a lifespan of 20 days (10, 11, 14). 
 
1.2.2. The adenoma-carcinoma cascade 
Colon cancer mostly arises from precancerous lesions in the epithelium which can be 
caused by chronic inflammation and the accumulation of genetic mutations. Two 
models for the nascence of colon tumors were recently discussed which differ in the 
origin of the cancer initiating cell: the “top-down” and the “bottom-up”-model.  
The “top-down”-model is based on one study in histological tissue sections of sporadic 
colon tumors where dysplastic cells were located at the crypt apex while the cells at the 
bottom of the crypts were morphologically normal. Therefore, it was hypothesized that 
transformed precursor cells migrated up the crypt, resided at the surface and initiated 
tumor formation. Then the tumor expands as transformed clones migrate laterally and 
downwards into adjacent crypts to displace the normal epithelium (15).  
This “bottom-up”-model summarized in Fig. 1.2  is nowadays the most widely accepted 
model for the development of colon cancer (13). It is based on the hypothesis that 
tumors arise from transformed stem cells located at the bottom of the crypt. The 
mutated stem cell divides and colonizes a single crypt forming a monocryptal 
microadenoma. This is consistent with the observation that the macroscopical count of 
adenomas in FAP patients is linear to the number of microscopically counted aberrant 
crypts suggesting an unicryptal evolution of adenoma (16). The development of 
microadenoma into small adenoma in the colon occurs by crypt fission and 
budding (17). Aberrant crypt foci are a frequent phenomenon in early adenomas 
isolated from FAP and sporadic APC mutated colon cancer patients (18-20). Crypt 
fission allows the progression from small adenoma to large adenoma rising into the 
colonic lumen. As the adenoma expands, nutrient supply via diffusion becomes 
insufficient (21). This leads to secretion of angiogenic factors that allow extensive 
vascularisation of the now early carcinoma to assure sufficient nutrient supply within 
the tumor mass. The early carcinoma laterally expands into adjacent crypts and further 
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infiltrates the mesenchymal layers thereby turning into a late carcinoma (22). Recent 
evaluations show that the timeframe for the adenoma-carcinoma take about two 
decades. In contrast, the transition from malignant carcinoma to the formation of distant 
metastases is believed to take less than two years (23).  
 
1.2.3. Metastasis formation 
A profound step for metastasis formation is the epithelial-mesenchymal 
transition (EMT) of colon cancer cells which is initiated by the tumor stroma cells. 
During tumor outgrowth, regional mesenchymal stroma cells are incorporated into the 
tumor mass. Besides regional stroma cells, further mesenchymal bone-marrow stem 
cells, which entered the blood circulation, can invade and migrate to the tumor tissue 
where they differentiate into myofibroblasts and endothelial cells. Stroma cells release 
paracrine and endocrine growth factors which are needed to initiate neovascularization 
of blood and lymph vessels and support tumor growth (24). The stroma cells are 
believed to take on attributes of cells that are chronically inflamed or exposed to wound 
healing processes during tumor progression thereby activating EMT (25). EMT is a 
highly conserved cellular program needed to allow epithelial cells to convert to 
mesenchymal cells. Epithelial cells are polarized, immotile cells that form a monolayer 
by tight intercellular connections. They can only migrate laterally along the epithelial 
cell-band, but are unable to invade the basal layer tissue. In contrast, mesenchymal 
cells form rarely contacts to neighboring cells, are highly motile and able to invade the 
tissue. During embryogenesis, mesenchymal cells arise from epithelial cells that 
performed EMT. EMT also occurs in the adult organism in the process of wound 
healing, for instance, during chronic inflammation.  
In the initiating process of metastasis formation (Fig. 1.2), EMT allows the transformed 
epithelial cell to acquire a mesenchymal phenotype characterized by the loss of cell-
adhesion, destruction of the extracellular matrix, invasion of the neighboring tissue and 
directed migration towards blood or lymph vessels (26). Invading tumor cells enter the 
circulation mostly by intravasation of thin-walled lymphatic channels or blood vessels.  
The majority of tumor cells entering the circulation will fail to form metastasis due to 
several hurdles (27). Once the tumor cell left the tumor tissue, the growth activating 
signals from the stroma cells are lost. Furthermore, cells can be damaged mechanically 
during circulation. Cells that survived the circulation are trapped in the lymph nodes or 
in the narrow capillaries. The cells need to express specific adhesion molecules to 
adhere to the vessel endothelium and extravasate into the foreign tissue. In the distant 
organ tissue, the invaded cell is exposed to foreign signaling factors and different 
17 
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extracellular matrix proteins to which it needs to attach in order to establish a 
microenvironment needed for the formation of micrometastases (28). These 
micrometastases are thought to perform the reverse mesenchymal-epithelial transition 




Fig. 1.2 Colon cancer development and metastasis formation. Colon cancer 
is initiated by a mutated colon stem cell which colonizes a crypt, thereby 
forming a microadenoma. Further accumulation of certain mutations and 
incorporation of regional stroma cells drives the transition to a large adenoma 
rising into the colon lumen. Neovascularization assures the nutrient supply 
within the tumor mass of the early carcinoma which further infiltrates into the 
basal layers and into neighboring crypts. Expression of EMT-TFs enables 
invasion of the neighboring tissue, followed by intravasation into the lymph and 
blood circulation, extravasation into foreign tissue and metastasis formation in 
lymph nodes and distant organs. Sequentially occurring mutations that regulate 
the development of colon cancer metastasis are indicated in grey. APC, 
adenomatous polyposis coli; CDC4, cell division control protein 4; CIN, 
chromosomal instability; EMT-TF, epidermial-mesenchymal transition-
transcription factors; MAGs, metastasis-associated genes; PI3K, 
phosphatidylinositol-3 kinase; PTEN, phosphatase tensine homolog; p53, tumor 
suppressor protein 53; TGFRII, TGF-β receptor 2. Modified after Jones, Pantel 




The above described model is often referred to as the classical metastatic model which 
describes a sequential development of metastasis. Recently, a second model has been 
described which indicates that tumor dissemination could occur early, concurrent to 
tumor development (30). This hypothesis is based on the observation that especially in 
breast cancer patients tumor cells are present in the circulation and in the bone marrow 
even after the resection of the early primary tumor (29). It was hypothesized that 
circulating tumor cells extravasate into bone marrow or lymph nodes and perform cell 
cycle arrest due to different growth signals and foreign extracellular-matrix-proteins. 
Those “metastatic seeds” can persist in a dormant state rendering them resistant to 
most chemotherapeutics which attack the active proliferating cell (31). It is yet unclear 
what reactivates dormant disseminated tumor cells. Recently, it was shown that 
overexpression of integrins in the extracellular matrix lead to proliferation of prior 
dormant cancer cells (32). These cells could again enter the circulation, extravasate 
into distant organ tissue and give rise to primary and secondary metastases (29, 33).  
 
1.2.4. Molecular pathways involved in colon cancer metastasis 
Comparative lesion sequencing recently revealed that most of the mutations enabling 
metastasis formation are not acquired late in the adenoma-carcinoma development, 
but are rather present in the correspondent premalignant lesion (23). Consistently, 
many prognostic markers for metastasis formation are already expressed early in the 
development of colon cancer (25, 34, 35).  
Accumulation of activating mutations in oncogenes and inactivating mutations in tumor 
suppressor genes is a profound step in cancer development (36). Sequential 
accumulation of certain mutations (Fig. 1.2) drives the development of colon 
cancer (37). The initial mutation thereby occurs in the canonical Wnt/β-catenin 
pathway, which is mutated in 90% of colon tumors (38). Additionally, the majority of 
colon cancers present chromosomal instability (CIN). Activating mutations of CIN-
causing genes is a key step in the development of microadenoma. For instance, as 
mentioned above, inactivating mutations in the mismatch-repair gene MHL1 lead to 
accumulation of single nucleotide mutations and thus to genetic instability often found 
in HNPCC patients (8). Furthermore, mutation in the ubiquitin ligase subunit named cell 
division control protein 4 (CDC4) causes CIN in most colorectal cancers (39, 40). CIN 
further leads to mutations in KRAS and BRAF, which activate the MAPK pathway 
resulting in increased cell proliferation and motility. Mutated BRAF is found even in 
small adenoma. Active MAPK signaling is thought to drive the transformation from 
small to large adenoma (37).  
19 
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Mutations promoting proliferation can further occur in the phosphatidylinositol-3 kinase 
(PI3K) pathway, either activating mutations on PI3K in 30% of colorectal cancers or, 
less often, loss of the PI3K inhibitor phosphatase tensine homolog (PTEN) (41). 
Inactivation of the tumor suppressor protein p53 is a second crucial step in the 
transition towards malignant carcinoma. Upon DNA-damage non-mutated p53 induces 
either DNA-repair or cell-cycle arrest and apoptosis. Loss of p53 results in the inability 
to undergo apoptosis which is a hallmark of cancer cells (36). Finally, inactivating 
mutations of the tumor growth factor-β (TGF-β) signaling pathway, usually occurring in 
the TGF-β receptor 2 (TGFRII), coincide with the transition of early carcinoma to highly 
invasive carcinoma (22).  
A key step in the dissemination of metastatic cells from the primary colon tumor is the 
upregulation of EMT-specific transcription factors (EMT-TFs). These transcription 
factors are highly conserved during evolution and under normal conditions regulate the 
EMT during embryogenesis. In cancer cells EMT-TFs enhance the invasive phenotype 
of metastatic cells, thereby initiating dissemination from the primary colon tumor (25). 
Finally, metastasis-specific mutations are needed to enhance the transition from the 
invasive carcinoma to a metastatic seeding cell (23). 
 
 
1.3. The canonical Wnt/β-catenin pathway 
 
The canonical Wnt/β-catenin pathway is one of the most crucial pathways in colon 
stem cell homeostasis regulating cell differentiation along the crypt-villus axis (42). 
Mutation of the Wnt pathway is an initiating event in colon cancer development and 
constitutively active Wnt signaling constitutes the basis for metastasis formation (31).  
 
1.3.1. Components of the Wnt pathway 
The initial identification of Wnt signaling components came from the field of 
developmental biology two decades ago. Not until one decade later the oncogenic and 
tumor suppressor abilities of many of those components were recognized. The first 
component identified in 1973 was int1 which was overexpressed in mammary gland 
tumors. Int1 later on was identified as the vertebrate homologue of wingless in 
Drosophila from which the wnts – as a combination of wingless and int1 - finally gained 
their name (43). 
In the absence of Wnt signaling, β-catenin levels are tightly controlled by the 
destruction complex (Fig. 1.3). In this complex β-catenin is anchored by APC and Axin. 
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This offers a platform for the kinases casein kinase-1α (CK1α) and glycogen synthase 
kinase-3β (GSK3-β) to enter the complex and sequentially phosphorylate β-
catenin (44). The initial phosphorylation occurs at the conserved serine 45 of β-catenin 
by CK-1α which is followed by further phosphorylation of serine 33, 37 and threonine 
41 by GSK3-β (45, 46). Phosphorylation on β-catenin generates a binding site for E3 
ubiquitin ligase and leads to rapid proteasomal degradation. Suppressed levels of β-
catenin assure that groucho proteins in the nucleus bind to transcription factors of the 
T-cell factor (TCF) family to inhibit transcription of β-catenin target genes (47, 48). 
 
 
Fig 1.3 The canonical Wnt/β-catenin pathway. In the absence of extracellular 
Wnts, β-catenin levels are tightly controlled by the destruction complex which 
enables β-catenin phosphorylation and subsequent proteasomal degradation or 
by E-cadherin which binds to β-catenin thus hindering it from entering the 
nucleus. Upon extracellular complexation of Wnt and frizzled/LRP-5/6 receptor, 
dishevelled sequesters Axin 2 from the destruction complex, β-catenin 
accumulates in the cytoplasm and translocates into the nucleus, binds TCF 
transcription factors and activates target gene transcription. APC, adenomatous 
polyposis coli; CK1α casein kinase 1α; DKK-1, dickkopf-1, Dvl, disheveled; 
GSK-3β, glycogen synthase kinase -3β; LRP-5/6, low density lipoprotein 
receptor-related protein-5/6; sFRP, secreted frizzled-related protein; TCF, T-cell 
factor; WIF-1, Wnt inhibitor factor-1. Modified after following Barker. Jeanes et 
al. (47, 49). 
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Activation of the Wnt/β-catenin signaling pathway is initiated by binding of secreted 
Wnts to their receptor from the frizzled family and their co-receptor named low density 
lipoprotein receptor-related protein-5 or -6 (LRP-5/-6). Association of dishevelled (dvl) 
with the cytoplasmic tail of frizzled receptor is thereby triggered. That activates 
phosphorylation of LRP-5/-6 by CK1γ which further sequesters Axin from the 
destruction complex to the membrane. Disruption of the destruction complex leads to 
the accumulation of cytoplasmic β-catenin which thus translocates into the nucleus. 
Nuclear β-catenin displaces groucho proteins and activates transcription factors from 
the TCF family. This family consists of four members: TCF-1, TCF-3, TCF-4 and 
lymphocyte enhancer factor- 1 (LEF-1) which share the same high mobility box needed 
for definition of TCF-family transcription sites. Target gene expression is further 
enhanced by recruitment of transcriptional enhancers such as legless, mediator, Hyrax 
or mastermind-like 1 (47, 50). 
 
1.3.2. Wnt signaling antagonists 
In non-malignant cells Wnt signaling is tightly controlled by its antagonists that can be 
divided into two functional classes: the secreted frizzled-related protein (sFRP) class 
and the dickkopf (DKK) class.  Proteins of the sFRP class such as sFRP family 
members, Wnt inhibitor factor-1 (WIF-1) and Cerberus bind directly to secreted Wnts 
and thereby sequester the Wnts from their receptor (51). In contrast, proteins of the 
DKK class specifically inhibit canonical Wnt signaling by interacting with LRP-5/6 and 
thus disrupting the Wnt receptor signaling complex.  
The DKK class comprises the secreted glycoproteins Wise and the proteins of the 
dickkopf family DKK-1 to -4. DKK-1 and DKK-4 act as inhibitors for Wnt signaling, 
whereas DKK-2 and DKK-3 were shown to have activating and inactivating actions on 
Wnt signaling which is dependent on the cellular context (52). DKK-1 is the most well 
studied member of its family. It was firstly identified as Wnt inhibitor in Xenopus where 
it controls head formation during embryogenesis (53). In the adult organism DKK-1 
plays a crucial role in bone formation and bone mass regulation and initiates the 
restitution of colon epithelium during inflammation and wound healing (52, 54). 
Overexpression of DKK-1 in transgenic mice inhibits intestinal epithelial cell 
proliferation and leads to complete loss of colon crypts (55).  
DKK-1 inhibits Wnt signaling by two distinct mechanisms. Firstly, DKK-1 binds to LRP-
5/6 and thus inhibits the formation of the Wnt receptor signaling complex (56-58). 
Secondly, DKK-1 forms a ternary complex with LRP-6 and the transmembrane receptor 
Kremen 2 which initiates rapid complex internalization and thus removal of the Wnt 
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signaling receptor LRP-6 (59). In colon cells DKK-1 itself is a Wnt/β-catenin target 
gene (60). Moreover, DKK-1 expression can be increased by the active vitamin D 
metabolite 1α25-dihydroxyvitamin D3, or pro-inflammatory cytokines such as tumor 
necrosis factor-α (TNF-α) or interferon-γ (IFN-γ) (61). During tumorigenesis the DKK-1 
gene expression is frequently aborted due to promoter hypermethylation which 
contributes to uncontrolled Wnt signaling in colon cancer (14).  
 
1.3.3. Wnt pathway in metastasis formation 
Aberrant Wnt pathway activity is an initial event during colon tumorigenesis and 
substantially contributes to metastasis formation. The majority of colon cancers bear 
mutated components of the Wnt/β-catenin pathway. In about 90% of colon carcinomas 
the Wnt/β-catenin pathway is constitutively active due to a loss-of-function mutation in 
the APC gene (62). Mutated non-functional APC leads to disruption of the β-catenin 
destruction complex and thus to unhindered β-catenin/TCF target gene transcription. 
Non-APC mutated colon cancer cells often express either mutated Axin 2 which 
disrupts the destruction complex as well, or mutant β-catenin which is resistant to 
degradation-activating phosphorylation (63, 64). Besides initial mutations targeting at 
β-catenin degradation, the loss of Wnt antagonist expression can further amplify the 
aberrant β-catenin/TCF target gene transcription. Moreover, the loss of E-cadherin 
adhesion receptors which usually sequester cytoplasmic β-catenin from entering the 
nucleus potentiates constitutively active β-catenin/TCF target gene transcription (49, 
60).  
One target gene that increases the metastatic potential of the colon cancer cells is 
S100A4 (65). Stein et al. firstly identified S100A4 as Wnt/β-catenin target gene by 
comparing gene expression profiles of colon cancer cells that were heterozygous for a 
gain-of-function mutated β-catenin with derivative cells which only expressed wildtype 
β-catenin. As a result they found S100A4 to be massively upregulated due to increased 
levels of nuclear β-catenin. Promoter analysis of S100A4 demonstrated that β-
catenin/TCF directly regulates the expression of S100A4. Moreover, β-catenin–induced 
effects on cell migration and invasion were mediated by S100A4. Those results 
provided the link between two previously unconnected molecular pathways which play 
important roles in tumor progression and metastasis in colorectal cancer: the Wnt/β-




1.4. S100A4  
 
S100A4 was independently discovered by several groups under various names such 
as metastasin 1 (mts1), fibroblast-specific protein (FSP1), calcium placental protein 
(CAPL), murine placental homolog, 18A2, pEL98, p9Ka, 42A, and calvasculin (66). 
This ubiquitous 11 kDa Ca2+-binding protein is one of the today 24 members of the 
S100 protein family which were named after their ability to be soluble in 100% 
ammonium sulphate (67). The expression of S100A4 is associated with many 
physiological processes such as wound healing, neurit outgrowth, fibrosis and 
neovascularisation, but also with pathological conditions such as cardiovascular 
diseases, tumor outgrowth, EMT, and metastasis formation (68, 69).  
 
1.4.1. S100A4 gene structure and transcription 
The S100A4 gene clusters together with most of the S100 gene family members in the 
epidermal differentiation complex located on human chromosome 1 (1q21). This region 
is frequently rearranged in human cancers (70). Consistently, S100A4 is 
overexpressed in many different types of cancer such as gallbladder, bladder, breast, 
oesophageal, gastric, pancreatic, hepatocellular, non-small cell lung, and colorectal 
cancer (71).  
The S100A4 promoter region contains an erythroblastosis oncogene B (Erb) B2 signal 
response element which activates S100A4 expression in medulloblastoma via the 
MAPK pathway (72). In breast cancer cells the S100A4 promoter was sensitive to α6β4 
integrin signaling which activated S100A4 transcription via the nuclear factor of 
activated T-cells-5 (NFAT5) transcription factor (73). In colon cancer cells S100A4 
expression is activated via the TCF-4 binding site in the S100A4 promoter (65). 
The S100A4 gene consists of four exons and three introns. The first intron of the 
S100A4 gene contains a positive regulatory enhancer region comprising at least six 
different cis-elements forming binding site for transcription factors such as SP-1, κB-
motif binding protein, activating protein-1 (AP-1) and core-binding-factor (CBF) family 
members (74-76). Moreover, the first intron of S100A4 bears a hypoxia responsive 
element motif. In gastric cancer cells hypoxia inducible factor (HIF) binds within the first 
intron of the S100A4 gene to activate S100A4 expression upon hypoxia induced 
cellular stress (77). 
The first two exons are located in the 5’ UTR and are thus non-coding (78). Exon 2 is 
only present in the longer variant of the two S100A4 mRNA splice variants which are 
512 and 564 bp in size, respectively. Both splice variants are differentially expressed in 
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different tissues; for instance the long variant is predominantly present in normal colon 
tissue, whereas the short variant is predominantly expressed in liver and blood cells. 
However, no functional differences between those splice variants were defined up to 
now, since both S100A4 mRNA variants encode the same amino acid sequence and 
are equally efficiently translated (79).  
 
1.4.2. S100A4 protein structure 
The S100 protein family of Ca2+-binding proteins presents high sequential and 
structural homology. Like most of the S100 proteins, S100A4 is a symmetrical 
homodimer which is stabilized by non-covalent binding of the first and the last helix of 




Fig. 1.3 The S100A4 protein. The primary structure of S100A4 consists of two 
EF-hands which are connected by a hinge region. Each EF-hand consists of a 
helix-loop-helix-motif, whereas each loop can bind one Ca2+ ion. Upon Ca2+-
binding the S100A4 protein undergoes a conformation shift, thus opens up the 
hinge region which is needed for interaction with S100A4 binding partners. Via 
its interaction with a list of different target proteins, S100A4 regulates many 
cellular processes needed for metastasis formation. Modified after Garrett (66).  
 
Each subunit of S100A4 consists of two EF hands connected by a less sequentially 
conserved hinge region (80). EF hands are defined by a helix-loop-helix motif of which 
the 12 amino acid long loop region constitutes a binding pocket for one Ca2+ ion. 
Additionally to the canonical EF hand at the C-terminus, S100 proteins are 
characteristic for their N-terminal pseudo EF hand. The loop of the N-terminal EF hand 
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consists of 14 amino acids. This elongation by two amino acids results in a lower 
affinity to Ca2+. Consequently, Ca2+-binding occurs sequentially, first at the C-terminal 
and subsequently at the N-terminal EF-hand (81). Upon Ca2+-binding a conformational 
shift is triggered which opens up two major hydrophobic binding sites partly formed by 
the hinge region (82). Residues of the hinge region as well as the long C-terminal tail of 
S100A4 share almost no sequence homology within the S100 protein family (83). 
Hence those regions confer specificity towards potential protein targets which are the 
basis for the manifold interactions of S100A4 that drive metastasis formation.  
 
1.4.3. S100A4 loosens cell adhesion 
Reduction of cell adhesions enables the dissociation of a cell from its tight tissue 
assembly which is an initial step in the process of cancer cell invasion. S100A4 was 
found to modulate cell-cell adhesion via downregulation of E-cadherin. E-cadherin is a 
transmembrane cell surface glycoprotein which mediates Ca2+-dependent cell-cell 
adhesion and therefore acts as invasion suppressor. Ectopic overexpression of E-
cadherin results in a decrease in S100A4-expression (84). Vice versa, S100A4 
overexpression suppresses E-cadherin expression, thereby reducing cell adhesion and 
inducing a more invasive cell phenotype (85). Consistently, S100A4 and E-cadherin 
are inversely expressed in many tumor types, whereby high levels of S100A4 and low 
level of E-cadherin promoted a highly metastatic phenotype (84-88).  
S100A4 was further found to influence cell-matrix adhesions by interacting with 
liprin β1 (89). S100A4 binds to liprin β1 thereby masking the PKC-mediated 
phosphorylation sites (89). Phosphorylation of liprin β1 is needed for crosslinking of 
leukocyte common antigen-related (LAR) protein on the cell surface to stably form focal 
adhesions (90). Inhibition of the liprin β1-LAR complex by S100A4 loosens cell 
adhesion and allows cell invasion.  
 
1.4.4. S100A4 increases cell migration 
The process of migration comprises the formation of flexible protrusions, lamellipod 
extensions, formation of focal contacts at the leading edge, and finally the retraction of 
the opposed cell tail towards the leading lamella. This process is dependent on the 
rearrangement of cytoskeleton proteins such as actin, myosin or tropomyosin.  
The presence of intracellular S100A4 is known to increase cell migration. Consistently, 
S100A4 was found to co-localize with actin filaments in transformed rat embryonic 
fibroblasts leading to disorder of stress fibers (91). Moreover, co-sedimentation assays 
revealed that S100A4 aggregated with F-actin in the presence of Ca2+. S100A4 further 
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binds to tropomyosin and non-muscle myosin II-A (92-95). Non-muscle myosin II-A is a 
chemo-mechanical cytoskeleton protein that participates in cell division, cell motility, 
and secretion. S100A4 binds to myosin II-A in a Ca2+-dependent manner and inhibits 
the actin-regulated ATPase activity of myosin II-A (93, 96). Thereby it promotes the 
disassembly of myosin filaments and inhibits their reassembly (95, 96).  
S100A4 is located at the leading edge of migrating cells (97), where it induces the 
formation of flexible protrusions. Moreover, in the presence of a chemo-attractant, 
S100A4 enhances directed migration (98). Directed migration is dependent on the 
interaction of S100A4 with myosin II-A, since an antibody which binds at the S100A4 
binding sites of myosin II-A also mimicked the formation of directed protrusions. In 
conclusion, the S100A4-myosin II-A interaction does not only increase cell motility, but 
also enhance cell polarization and directed migration.  
In contrast, the S100A4-myosin II-A interaction is inhibited in the presence of S100A1. 
Yeast two hybrid screening identified the S100 family protein S100A1 as a binding 
partner for S100A4 (99, 100). Titration of S100A1 to S100A4 and myosin II-A inhibited 
the S100A4-mediated depolimerization of myosin filaments. Furthermore, in a rat 
breast cancer model, the co-expression of S100A4 and S100A1 inhibited S100A4-
driven metastasis formation (101). Consistently, in colon cancer tumors S100A1 
overexpression occurs in non-malignant epithelial cells, but S100A1 is absent in 
metastatic cells with overexpressed S100A4 (102). 
S100A4 was found to bind to the septines 2, 6 and 7 (103). Septines play a central role 
in cytokinesis, cell polarity determination, cytoskeletal reorganization, and membrane 
dynamics (104). Therefore, the S100A4-septine interaction might contribute to the 
process of migration. However, no direct function of this protein-protein interaction has 
been determined so far.   
More recently, a yeast two hybrid screening identified CCN3 (cystein-rich 61-
connective tissue growth factor-nephroblastoma overexpressed-family member 3), as a 
binding partner of S100A4 (105). Furthermore, it was shown that CCN3 overexpression 
in glioma and neuroblastoma cells increases intracellular Ca2+ concentration in cell 
protrusions. This would be in line with S100A4 being dependent on increased Ca2+ 




Table 1.1 Interaction partners of S100A4 and their functional impact on metastasis 
formation. 
Target Cellular function Model Ref. 
intracellular 
CCN3 unknown yeast two hybrid assay 
 
(105) 
F-actin disorder of stress fibers rat embryonic fibroblasts; cell-free assays 
 
(91, 95) 
liprin-β1  decrease of cell adhesion mouse mammary adenocarcinoma cells 
 
(89) 
MetAP2 potential enhancement of 
angiogenesis 
human embryonic kidney cells; mouse 




myosin II-A  depolymerization of 
myosin filaments, 
formation of flexible 
protrusion  
human acute myeloid leukemia and 
breast cancer cells; mouse mammary 




p37 increased Ca2+ affinity cell-free assay 
 
(108) 
p53 oligomerization/ nuclear 
localization of p53 
human breast cancer, osteosarcoma, 
colon cancer, rabdomyosarcoma, prostate 
cancer and pancreas carcinoma cells; 
mouse mammary adenocarcinoma cells 




p63, p73 unknown cell-free assay 
 
 
S100A1 inhibition of S100A4-
induced metastasis 
human breast cancer cells; rat mammary 
cells; mouse mammary adenocarcinoma 




septin 2, 6, 7 unknown cell-free assay 
 
(103) 
tropomyosin interference with 
tropomyosin-F-actin 
interaction 
mouse embryonic fibroblasts (92) 
extracellular 
amphiregulin stimulation of EGFR 
signaling 
mouse embryonic fibroblasts 
 
(114) 
annexin II conversion of plasminogen 
to plasmin, induction of 
angiogenesis 
 
primary human cerebromicrovascular 
endothelial cells 
(115) 
MAP rearrangement of 
extracellular matrix 
bovine aortic smooth muscle cells (116) 
RAGE stimulation of MMP 
expression for invasion 
 
chondrocytes, cell-free assay (117-119) 
S100A4 
oligomer 
increase of intracellular 
Ca2+, angiogenesis 




The table summarizes all the proteins which are known to interact with S100A4 
both in the intracellular or extracellular compartments. CCN3, cystein-rich 61-
connective tissue growth factor-nephroblastoma overexpressed-family member 
3; MetAP2, methionine aminopeptidase 2; MAP, microfibrill-associated 
glycoprotein; RAGE, receptor for advanced glycation endproducts. 
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1.4.5. S100A4 increases cell invasion 
Cell invasion is dependent on the rearrangement of extracellular matrix proteins. 
S100A4 was firstly discovered to bind microfibrill-associated glycoprotein (MAP) in the 
extracellular compartment of bovine aortic smooth muscle cells (116). This binding was 
Ca2+-dependent. It was suggested that S100A4 binding affects the network of 
extracellular matrix proteins thereby enabling cell invasion.  
Cell invasion is further facilitated by matrix metalloproteinases (MMPs) which catalyze 
the proteolytical cleavage of extracellular matrix proteins. Extracellular S100A4 was 
shown to induce the expression of several MMPs. In mouse endothelial cells 
extracellular S100A4 stimulates the expression and secretion of MMP-13 which leads 
to increased cell invasion (122). In osteosarcoma and neuroblastoma cells 
downregulation of S100A4 was concomitant with a decrease of MMP-2 expression and 
activity, accompanied with impaired cell invasion (123, 124). S100A4 overexpression 
lead to induction of MMP-9 expression and increased MMP-9 proteolytic activity in 
human prostate cancer (125). Extracellular oligomeric S100A4 induced the expression 
of MMP-1, MMP-3, MMP-9 and MMP-13 in human synovial fibroblasts which were 
isolated from rheumatoid arthritis or osteoarthritis patients (126).  
Stimulation of MMP expression by extracellular S100A4 is likely to depend on a 
membrane associated receptor. One receptor that mediates S100A4 signaling is the 
receptor for advanced glycation endproducts (RAGE). In chondrocytes S100A4 
stimulated MMP-13 overexpression via binding to RAGE (119). Furthermore, 
extracellular S100A4 mediated effects can be abolished by extracellular addition of 
soluble RAGE, which has no signaling activity but captures S100A4 from binding to 
membrane-associated RAGE (127). In human salivary gland cells extracellular S100A4 
induced RAGE expression via activation of the NFκB pathway (128). Thereby, S100A4 
induces a positive feedback loop in RAGE signaling. However, extracellular S100A4 is 
able to induce cell invasion and capillary-like growth in RAGE-negative cells through a 
yet undefined cell surface receptor (122, 129). 
 
1.4.6. S100A4 enhances angiogenesis 
Angiogenesis describes the development of new blood vessels from pre-existing ones 
to optimize the oxygen and nutrient supply within the tumor tissue and the removal of 
waste products. Ambartsumian et al. firstly described that the blood vessel network in 
S100A4 positive tumors was more pronounced than that of S100A4-negative tumors in 
vivo (120). Furthermore, increase of extracellular S100A4 oligomers enhanced 
endothelial cell motility in vitro and stimulated the corneal neovascularization in vivo. 
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S100A4 was further found to bind annexin II (115). S100A4-annexin II interaction 
induced capillary-like tube formation of primary human cerebromicrovascular 
endothelial cells. Annexin II was exposed on the surface of endothelial cells. In the 
presence of S100A4 the conversion of plasminogen to plasmin was stimulated. Active 
plasmin further activates MMPs. Active MMPs and plasmin together induce 
extracellular matrix remodeling and thereby facilitate angiogenesis (130).  
Intracellular S100A4 also enhances angiogenesis by interacting with methionine 
aminopeptidase 2 (MetAP2). MetAP2 is known to catalyze the removal of translation 
initiating methionine from nascent peptides in endothelial cells (106). Moreover, 
MetAP2 is a common target for pharmaceutical inhibition of angiogenesis. Ca2+-
dependent binding of S100A4 to MetAP2 modulated the MetAP2 activity which could 
promote endothelial growth and angiogenesis. However, the exact mechanism still 
needs to be elucidated.  
 
1.4.7. S100A4 and cell growth  
In certain entities S100A4 was found to control cell proliferation. Targeting S100A4 by 
shRNA led to decreased cell proliferation in pancreatic and breast cancer cells and 
reduced tumor growth in gastric cancer xenograft mice (14, 73, 131). Cell proliferation 
of S100A4-null mouse embryonic fibroblasts was stimulated by extracellular interaction 
of S100A4 with amphiregulin which subsequently activated epidermal growth factor 
receptor (EGFR) signaling (114).  
Several studies have demonstrated the binding of S100A4 to p53 (70, 109, 110, 112, 
113). Upon recognition of a variety of cellular stresses and DNA damages, p53 controls 
cell cycle arrest, DNA repair and/or apoptosis. Mutation of this tumor suppressor gene 
is a frequent event in all types of human cancers (132). S100A4 controls the 
localization of p53 within the cell. Nuclear co-localization of p53 and S100A4 was 
observed in colon cancer cells (133). Nuclear transition of p53 occurs preferably in its 
monomeric state (134). Consistently, S100A4 binds at the tetramerization domain of 
p53 and therefore shifts the equilibrium from p53 oligomers to the monomeric 
state (70). Moreover, nuclear translocation of p53 is inhibited by C-terminal PKC 
phosphorylation. Phosphorylation stabilizes p53 tetramerization and aborts its nuclear 
translocation. S100A4 was found to mask those C-terminal PKC phosphorylation sites 
on p53 (109). By controlling p53 nuclear translocation S100A4 could abolish the tumor 
suppressor function of p53, thus enhancing tumor growth. However, no direct impact of 
the p53-S100A4 interaction on cancer growth or metastasis was yet shown and 
therefore requires further investigation (132).  
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1.4.8. S100A4 drives metastasis formation in vivo 
S100A4 was firstly shown to promote metastasis formation of mouse mammary 
adenocarcinoma cells by Ebralidze et al. (135). Since then several studies have 
confirmed the metastatic potential of S100A4 in xenograft models for a great many of 
different cell types (69). For instance, overexpression of S100A4 in usually non-
metastatic mouse or human breast cancer cells led to increased tumor invasiveness, 
and the formation of lymph node and distant lung metastases (136, 137). Comparison 
of the metastatic potential of human pancreatic cancer cells in xenograft mice revealed 
that only S100A4 overexpressing cell lines were able to form liver metastases (138). In 
colon cancer cells, the exogenous overexpression of S100A4 increased the number 
and size of liver metastasis after intracardial and intrasplenic transplation of xenograft 
mice (65).  
Surprisingly, S100A4 knock-in mice present no abnormal phenotypic features and 
especially do not develop tumors per se, suggesting that S100A4 itself is not 
tumorigenic (139). However, when crossed into a tumorigenic background, the 
offspring presented highly aggressive primary tumors and increased formation of 
metastasis (140). Further, tumors in those mice were massively infiltrated by 
leukocytes generating an inflammatory milieu which facilitated tumor spreading (141).  
S100A4 knock-out mice are fertile, grow normally and show no severe abnormalities, 
but present impaired chemotactic recruitment of macrophages to inflammatory sites 
(142). Orthotopic injection of highly metastatic mouse mammary carcinoma cells into 
these mice lacked the formation of lung metastases. However, the metastatic potential 
of these mammary carcinoma cells was reactivated, when cells were co-injected with 
S100A4 positive fibroblasts (143). Co-injection of oestrogen-dependent breast cancer 
cells with S100A4 overexpressing fibroblasts in xenograft mice also increased tumor 
growth even in the absence of oestrogen (144). These studies further constitute 
S100A4 as a mediator for metastasis formation in vivo. 
 
1.4.9. S100A4 expression correlates with metastasis in colon cancer patients 
S100A4 overexpression is associated with poor survival and increased occurrence of 
metastasis in many cancer entities such as breast, gallbladder, pancreatic, lung 
squamous cell, renal cell, prostate, and esophageal squamous cell cancer (145-151).  
In colon cancer the level of S100A4 expression increases with the developmental stage 
of the colon tumor. In normal colon tissue S100A4 mRNA and protein is not or only 
very weak expressed (65, 152). Similarly, in adenomas S100A4 expression is very 
rare. In contrast, in early carcinomas the expression of S100A4 is more frequent and 
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the frequency even increases in late carcinomas. However, S100A4 expression is most 
abundant in liver metastasis (153, 154).  
Several independent studies analysed the correlation of S100A4 expression levels in 
colon tumor tissue with clinical data in order to investigate the prognostic value of 
S100A4. For instance, high levels of S100A4 protein expression were associated with 
lymph node metastasis (152). Increased levels of S100A4 mRNA significantly correlate 
with reduced metastasis-free and overall-survival of colon cancer patients (65). In re-
sected colon tumor tissue S100A4-positive immunohistological staining correlated with 
a 2-fold reduction of patient’s five year survival rate (34, 155). S100A4 was prognostic 
for metastasis and adverse disease outcome independent on the progression stage of 
the disease (155). Moreover, the subcellular localization of S100A4 was found to be 
differentially prognostic for metastasis and overall survival. Immunohistochemical 
staining for nuclear S100A4 highly correlated with metastasis formation and reduced 
overall survival of colon cancer patients. In contrast, cytoplasmatic S100A4 was not 
statistically prognostic for the disease outcome (156, 157). More recently, quantification 
of S100A4 mRNA in blood of colon cancer patients was shown by Stein and colleagues 
to be specifically and sensitively diagnostic for the colon cancer stage and prognostic 
for the patient’s risk to develop metastases (158). 
In summary, these studies establish a prognostic value of S100A4 and thus further 
emphasize the central role for S100A4 in the progression of colon cancer metastasis.  
 
 
1.5. Inhibition of S100A4 expression for therapeutic intervention 
Since the discovery of S100A4, many studies have proven its central role in metastasis 
formation (69). Hence targeting S100A4 expression provides a promising strategy for 
rational anti-metastatic therapies (159). In cooperation with the National Cancer 
Institute in Frederick, Maryland, USA, PD. Dr. W. Walther, Prof. Dr. U. Stein (both 
Experimental and Clinical Research Center, Charité University Medicine, Berlin at the 
Max Delbrück Centrum Berlin-Buch) and colleagues performed a high throughput 
screening (HTS) to identify potential S100A4 expression inhibitors.  
The HTS was based on the S100A4 promoter comprising the sequence from -1487 bp 
to +33 bp surrounding the S100A4 transcription start site which was cloned upstream 
of the firefly luciferase reporter gene (Fig. 1.4). This construct was stably introduced 
into the human colon cancer cell line HCT116, which bears a constitutively active Wnt 
pathway and therefore presents high activity of the S100A4-promoter. In the HTS these 
generated HCT116/S100A4pLUC cells were exposed to compounds of the Library of 
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Pharmacologically Active Compounds (LOPAC). The LOPAC library represents a 
collection of well characterized small molecules which were shown to interfere with 
different biological functions. HCT116/S100A4pLUC cells were treated with 0.1 µM, 
1 µM, 10 µM and 100 µM dilutions of each compound for 24 h, respectively, and 
luciferase activity as read-out for S100A4 promoter-driven reporter gene expression as 
well as cell viability were analyzed. From a total number of 1,280 compounds, 
34 compounds were found to inhibit luciferase activity to less than 50% of control cells. 
In parallel, cell viability was determined to separate cytotoxicity-related reporter 
reduction from real expression inhibitory effects. From the 34 effective compounds, 
11 compounds efficiently inhibited luciferase activity at concentrations which were non-
toxic or only slightly affected cell viability. These 11 compounds were titrated using 
twenty 2-fold dilutions with a high test concentration of 100 μM. The titration 
confirmation identified niclosamide and calcimycin as the strongest candidates to inhibit 
luciferase activity at maximum with minimal cytotoxicity. The effective concentration 50 
(EC50) in the high throughput screening was measured to be 1.7 µM and 2.7 µM for 




Fig. 1.4 High throughput screening for S100A4 expression inhibitor. The 
S100A4 promoter was cloned upstream of a reporter gene. The cloned 
construct was stably introduced into human colon cancer cells which were 
exposed to 1,280 compounds of the library of pharmaceutically active 
compounds (LOPAC). In a 4 dose-screen 34 compounds presented reduced 
luciferase activity. Of those, 11 compounds reduced luciferase activity without 
affecting cell viability to less than 50%. A 20-dose re-screen identified 
niclosamide and calcimycin to be the strongest candidates with respect to 





1.6. Identification of the molecular mechanism underlying S100A4-driven 
metastasis 
Many interaction partners of S100A4 that explain the action of S100A4 in the cell to 
drive metastasis formation have been identified (160). However, less is known about 
the transcriptional changes which occur upon S100A4 upregulation and which are 
needed for the metastatic phenotype. To identify the transcriptional mechanism 
underlying S100A4-driven metastasis, Stein and colleagues performed a gene 
expression profiling using a Human OncoChip array (35K probe cDNA arrays from the 
NCI/CCR microarray center) at the National Cancer Institute, Frederick. They applied 
the HCT116 derivative cell line HAB92wt which is monoallelic for wildtype β-catenin and 
thus presents reduced Wnt pathway activity and very low levels of S100A4 expression. 
HAB92wt cells were further stably transfected with S100A4 cDNA or the empty vector 
as control.  
 
Fig 1.5 Gene expression profiling of S100A4 overexpressing cells. 
HAB92wt cells are HCT116 derivate cells in which the mutated β-catenin allele 
was depleted. Thus these cells present reduced Wnt pathway activity and very 
low expression of S100A4. HAB92wt cells were either transfected with the 
S100A4 cDNA (HAB92/S100A4) or the empty vector as control (HAB92/vector). 
The reverse-transcribed mRNA was labeled with Cy5 (red) and Cy3 (green) as 
indicated and applied on a Human OncoChip 35K probe cDNA array. 256 
genes were regulated more than 3-fold, with DKK-1 being 4-fold down regulated 
due to overexpression of S100A4. 
 
To set up the microarray, isolated mRNA from HAB92wt, HAB92wt/vector and 
HAB92wt/S100A4 cells was reversely transcribed and labeled with Cy5 (red) and Cy3 
(green) as indicated in Fig 1.5. Labeled cDNA was hybridized to the arrays and 
fluorescence was read in GenePix 4100A microarray scanner. The data was analyzed 
through GenePix Pro 4.1 software and the microarray intensity was normalized by 
setting the Ratio of Medians to 1. Data was analyzed with available tools on mAdB 
including Significance Analysis of Microarrays (SAM) (161), prediction analysis of 
Microarrays (PAM) (162), and DAVID/EASE functional analysis (163). Among the 256 





Taken together, the intensive research of the last two decades that is summarized in 
the preceeding pages provides profound evidence that S100A4 is a central mediator 
for metastasis formation which is still the major burden for colon cancer patients. Many 
interaction partners of S100A4 were described explaining its metastasis promoting 
ability. However, fewer investigations were concentrated on the inhibition of S100A4 to 
impair its metastasis-driving functions. Moreover, little is known about the 
transcriptional consequences of S100A4 overexpression, which might play a decisive 
role in S100A4-induced metastasis formation.  
 
Against this background, the aim of this study is to evaluate the potential of the small 
molecules niclosamide and calcimycin to function as inhibitors targeting S100A4 
expression and to investigate their efficiency to repress S100A4-induced cell motility. 
Moreover, the mechanism by which the small molecules could interfere with S100A4 
expression was to be elucidated. Thus, with respect to future anti-metastatic 
treatments, the applicability and efficiency of the small molecules to inhibit S100A4-
induced metastasis formation was to be investigated. Within the scope of the project, a 
human colon cancer xenograft mouse model needed to be installed to monitor 
S100A4-induced metastasis formation in vivo by non-invasive bioluminescence 
imaging. Moreover, the relation of S100A4 to the Wnt/β-catenin pathway inhibitor DKK-
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3. MATERIALS AND METHODS  
 
3.1. Cloning  
DNA was digested with FastDigest® Restriction Enzymes in 1x FastDigest® Buffer (both 
Fermentas) at 37 °C for 1 h. Digested DNA was separated by agarose gel 
electrophoresis at 100 V for 30 min in gels containing 0.8% w/v agarose (Invitrogen) in 
TAE-buffer (40 mM Tris, 1 mM Na2EDTA and 20 mM acetic acid, pH 8). 
DNA was purified from the agarose gel using Invisorb® Spin DNA extraction Kit 
(Invitek) according to the manufacturer’s instructions. DNA was ligated in a 1:10 ratio of 
vector backbone and inserted using 0.25 U/µl T4 Ligase in 1x Ligase Buffer (both 
Fermentas) at 14°C, overnight. Bacterial transformation was performed in Subcloning 
Efficiency™ DH5α™ Chemically Competent Cells (Invitrogen) according to the 
manufacturer’s instructions. Transformed bacteria were spread on selective agar plates 
and allowed to grow overnight at 37°C. DNA plasmid preparation from positive colonies 
was performed with Invisorb ® Spin Plasmid Mini Two (Invitek). Control digest of 
plasmids followed by agarose gel electrophoresis identified positive clones. For 
transfection, plasmids were isolated with endotoxin-free plasmid DNA Maxi Prep using 
the JETSTAR 2.0 Maxi (Genomed). Cloned constructs were sequenced for correct in 
frame orientation (sequencing service, Invitek).  
 
3.1.1. S100A4 cDNA expression vector 
The S100A4 cDNA was cloned into a vector with a puromycin resistance cassette to 
allow selection of successful transfected HAB92wt cells which already beard a 
neomycin resistance. 
The S100A4 cDNA was cut with HindIII and XbaI from the pcDNA3-neomycin-
S100A4cDNA vector, which was a kind gift from Claus Heizmann (University of Zurich, 
Zurich, Switzerland) and ligated into the pcDNA3-puromycin vector, which was a kind 
gift from Dr. Jörn Lausen (AG Leutz, MDC, Berlin, Germany). Control digest of 
plasmids with NcoI or SmaI identified positive clones. Plasmid was purified and 
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3.2. Cell culture 
3.2.1. Colon cancer cell lines  
Cell culture media, PBS and Trypsin/EDTA solution were obtained from PAA 
Laboratories. Cell culture plastic ware was obtained from TPP, BD Biosciences or 
Greiner BioOne. All human colon cancer cell lines used in this study are summarized in 
Table 3.1. If not stated otherwise, the colon cancer cell lines were kindly provided by 
Prof. Dr. W. Birchmeier and Prof. Dr. Ulrike Stein. Cells were maintained in DMEM or 
RPMI 1640 medium supplemented with 10 % FBS in a humidified incubator at 37°C 
and 5 % CO2. Cells were trypsinized and split in a 1:4 ratio every 3-4 days.  
 
Table 3.1 Summary of all colon cancer cell lines used in this study 
Cell line Medium ATCC number 
Caco2 DMEM, 10 % FBS HTB-37 
Colo205 RPMI 1640, 10 % FBS CCL-222 
DLD1 DMEM, 10 % FBS CCL-221 
HCT15 RPMI 1640, 10 % FBS CCL-225 
HCT116 RPMI 1640, 10 % FBS CCL-247 
HT29 DMEM, 10 % FBS HTB-38 
KM12 RPMI 1640, 10 % FBS CRL-12496 
Lovo RPMI 1640, 10 % FBS CCL-229 
LS174T DMEM, 10 % FBS CCL-188 
SW48 RPMI 1640, 10 % FBS CCL-231 
SW480 RPMI 1640, 10 % FBS CCL-227 
SW620 RPMI 1640, 10 % FBS CCL-228 
WiDr RPMI 1640, 10 % FBS CCL-218 
The central column depicts the cell culture medium used for each cell line. All 
cell lines are registered in the American type culture collection (ATCC).  
 
3.2.2. Transfections  
The constructs used in transfection experiments are summarized in Tables 3.2 and 3.3. 
1x106 cells were plated in a 10 cm Ø dish 24 h before transfection occurred. For each 
transfection reaction 15 µl Fugene HD (Roche), 10 µg plasmid and 500 µl serum-free 
DMEM were incubated for 15 min at room temperature, and then added to the cells of 
70% confluence in a total volume of 5 ml RMPI 1640 medium. After 48 h, selection of 
positive transfected cells occurred with 1 mg/ml neomycin and/or 1 µg/ml puromycin. 
Antibiotics were continuously present and only removed 24 h before cells were used in 
experiments to avoid their interference. 
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3.2.3. HCT116 derivative cells 
The HCT116 derivative cells HAB92wt and HAB68mut were a kind gift from Todd 
Waldman (Georgetown University, Washington). HAB92wt and HAB68mut cells were 
generated from HCT116 cells, which are heterozygous for a gain-of-function mutated 
Δ45-β-catenin. To obtain HAB92wt and HAB68mut cells the respective mutated or wild-
type allele of β-catenin was replaced by a neomycin resistance cassette via 
homologous recombination (164). Cell lines were tested regularly for the correct β-
catenin genotype by restriction fragment length polymorphism (section 3.4.4). 
HCT116/S100A4 and HCT116/vector cells as well as HAB92wt/S100A4 and 
HAB92wt/vector cells were obtained by transfection of HCT116 or HAB92wt cells, 
respectively, with pcDNA3.1-cmv-S100A4cDNA or the empty vector as control. Stable 
expression of transgene was regularly tested with quantitative real-time PCR (section 
3.4.3).  
HCT116/LUC cells applied in in vivo imaging experiments were obtained by 
transfection of HCT116 with pcDNA3.1-puro-LUC. Stable expression of transgene was 
controlled regularly by Steady GlowTM Luciferase Assay System (Promega) according 
to the manufacturer’s instructions.  
 
Table 3.2 Plasmids used for colon cancer cell transfection 
Plasmid Features 
gene overexpression  
pcDNA3.1-puro-S100A4 
CMV promoter-driven S100A4 cDNA (long variant); puromycin 
resistance 
pcDNA3.1-puro CMV promoter; puromycin resistance 
pcDNA3.1-puro-LUC 
CMV promoter-driven firefly luciferase cDNA; puromycin 
resistance 
shRNA interference  
pGeneClip-puro-shDKK-1 
U1 promoter driven shRNA sequence targeting DKK-1;  
5’-GGA CAA GAA GGT TCT GTT TGT-3’; puromycin 
resistance 
pGeneClip-puro-shS100A4 
U1 promoter driven shRNA sequence targeting S100A4;  
5’-CCA GAA GCT GAT GAG CAA CTT-3’; puromycin 
resistance 
pGeneClip-puro-shcon 
U1 promoter driven control shRNA sequence;  
5’-GGA ATC TCA TTC GAT GCA TAC-3’; puromycin resistance 
The table depicts the plasmids and their features used for gene overexpression 
of RNA interference. The DKK-1 or S100A4 gene-specific shRNA sequences 
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3.3. Drugs and treatments 
3.3.1. RNA interference  
RNA interference using short hairpin RNA (shRNA) which target the S100A4 or DKK-1 
mRNA was performed with SureSilencingTMshRNA plasmids (SA Biosciences). For 
each gene four different shRNA sequences were designed and tested by transient 
transfection of cells. The expression of the shRNA targeted mRNA was analyzed by 
quantitative real-time PCR (section 3.4.3) after 24 h and 48 h of transfection. The most 
efficient shRNA sequence, decreasing target gene expression to less than 50 %, is 
shown in Table 3.2 and was used for stable transfection of HCT116 or HAB92wt cells. 
As a control a non-functional shRNA sequence, tested by SA Biosciences to have no 
mRNA target, was used. Selection of stable transfectants was performed with 
neomycin (1 mg/ml) and/or puromycin (1 µg/ml). 
 
3.3.2. Small molecules 
The small compound inhibitors niclosamide (2',5-dichloro-4'-nitrosalicylanilide) and 
calcimycin were obtained from Sigma. Niclosamide derivatives were obtained from the 
Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, NCI, 
Bethesda, MD. Analysis of the 2D and 3D structure of niclosamide and its derivatives 
was performed with MarvinSketch and MarvinSpace version 5.2.3_1. All drugs were 
solubilized in dimethylsulfoxide (DMSO) for in vitro application. To exclude adverse 
effects caused by DMSO, control cells were always treated with the equal amount of 
solvent. In vivo niclosamide was administered as suspension in 10 % cremophore EL 
(BASF) and 0.9 % NaCl solution.  
 
3.3.3. Recombinant DKK-1 protein 
Recombinant DKK-1 protein (rDKK-1) was obtained lyophilized from R&D Systems and 
was dissolved in sterile filtered 1 % w/v BSA/PBS solution. Dissolved rDKK-1 was 
stored at 4 °C for two weeks at maximum. Control cells were treated with the 
respective amount of 1 % w/v BSA/PBS solution. 
 
3.3.4. Cytotoxicity assay 
Analysis of cell cytotoxicity was performed with AlamarBlue™ (AbD Serotec) according 
to the manufacturer’s instruction. Briefly, 1x105 cells were seeded into 96-well-plates 
and allowed to accommodate for 24 h. The cells were exposed to different 
concentrations of a compound or its solvent for 24 h. 10 % v/v AlamarBlue™ was 
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added and incubation for 3 h at 37°C in a humidified incubator allowed AlamarBlue 
reduction to occur. The absorbance of reduced and oxidated AlamarBlue was 
measured at 620 nm and 560 nm, respectively, in the absorbance reader SpectraFluor 
Plus (Tecan). Cell viability was determined by dividing the absorbance ratio of reduced 
and oxidated AlamarBlue of treated cells by the ratio obtained from untreated cells 
which was defined as 100 % cell viability.  
 
 
3.4. Gene expression analysis 
3.4.1. RNA isolation 
Total RNA was isolated from 4x105 cells plated in a 6-well-plate 24 h before cells were 
lyzed with Trizol Reagent (Invitrogen). RNA was isolated according to the 
Trizol/chloroform extraction protocol as described earlier (165). Precipitation of RNA 
from the watery phase occurred by addition of isopropanol at -20°C overnight and 
subsequent centrifugation at 14,000 rpm for 15 min. Precipitated RNA was resolved in 
ddH2O and stored at -80°C. Quantification of the RNA concentration was performed 
with Nanodrop (Peqlab).  
 
3.4.2. Reverse transcription 
For each sample, 50 ng total RNA was reversely transcribed. Reverse transcription of 
250 ng total RNA isolated from HCT116 cells was used for the standard curve. 
Reverse transcription was performed with random hexamers in 10 mM MgCl2; 1x RT-
buffer, 250 µM pooled dNTPs, 1 U/µl RNAse inhibitor and 2.5 U/µl MuLV reverse 
transcriptase (all Applied Biosystems). Reaction occurred at 42 °C for 15 min, 99 °C for 
5 min and subsequent cooling at 5 °C for 5 min. Reverse transcripts were either stored 
at -20 °C or directly used for quantitative real-time PCR or restriction fragment length 
polymorphism analysis.  
 
3.4.3. Quantitative real-time PCR 
If not stated otherwise, all material used for quantitative real-time PCR (qPCR) was 
obtained from Roche. The primer and probe design was obtained from the Sigma 
OligoDesign Service. Probes were obtained from Sigma and primers were obtained 
from Biotez. Table 3.3 summarizes all primers and probes used for qRT-PCR in this 
study.  
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For quantification of β-catenin, DKK-1 and S100A4 cDNA hybrid probe based qRT-
PCR was performed with the FastStart DNA Master HybProbe Kit according to the 
manufacturer’s instructions. Quantification of Cyclin D1 and c-myc cDNA was 
performed with SYBR green based qRT-PCR using the FastStart DNA Master SYBR 
Green I Kit according to the manufacturer’s instructions. Each qRT-PCR reaction was 
performed in duplicate and in parallel to the cDNA quantification of the housekeeping 
gene glucose-6-phosphate dehydrogenase (G6PDH) using primers and probes from 
the LightCycler® hG6PDH Housekeeping Gene Set.  
 
Table 3.3 Primers and probes used in quantitative real-time PCR 
Primer/probe Sequence 5’- 3’ 
β-catenin-F GTG CTA TCT GTC TGC TCT AGT A 
β-catenin-R CTT CCT GTT TAG TTG CAG CAT C 
β-catenin-FITC AGG ACT TCA CCT GAC AGA TCC AAG TCA-FITC 
β-catenin-LCRed640 LCRed640-CGT CTT GTT CAG AAC TGT CTT TGG ACT CTC-phosphate 
c-myc-F ACC CTT GCC GCA TCC ACG AAA C 
c-myc-R CGT AGT CGA GGT CAT AGT TCC TGT TGG 
Cyclin D1-F CTG TTT GGC GTT TCC CAG AGT CAT C 
Cyclin D1-R AGC CTC CTC CTC ACA CCT CCT C 
DKK-1-F TAG CAC CTT GGA TGG GTA TTC 
DKK-1-R ATA TTT CTA GTC CAT GAG AGC C 
DKK-1-FITC GTC TCC GGT CAT CAG ACT GTG CC-Fluorescein 
DKK-1-LCRed640 LCRed640-AGG ATT GTG TTG TGC TAG ACA CTT CTG G-phosphate 
S100A4-F CTC AGC GCT TCT TCT TTC 
S100A4-R GGG TCA GCA GCT CCT TTA 
S100A4-FITC TGT GAT GGT GTC CAC CTT CCA CAA GT-Fluorescein 
S100A4-LCRed640 LCRed640-TCG GGC AAA GAG GGT GAC AAG T-phosphate 
Primers and probes were applied to a final concentration of 250 and 150 nM, 
respectively. 
 
Each PCR reaction was performed in a total volume of 10 µl in 96-well-plates in the 
LightCycler 480. The PCR protocol for hybrid probe based qRT-PCR comprised a pre-
incubation step at 95 °C for 10 min followed by 45 cycles of (a) denaturation at 95 °C 
for 10 sec, (b) annealing at 61 °C for 30 sec and (c) elongation at 72 °C for 4 sec.  The 
PCR protocol for SYBR green based qRT-PCR comprised a pre-incubation step at 
95 °C for 10 min followed by 45 cycles of (a) denaturation at 95 °C for 7 sec, (b) 
annealing at 61 °C for 10 sec and (c) elongation at 72 °C for 5 sec. To control for 
primer dimers or unwanted PCR side products the melting curve was measured with a 
continuous temperature increase from 65°C to 95°C with a rate of 0.1 °C/sec.  
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Data analysis was performed with LightCycler® 480 Software release 1.5.0 SP3. For 
each qRT-PCR reaction a mean of the duplicate was calculated. Each mean value of 
the expressed gene was normalized to the respective mean amount of the G6PDH 
cDNA.  
 
3.4.4. Restriction fragment length polymorphism analysis 
Restriction fragment length polymorphism (RFLP) analysis was performed as 
described earlier to analyze the β-catenin genotype of HCT116 and its derivative cells 
(65). Total RNA was isolated from 4x105 cells and reverse transcribed as described in 
section 3.4.2. The region comprising the deletion mutation of the S45 of β-catenin was 
PCR amplified using 1.25 U AmpliTaq Gold (5 U/µl), 1x GeneAmp PCR Gold buffer, 
250 µM pooled dNTPs, 2.5 mM MgCl2 (all Applied Biosystems) and 750 µM forward 
and reverse primers (Biotez) shown in Table 3.4.  
 
Table 3.4 Sequences of primers used in RFLP assay 
Primer Sequence 5’- 3’ 
RFLP-cat-fwd CCT GTT CCC CTG AGG GTA TTT 
RFLP-cat-rev CAG CTA CTT GTT CTT GAG TGA AG 
 
PCR was performed in the T3000 Thermocycler (Biometra) with a pre-incubation at 
95 °C for 10 min, followed by 40 cycles of (a) denaturation at 95 °C for 30 sec, (b) 
annealing at 61 °C for 30 sec and (c) elongation at 72 °C for 1 min. Final elongation at 
72 °C was performed for 7 min. PCR product was precipitated with 161 mM NaCl and 
62 % v/v ethanol at -20 °C overnight, followed by centrifugation at 14,000 rpm for 
15 min. Precipitated DNA was washed once with 75 % v/v ethanol, digested with Bsl I 
FastDigest® Restriction Enzyme (Fermentas) and separated with agarose gel 
electrophoresis as described in section 3.1. Appearance of 2 bands at 100 and 200 bp 
represented the Δ45-mutated allele of the β-catenin gene, a 300 bp band represented 
the wildtype allele of the β-catenin gene. 
 
3.4.5. Protein extraction 
Cultured cells were trypsinized, scraped into 1.5 ml tubes and pelleted at 6,000 rpm for 
5 min. The pellet was either frozen at -20 °C or immediately subjected to protein 
extraction.  
For total protein extraction cells were lysed with RIPA buffer (50 mM Tris-HCl, 150 mM 
NaCl, 1 % Nonidet P-40, supplemented with complete protease inhibitor tablets; 
Roche) for 30 min on ice. Cell debris was pelleted at 14,000 rpm for 10 min at 4 °C. 
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The supernatant was transferred to a new tube, stored at -20°C or directly subjected to 
Western blot analysis. 
For isolation of the nuclear protein fraction, the NE-PER Nuclear and Cytoplasmic 
Extraction Kit (Pierce) was used according to the manufacturer’s instructions. Briefly, 
cell membranes were broken in a hypotonic buffer and nuclei were isolated by 
centrifugation. Nuclei were washed once with PBS to remove residual cytoplasmic 
protein and resuspended in nuclear extraction buffer. Sonication for 1 pulse at 40 % 
output was performed to break the nuclear membrane. Membrane debris was removed 
by centrifugation at 14,000 rpm for 10 min and supernatant was transferred to a new 
tube. Protein extracts were stored at -20 °C or directly subjected to Western blot 
analysis. 
 
3.4.6. Protein quantification 
Protein concentration was quantified before samples were applied in Western Blot 
analysis. Quantification was performed with Bicinchoninic Acid (BCA) Protein Assay 
Reagent (Pierce) according to manufacturer’s instructions using 2 mg/ml BSA solution 
for the standard curve (166). BCA reaction was incubated at 37 °C for 15 min and 
absorption was measured at 560 nm in the absorbance reader SpectraFluor Plus 
(Tecan). 
 
3.4.7. Western blot analysis 
Sodiumdodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) and 
immunoblotting was used to analyze protein expression levels. All the materials were 
obtained from Invitrogen, unless stated otherwise. 
Protein extracts were diluted with PBS to obtain 50 µg total protein in 1x NuPAGE® 
loading buffer and 10 % DTT. Protein samples were loaded onto pre-cast NuPAGE® 
Novex 10 % Bis-Tris Gels or NuPAGE® Novex 4-12 % Bis-Tris Gels. Protein 
electrophoresis occurred in running buffer 1x NuPAGE® MES or 1x NuPAGE® MOPS 
at 200 V for 60 min within the XCell SureLock™ Mini Cell System. The pre-stained 
Spectra™ Multicolor Broad Range Protein Ladder (Fermentas) was used to determine 
band size.  
Semi-dry electrotransfer blotting of proteins onto the Hybond C Extra nitrocellulose 
membrane (Amersham Biosciences) occurred in blotting buffer (25 mM Tris-HCl, 
200 mM glycin, 0,1 % SDS, 20 % methanol, pH7.5) at 20 V for 30-60 min in the Trans-
Blot® SD Cell (Bio-Rad). Quality of the protein transfer was analyzed by protein staining 
with Ponceau S solution (Sigma).  
43 
MATERIALS AND METHODS 
The membrane was washed with TBS-T (50 mM Tris-HCl, 150 mM NaCl, 0.05 % 
Tween 20, pH 7.5) and blocked for 1 h at room temperature with blocking buffer (TBS-
T, 5 % milk powder, 1 % BSA). Primary antibodies were diluted in blocking buffer and 
incubated at 4 °C overnight. Secondary antibodies were diluted in TBS-T and 
incubated for 1 h at room temperature. Table 3.5 summarizes the antibodies used and 
their dilution. Proteins bands were visualized by incubation of the membrane in 
electrochemical-luminescence reagent (100 mM Tris-HCl, 0.025 % w/v luminol, 
0.011 % w/v para-hydroxycoumaric acid, 10 % v/v dimethylsulfoxide, 0.004 % v/v H2O2, 
pH 8.6) for 1 min and its exposure to CL-XPosure™ Films (Pierce) for 1 sec to 20 min.  
 
Table 3.5 Antibodies used for Western blot analysis, their dilutions and their origins 
Target Dilution Antibody 
primary antibodies 
anti-β-catenin  1:1000 mouse monoclonal IgG, BD Biosciences 
anti-GAPDH  1:1000 goat polyclonal IgG, Santa Cruz 
anti-PCNA 1:1000 mouse monoclonal IgG, CellSignaling 
anti-S100A4  1:1500 rabbit polyclonal IgG, Dako 
anti-tubulin 1:1000 mouse monoclonal IgM, BD Pharmingen 
secondary antibodies 
anti-goat-HRP 1:10000 HRP conjugated antibody, Santa Cruz 
anti-rabbit-HRP 1:10000 HRP conjugated antibody, Promega 
anti-mouse-IgG-
HRP 
1:10000 HRP conjugated antibody, Pierce 
 
 
3.4.8. Enzyme-linked immunosorbent assay  
For quantification of secreted DKK-1, the DuoSet® human DKK-1 ELISA System (R&D 
Systems) was used according to manufacturer’s instructions. 96-well stripes (NUNC) 
were coated with 4 µg/ml DKK-1 capture antibody in PBS overnight. In parallel, 4x105 
cells were plated into 6-well plates and after 24 h the supernatant was collected and 
centrifuged at 6000 rpm for 10 min to remove residual cells. Wells were blocked with 
blocking reagent (PBS with 1 % BSA) for 1 h. Supernatant was diluted 1:4 and 1:8 with 
blocking reagent before entering the blocked wells. A standard recombinant human 
DKK-1, dissolved in blocking reagent, was used at a maximum concentration of 
18 ng/ml. DKK-1 protein was incubated with 50 ng/ml detection antibody and HRP-
conjugated streptavidin (R&D Systems). For colorimetric quantification, 3,3’,5,5’-
tetramethylbenzidine liquid substrate system (Sigma) solution was added and the 
reaction was stopped with STOP solution (Biosource) containing 2 N H2SO4. Each 
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experiment was performed in duplicates with at least two different dilutions to assure 
that ELISA reaction occurred in the linear range of sensitivity. The mean values of 
secreted DKK-1 from each supernatant were normalized to the amount of total protein 
extracted from the respective cells.  
 
 
3.5. Functional in vitro Assays 
3.5.1. Migration assay 
Cell migration was quantified applying the Boyden chamber assay (167). Transwells 
were incubated in RPMI 1640 medium 24 h before 2.5x105 cells were seeded onto the 
filter membrane of the transwell. The filter membrane comprised pores of 12 µm in 
diameter through which the cells needed to migrate to reach the lower chamber 
(Millipore). Cells were allowed to accommodate for 15 h before drugs were added, and 
then incubated for additional 24 h. To quantify cells which migrated to the lower 
chamber, transwells were removed and cells were trypsinized and counted in a 
Neubauer chamber. Each well was counted ten times and each migration experiment 
was performed in duplicates.  
 
3.5.2. Invasion assay 
Analysis of cell invasion was based on the Boyden chamber assay and was performed 
in analogy to quantification of cell migration (167). To measure cell invasion, transwells 
were covered with Matrigel (BD Biosciences) simulating the extracellular matrix. 
Matrigel was diluted 1:3 in cell culture media and 50 µl were applied to coat the filter 
membrane in transwells. Incubation in a humidified incubator at 37 °C and 5 % CO2  for 
30 min allowed polymerization of the Matrigel. 5x105 cells were seeded onto the 
Matrigel layer 15 h before treatment occurred. Cells which invaded the Matrigel and 
migrated to the bottom of the well were trypsinized and counted in a Neubauer 
chamber. Each well was counted ten times and each cell invasion experiment was 
performed at least in triplicates. 
 
3.5.3. Wound healing assay  
The wound healing assay was used to analyze directed cell migration. On day 0, 
2.5x105 cells were seeded into a 6-well plate and were allowed to accommodate for 
24 h to reach about 60 % confluence. A wound of about 300 µm width was inflicted into 
this monolayer of cells with a pipette tip and the medium was exchanged to remove cell 
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debris. The progress of wound closure was monitored daily and microphotographs of 
10x and 40x magnification were taken with the Leica DM IL light microscope (Leica 
Microsystems) on day 0 and day 4. Each wound healing assay was performed in 
triplicates.  
 
3.5.4. Proliferation assay 
For determination of anchorage-dependent cell proliferation, 8x103 cells were plated 
into 96-well-plates and were allowed to accommodate for 15 h, before treatment was 
started. Cells were treated daily for 4 days with inhibitor or solvent. For determination of 
viable cells 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide (MTT; 
Sigma) was added to a final concentration of 0.5 mg/ml, incubated for 3 h, and 
dissolved by 10 % SDS in 10 mM HCl overnight. The optical density (OD) was 
measured at 560 nm. Each cell proliferation experiment was performed in triplicates.  
 
3.5.5. Colony formation assay 
Analysis of anchorage-independent cell proliferation was achieved by soft agar colony 
formation assay. A bottom layer containing 0.5 % w/v agarose, RPMI 1640 medium, 
10 % FBS and inhibitor or solvent was added to a 6 cm Ø dish. Onto the solidified 
bottom layer a top layer was added containing 8x103 cells, 0.33 % w/v agarose, RPMI 
1640 medium, 10 % FBS and inhibitor or solvent. Cells were seeded as single cells into 
the soft agar and incubated in a humidified incubator at 37 °C and 5 % CO2 for 7 days. 
Colony formation was visualized by 10x magnification for an overview and 40x 
magnification for single colonies in the Leica DM IL light microscope (Leica 
Microsystems). Colony quantification was achieved by counting cell colonies of more 
than 4 cells in 10 squares of 1 µm2. 
 
 
3.6. Wnt/β-catenin pathway analysis 
3.6.1. TOP/FOPflash reporter assay 
The TOP/FOPflash assay (Promega) was used to determine Wnt/β-catenin pathway 
activity. The TOPflash contained a hexameric repetition of the T-cell factor (TCF)-
binding element upstream of a thymidine kinase (TK) promoter and firefly luciferase as 
reporter gene. The FOPflash plasmid comprised the exact sequence of the TOPflash 
plasmid, but with point mutated TCF-binding sites. In the assay, 8x105 cells were 
plated in 24-well-plates and let accommodate for 15 h. Cells were transfected with 
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TOPflash or FOPflash plasmids 24 h before being treated with inhibitor or solvent. 
Luciferase activity was measured by the Steady GlowTM Luciferase Assay System 
(Promega) according to the manufacturer’s instructions in the luminescence reader 
SpectraFluor Plus (Tecan) with 1,500 ms exposure time and a gain of 150. TOPflash 
reporter gene expression, representing the Wnt pathway activity, was normalized to 
FOPflash reporter gene expression, representing basal reporter gene expression and 
transfection efficiency. Each assay was performed in triplicates. 
 
3.6.2. Electrophoretic mobility shift assay 
Electrophoretic mobility shift assay (EMSA) for analysis of the β-catenin/TCF-S100A4-
promoter-complex was described earlier (65). If not stated otherwise, the materials 
were obtained from Pierce. In a total volume of 20 µl, 5 µg of nuclear extracted protein 
was incubated for 30 min at room temperature along with 0.05 % w/v poly dI·dC, 
0.5 mM Tris, 0.05 mM EDTA, 2.5 % v/v glycerol, 0.2 % v/v NP-40, 5 mM MgCl2 and 
double-stranded biotinylated oligonucleotides encompassing the TCF-binding site of 
the S100A4-promoter (Biotez; for sequence see Table 3.6). For supershift 1.25 µg 
monoclonal β-catenin antibody (BD Biosciences) was added. Electrophoretic 
separation of the protein-oligonucleotide-complexes was performed in pre-cast Novex 
6 % TBE gels (Invitrogen) and in TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM 
EDTA, pH 8.3) for 60 min at 100 V. Capillary transfer of the protein-oligonucleotide-
complexes to the HybondTM-N nylon membrane (Amersham Biosciences) occurred in 
20x SSC buffer (3 M NaCl, 300 mM Na3C6H5O7, pH 7) overnight. Cross-linkage of 
transferred DNA to the membrane occurred at 250 mJ/cm2 for 1 min in the FL-20-
M FluoLink Crosslinker (Bachofer). Visualization of biotin-labeled DNA was performed 
with LightShift Chemiluminescent EMSA Kit (Pierce) according to manufacturer’s 
instructions.  
 
Table 3.6 Oligonucleotide sequences used for EMSA 
Primer Sequence 5’- 3’ 
TCF-site-antisense Biotin-TGT CTC TTA AAA AAA TAA AGA TTC AGA AAC AAA AAC TGG GGT GGG GAT CCC CAT GCC CGG 
TCF-site-sense Biotin-CAC CGG GCA TGG GGA TCC CCA CCC CAG TTT TTG TTT CTG AAT CTT TAT TTT TTT AAG AGA CA 
The sequence of the oligonucleotides comprised the TCF-binding site of the 
S100A4-promoter and was described by Stein et al. (65). 
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3.6.3. Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation (ChIP) was described earlier to measure the binding of 
β-catenin to the S100A4-promoter (65, 168). For the preparation of cell lysates 1x106 
cells were plated in 10 cm Ø dish 15 h before being treated with inhibitor or solvent. 
Cells were incubated with 1 % formaldehyde for 10 min at room temperature to assure 
reversible cross-linking of proteins and DNA. Cells were washed twice with ice-cold 
PBS and lyzed with Lysis Buffer A (1 % SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8) for 
10 min on ice. Cell lysates were sonicated for 20 pulses at 40 % output and centrifuged 
at 10,000 rpm for 10 min. Supernatant was transferred to a new tube and diluted with 
Lysis buffer A to reach an absorption at 260 nm of 2 units/ml. One third of the diluted 
supernatant was stored at -20 °C and served in the end as input control.  
For immunoprecipitation the diluted supernatant was incubated with 5 µg monoclonal 
β-catenin antibody or 5 µg control IgG (both BD Biosciences) overnight at 4 °C. 
Protein G beads (Invitrogen) were added and incubated for 2 h at 4 °C. Non-bound 
protein was washed away twice with Wash Buffer A (10 mM Tris, 0.1 % SDS, 0.1 % 
Na-deoxycholate, 1 % Triton X-100, 1 mM EDTA, 0.5 mM EGTA, 140 mM NaCl, pH 8), 
once with Wash Buffer B (Wash Buffer A, 6 % w/v NaCl) and twice with TE buffer 
(20 mM Tris, 1 mM EDTA, pH 8). Elution of the protein-DNA-complex from the beads 
occurred by incubation with 1.5 % w/v SDS solution for 15 min at room temperature 
followed by centrifugation at 3,000 rpm for 1 min. To assure complete elution a second 
elution step was performed by incubation of the beads in 0.5 % SDS solution for 15 min 
at room temperature followed by centrifugation at 3,000 rpm for 1 min. 
Cross linking of protein and DNA was reversed at 68 °C for 4 h and residual protein 
was digested by proteinase K (Fermentas) at 55 °C for 2 h. DNA was purified by 
precipitation as described in section 3.4.4. PCR amplification of the S100A4-promoter 
TCF-binding site was performed with the Taq-PCR protocol as described in section 
3.4.4 with primers summarized in Table 3.7. PCR amplification of the non-β-catenin 
regulated fos-promoter sequence served as a control. The expected amplicons were 
167- or 149 bp in size, respectively.  
 
Table 3.7 Primer sequences applied in the ChIP assay 
Primer Sequence 5’- 3’ 
fos-promoter-F CCT TAA TAT TCC CAC ACA TGG C 
fos-promoter-R CTG CGT TTG GAA GCA GAA AGT 
S100A4 promoter-F TGT TCC CCT CCA GAT CCC 
S100A4 promoter-R GGC TAT GCT CAA GCC ACT G 
Primers were designed by Stein et al. (65) and used to a final concentration of 
750 nM. 
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3.7. In vivo metastasis formation and bioluminescence imaging 
All animal experiments were performed in accordance with the UKCCCR guidelines 
and in cooperation with Dr. Iduna Fichtner (MDC Berlin, Germany). Further, all animal 
experiments were approved by the State Office of Health and Social Affairs, Berlin, 
Germany in the G0413 permit. 
 
3.7.1. Intrasplenal tumor transplantation 
For intrasplenical transplantation 6-week-old female non-obese diabetic/ severe 
combined immunodeficiency (NOD/SCID) mice (EPO GmbH) and SCID beige mice 
(Charles Rives Laboratories) were used. Disinfectant, suture and surgical instruments 
were obtained from Heiland, syringes and needles were obtained from Braun. For 
intrasplenal tumor application, mice were anesthetized with 35 mg/kg Hypnomidate® 
(Jassen-Cilag) and the skin and peritoneum were laterally incised to exteriorize the 
spleen. HCT116/LUC cells were resuspended in PBS and kept on ice during the 
surgery. 3×106 of these cells were intrasplenically injected with a 27-gauge needle. The 
spleen was carefully placed back, the peritoneum was closed with Surgicryl ® 
absorbable suture and the skin was clamped twice.  
 
3.7.2. In vivo dose-finding for niclosamide 
For dose finding experiments intrasplenical transplanted NOD/SCID mice were 
randomly assigned to four groups with 2 animals per group. Treatment started 24 h 
after transplantation and was performed daily by intraperitoneal injection of 6, 12 or 
24 mg/kg niclosamide or the respective amount of solvent. Body weight was analyzed 
daily to observe toxic effects of the drug. Mice were sacrificed at day 24 for ethical 
reasons. The size and number of metastases was determined as described in section 
3.7.3. 
 
3.7.3. Analysis of metastasis formation in vivo 
Intrasplenical transplanted NOD/SCID mice were randomly assigned to 3 groups of 
9 animals. Treatment of animals started 24 h after cell transplantation. Mice were daily 
treated intraperitoneally with either one dose of 20 mg/kg or two doses of 15 mg/kg 
niclosamide. Control animals received the corresponding amount of solvent. Mice were 
sacrificed at day 24 for ethical reasons. Spleen (as the transplantation site) and liver 
(as a metastasis target organ) were removed. The level of metastasis was evaluated 
49 
MATERIALS AND METHODS 
50 
by scoring considering both the number and the size of metastatic nodules (1 mm = 
score 1; 2 mm = score 8; 3 mm = score 27; 4 mm = score 64; 5 mm = score 125).  
 
3.7.4. In vivo bioluminescence imaging  
Intrasplenically transplanted SCID mice were randomly assigned to 2 groups of 
4 animals each. Mice were treated intraperitoneally with daily doses of 20 mg/kg 
niclosamide or solvent. For non-invasive bioluminescence imaging mice were 
anesthetized every 3 days with 35 mg/kg Hypnomidate® (Jassen-Cilag) and received 
intraperitoneally 150 mg/kg D-luciferin (Biosynth) dissolved in PBS. Imaging was 
performed with the NightOWL LB 981 system (Berthold Technologies) with exposure 
times of 1 sec to 20 sec. ImageJ version 2.3 was used for color coding of the signal 
intensity (presenting a 256 grayscale) and for overlay pictures.   
 
3.7.5. Human S100A4 expression in murine xenograft tissue 
Spleen tumor tissue was shock frozen with liquid nitrogen after resection and stored at 
-80°C. For isolation of mRNA, the tumor tissue was fixed with Tissue-Tek Medium 
(satura Tek) in a Cryomicrotom (CM1900, Leica) and dissected into 6 slices each of 
10 µm in size. Trizol reagent was added to tissue slices and samples were sonicated 
for 10 pulses at 40 % output to assure complete cell lysis. RNA isolation and reverse 
transcription was performed as described in sections 3.4.1 and 3.4.2, respectively. 
Primers for quantification of S100A4 cDNA were designed to be specific to the human 




3.8. Statistical analysis 
All calculations and statistics were performed with GraphPad Prism version 4.01. 
Comparison of two groups was done by Student’s t-test. Comparison of a control 
versus several treated groups was performed by one-way analysis of variance 
(ANOVA) and Bonferroni post hoc multiple comparison. The inhibiting concentration 50 
(IC50) and the effective concentration 50 (EC50) were calculated by sigmoidal dose-
response curve fit of x=log(x) transformed data. For correlation analysis data was 
tested for Gaussian distribution with Shapiro-Wilk normality test. Since no Gaussian 
distribution was detected, correlation analysis was performed with non-parametric 
Spearman correlation test. All significance tests were two-sided, and P values smaller 




Walther, Stein and colleagues identified niclosamide and calcimycin in a high 
throughput screening for S100A4 transcription inhibitors. The two compounds were 
most efficient to reduce firefly luciferase activity without affecting cell viability. 
Expression of the reporter firefly luciferase was regulated by the S100A4-promoter. 
From the reduced firefly luciferase activity it was hypothesized that S100A4-promoter 
activity was repressed. Based on those results, the small molecules bore a great 
potential to inhibit S100A4 expression in colon cancer cells. In the present study, this 
potential and the applicability of the two small molecules was investigated. As a cellular 
model, the colon cancer cell line HCT116 was used due to its endogenous high level of 
S100A4 expression, which was earlier described by Stein et al. (65).  
 
4.1. Small molecules interfere with cell viability  
To analyze the inhibitory potential of niclosamide and calcimycin on S100A4 
expression, a concentration range needed to be defined in which the inhibitors were 
applicable to HCT116 cells. In the high throughput screening both small molecules 
showed an inhibitory effect at concentrations between 1-100 µM. To cover a wider 
concentration range, HCT116 cells were exposed to 12 2-fold dilutions of niclosamide 
and calcimycin starting at 300 µM. Cell viability was evaluated 24 h post treatment.  
Niclosamide treatment affected the viability of HCT116 cells in a concentration-
dependent manner (Fig. 4.1A). The inhibiting concentration 50 (IC50), representing the 
concentration at which cell viability was decreased to 50 %, was calculated to be 
2.2 µM (95 % CI, 1.9-2.9 µM). In analogy, calcimycin treatment of HCT116 cells also 
reduced cell viability in a concentration-dependent manner (Fig. 4.1B) with a calculated 
IC50 of 2.1 µM (95 % CI, 1.5-2.2 µM). In contrast, DMSO as the solvent control  
affected the cell viability of HCT116 cells only slightly at the highest concentration 




Fig. 4.1 Niclosamide and calcimycin inhibit cell viability in a 
concentration-dependent manner. HCT116 cells were exposed to increasing 
concentrations of niclosamide (A), calcimycin (B) or the respective amount of 
solvent. Cell viability was determined after 24 h. The IC50 for niclosamide and 
calcimycin were calculated to be 2.2 µM  (95 % CI, 1.9-2.9 µM)  and 2.1 µM 
(95 % CI, 1.5-2.2 µM), respectively. Data represent mean ± SE (n>3). 
 
 
4.2. Small molecules restrict S100A4 expression 
4.2.1. Inhibition of S100A4 expression is concentration-dependent 
The ability of the small molecules to reduce endogenous S100A4 expression was 
analyzed in HCT116 cells treated with increasing concentrations of niclosamide or 
calcimycin for 24 h. Niclosamide treatment reduced the S100A4 mRNA level in a 
concentration-dependent manner (Fig. 4.2A). Concentrations of more than 0.5 µM 
niclosamide significantly reduced the endogenous S100A4 mRNA amount to less than 
50 % of the solvent-treated control. In parallel, the S100A4 protein was clearly reduced 
in HCT116 cells treated with 1 µM and higher concentrations of niclosamide. No 
52 
RESULTS 
change in S100A4 expression could be detected when cells were treated with 
concentrations lower than 1 µM niclosamide.  
 
Fig. 4.2 Niclosamide and calcimycin inhibit S100A4 expression in a 
concentration-dependent manner. HCT116 cells were treated with increasing 
concentrations of niclosamide (A) or calcimycin (B) for 24 h and S100A4 mRNA 
and protein expression was determined by qRT-PCR and Western blot analysis, 
respectively. 1 µM niclosamide (black bar) or calcimycin (grey bar) were 
sufficient to inhibit S100A4 expression to less than 50 % of solvent-treated cells. 
Data represent mean ± SE (n>3). Statistical significance was analyzed by two-
sided ANOVA and Bonferroni post hoc multiple comparison test. 
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Similar to the effects seen for niclosamide, increasing concentrations of calcimycin also 
inhibited S100A4 mRNA expression in a concentration-dependent manner (Fig. 4.2B). 
A slight reduction of the S100A4 mRNA level to about 60 % of the solvent-treated 
control was already seen when HCT116 cells were treated with 0.3 µM to 0.8 µM 
calcimycin. However, concentrations of 1 µM calcimycin or higher significantly 
restricted the S100A4 mRNA level to less than 30 % of the solvent-treated control. 
Additionally, treatment with 1 µM or higher concentrations of calcimycin led to a clearly 
reduced S100A4 protein expression.  
For further experiments a drug concentration with a minimal effect on cell viability and a 
maximized inhibitory effect on S100A4 expression had to be selected. A concentration 
of 1 µM niclosamide or calcimycin was sufficient to restrict S100A4 expression to less 
than 50 % of the solvent-treated control. Moreover, at that concentration niclosamide 
and calcimycin treatment assured cell viability to be less affected. Therefore, the small 
molecules were used at a concentration of 1 µM for all further experiments.  
 
4.2.2. Inhibition of S100A4 expression is time-dependent 
With the applicable concentration evaluated for niclosamide and calcimycin the time 
dependency of the inhibitory effect on the S100A4 expression caused by the small 
molecules was analyzed. After 18 h exposure of HCT116 cells to a single dose of 1 µM 
of niclosamide, the S100A4 mRNA was significantly reduced to less than 50 % of the 
solvent-treated control (Fig. 4.3A). This reduction was maintained after 24 h before the 
S100A4 expression recovered and reached its starting level after 48 h. A single dose of 
1 µM of niclosamide did also reduce the S100A4 protein expression after 24 h, an 
effect that was abolished after 30-48 h. To achieve a constant decrease of S100A4 
expression, serial treatment of HCT116 cells with 1 µM niclosamide every 24 h was 
applied (Fig. 4.3B). Thereby, the S100A4 mRNA and protein levels were reduced to 
about 50 % of solvent-treated control cells for at least three consecutive days.  
Analysis of the kinetics underlying calcimycin-mediated inhibition of the S100A4 
expression revealed that a single dose of calcimycin reduced the S100A4 expression 
also in a time-dependent manner (Fig. 4.3C). After 6 h treatment of HCT116 cells with 
1 µM of calcimycin, the S100A4 mRNA level was significantly reduced to less than 
70 % of the solvent-treated control. After 12 h, the lowest S100A4 mRNA level was 
reached at about 30 % of the solvent-treated control cells. After 18 h the S100A4 
protein was clearly reduced. In contrast to niclosamide which presented a reversible 





Fig. 4.3 Niclosamide and calcimycin inhibit S100A4 expression in a time-
dependent manner. HCT116 cells were treated with 1 µM niclosamide (A,B) or 
calcimycin (C,D) for the time indicated. S100A4 mRNA and protein was 
analyzed by qRT-PCR and Western blot, respectively. (A) 24 h of niclosamide 
treatment (black bar) reduced S100A4 expression. (B) Treatment with 1 µM 
niclosamide every 24 h constantly reduced S100A4 expression. (C) 18 h to 24 h 
of calcimycin treatment (grey bar) reduced S100A4 expression. (D) A single 
dose of calcimycin constantly inhibited S100A4 expression. Data represent 
mean ± SE (n>3). Statistical significance was analyzed by two-sided ANOVA 
and Bonferroni post hoc multiple comparison test. 
 
Treatment of HCT116 cells with a single dose of 1 µM of calcimycin was sufficient to 
reduce the S100A4 mRNA and protein level to less than 30 % of solvent-treated control 
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cells for at least five consecutive days. Interestingly, the decreased S100A4 protein 
expression induced by the treatment of HCT116 cells with either of the small molecules 
appeared with a 6 h delay relative to the decreased S100A4 mRNA level. 
 
4.2.3. Exogenous expression of S100A4 is not affected by small molecules 
To test if any effect of the small molecules was specific to their inhibition of S100A4 
expression, a cellular model was needed which provided high levels of S100A4 despite 
the treatment with either of the small molecules. Considering that the small molecules 
were shown to inhibit the S100A4 expression by repressing the S100A4-promoter 
activity, it was hypothesized that CMV-promoter-driven S100A4 cDNA could be 
resistant to the inhibitory effect of niclosamide or calcimycin. 
Therefore, HCT116 cells were stably transfected to express CMV-promoter-driven 
S100A4 cDNA or the empty vector as control. As result, HCT116/S100A4 cells had a 
7-fold increased S100A4 mRNA level compared to HCT116/vector cells. Additionally, 
the S100A4 protein level was clearly increased in those cells compared to 
HCT116/vector cells. 
Treatment of HCT116/vector cells with niclosamide reduced the S100A4 mRNA level to 
about 50 % of the solvent-treated control, which was similar to the effect observed in 
HCT116 cells (Fig. 4.4A). In contrast, the exposure of HCT116/S100A4 to niclosamide 
did not result in a significant reduction of the S100A4 mRNA. S100A4 protein 
expression in HCT116/vector cells was decreased when cells were treated with 
niclosamide, but stayed unchanged in niclosamide-treated HCT116/S100A4 cells.  
Similar to niclosamide, the exposure of HCT116/vector cells to calcimycin reduced the 
S100A4 mRNA to less than 30 % of solvent-treated control cells, but had no significant 
effect on the S100A4 mRNA level of HCT116/S100A4 cells (Fig. 4.4B). Further, 
S100A4 protein expression was inhibited upon calcimycin treatment in HCT116/vector 
cells, but not in HCT116/S100A4 cells. 
The vector backbone including an antibiotic resistance entered in HCT116/vector cells 
did not interfere with the inhibitory effect of the small molecules on the S100A4 
expression, since the effects seen in HCT116/vector cells were similar to the effects 
observed in niclosamide- or calcimycin-treated HCT116 cells. In contrast, the 
exogenously overexpressed S100A4 cDNA under the control of a CMV-promoter was 
not targeted by niclosamide or calcimycin treatment since HCT116/S100A4 cells 






Fig. 4.4 Niclosamide and calcimycin do not affect exogenous S100A4 
expression. HCT116 cells were either stably transfected to express CMV-
promoter-driven S100A4 cDNA (HCT116/S100A4) or the empty vector 
(HCT116/vector) as control. Cells were treated with 1 µM niclosamide (A) or 
calcimycin (B) for 24 h and S100A4 mRNA and protein level was analyzed by 
qRT-PCR and Western blot, respectively. (A) Niclosamide reduced S100A4 
expression in HCT116/vector cells, but not in HCT116/S100A4 cells. (B) 
Calcimycin decreased S100A4 expression in HCT116/vector cells, but had no 
effect on the S100A4 expression of HCT116/S100A4 cells. Data represent 
mean ± SE (n>3). Statistical significance was analyzed by Student’s t-test.  
 
 
4.3. Small molecules decrease cell migration, invasion and proliferation 
S100A4 is an abundant protein in the cell, which interacts with a multitude of target 
proteins to drive cellular processes needed for metastasis formation (69). Stein et al. 
had previously shown that S100A4 increased cell migration and invasion of colon 
cancer cells (66). Since niclosamide and calcimycin were found to inhibit S100A4 
expression, the functional consequences on cell migration, invasion and proliferation 
were analyzed.  
 
4.3.1. Small molecules reduce cell migration of colon cancer cells 
Intracellular S100A4 is a major regulator of cell migration which is one of the first 
cellular processes triggering metastasis formation (71, 97). Analysis of cell migration 
revealed that the number of migrated cells did not change in solvent-treated HCT116, 
HCT116/vector and HCT116/S100A4 cells (Fig. 4.5A). However, differences were 
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discovered, when cells were treated with either of the small molecules. 
 
 
Fig. 4.5 Niclosamide and calcimycin inhibit cell migration in an S100A4-
specific manner. (A) HCT116, HCT116/vector and HCT116/S100A4 cells were 
treated with 1 µM niclosamide or calcimycin for 24 h and cell migration was 
measured with the Boyden chamber assay. Both small molecules restricted cell 
migration in HCT116 and HCT116/vector cells, but not in HCT116/S100A4 
cells. Data represent mean ± SE (n>3). Statistical significance was analyzed by 
two-sided ANOVA and Bonferroni post hoc multiple comparison test. (B) 
Directed migration of niclosamide-, calcimycin- or solvent-treated HCT116, 
HCT116/vector and HCT116/S100A4 cells was analyzed by wound healing 
assay. Both small molecules inhibited directed migration of HCT116 or 
HCT116/vector cells, but not of HCT116/S100A4 cells. Microphotographs were 
taken on day 4 with 10x magnification. Assay was performed three times; one 
representative picture for each condition is presented here. 
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In HCT116 cells treated with niclosamide or calcimycin the number of migrated cells 
was reduced to less than 35 % of the solvent-treated HCT116 cells. Cell migration of 
niclosamide- or calcimycin-treated HCT116/vector cells was also reduced to less than 
50 % or even less than 25 % of HCT116 control cells, respectively. In contrast, the 
number of migrated HCT116/S100A4 cells was not significantly changed upon 
treatment with either of the small molecules. Since the S100A4 protein level in those 
cells was not affected by niclosamide or calcimycin, those cells were still able to 
migrate despite treatment with the small molecules. 
Similar effects were seen for directed migration of HCT116, HCT116/vector and 
HCT116/S100A4 cells analyzed by wound healing assay as previously described 
(169). When cells were treated only with solvent, all three cell species were able to 
infiltrate the wound and close it until day 4 (Fig. 4.5B). Treatment of HCT116 and 
HCT116/vector cells with daily doses of 1 µM niclosamide inhibited wound closure until 
day 4. Moreover, a single dose of 1 µM calcimycin given on day 1 also impaired wound 
closure of HCT116 and HCT116/vector cells until day 4. In contrast, HCT116/S100A4 
cells were able to infiltrate the wound and close the gap despite the treatment with 
niclosamide or calcimycin.  
In summary, it can be concluded that the anti-migratory effect of the small molecules 
was due to the specific inhibition of the S100A4 expression, since this effect was 
absent in HCT116/S100A4 cells, which still expressed S100A4 protein despite 
treatment with niclosamide or calcimycin. 
 
4.3.2. Small molecules impair cell invasion 
S100A4 is a major activator of cell invasion which is crucial for tissue infiltration during 
metastasis formation (69, 122, 125). Comparing the cell invasion rate of solvent-treated 
HCT116, HCT116/vector and HCT116/S100A4 cells, no significant difference could be 
detected (Fig. 4.6). However, when HCT116 and HCT116/vector cells were treated 
with niclosamide the number of invaded cells was decreased to less than 50 % of 
HCT116 control cells. Cell invasion of calcimycin-treated HCT116 and HCT116/vector 
cells was inhibited to less than 30 % of the solvent-treated control cells. In contrast, cell 
invasion of HCT116/S100A4 cells was not significantly changed upon treatment of cells 
with either of the small molecules. Thus, the anti-invasive effect of niclosamide or 





Fig. 4.6 Niclosamide and calcimycin inhibit S100A4-induced cell invasion. 
Cell invasion of HCT116, HCT116/vector and HCT116/S100A4 cells was 
analyzed in a Matrigel-coated Boyden chamber assay under the treatment of 
1 µM niclosamide or calcimycin for 24 h. Both small molecules restricted cell 
invasion of HCT116 and HCT116/vector cells, but not of HCT116/S100A4 cells. 
Data represent mean ± SE (n>3). Statistical significance was analyzed by two-
sided ANOVA and Bonferroni post hoc multiple comparison test. 
 
 
4.3.3. Small molecules decrease cell proliferation 
A major characteristic of cancer cells is their increased proliferation rate (36). 
Therefore, the effect of the small molecules on anchorage-dependent proliferation was 
analyzed. Despite their differences on the S100A4 expression level, the proliferation 
rate of solvent-treated HCT116, HCT116/vector and HCT116/S100A4 cells did not 
present significant differences (Fig. 4.7A). Treatment of HCT116 cells with either daily 
doses of niclosamide or a single dose of calcimycin on day 0 resulted in a significantly 
reduced cell proliferation on day 3 (Fig. 4.7B). Similarly, in HCT116/vector cells the 
same treatment inhibited anchorage-dependent cell proliferation (Fig.4.7C). Ectopic 
overexpression of S100A4 did not rescue cell proliferation. Exposure of 
HCT116/S100A4 cells to either of the small molecules restricted cell proliferation to a 
similar intent found in HCT116 and HCT116/vector cells. From those observations it 
could be concluded that the anti-proliferative effect of niclosamide and calcimycin was 






Fig. 4.7 Niclosamide and calcimycin inhibit anchorage-dependent cell 
proliferation. Cell proliferation rate of untreated (A) HCT116, HCT116/vector 
and HCT116/S100A4 cells or HCT116 (B), HCT116/vector (C) and 
HCT116/S100A4 (D) treated either with daily doses of 1 µM niclosamide or with 
a single dose of 1 µM calcimycin was analyzed daily with MTT assay. The 
proliferation rate of untreated HCT116, HCT116/vector and HCT116/S100A4 
cells was not different. Both small molecules decreased cell proliferation of all 
three cell species. Data represent mean ± SD (n=3). Statistical significance ( *, 
P<.05 ) of the difference between control and niclosamide- or calcimycin-treated 
cells was analyzed by two-sided ANOVA and Bonferroni post hoc multiple 
comparison test. 
 
4.3.4. Small molecules arrest colony formation 
The ability to grow in an anchorage-independent manner is a characteristic needed for 
metastatic cells to survive, for instance, in the blood stream during the progress of 
metastasis formation. Anchorage-independent growth was investigated with the colony 
formation assay. Solvent-treated HCT116, HCT116/vector and HCT116/S100A4 cells 
were able to form large, clearly visible colonies within 7 days (Fig. 4.8A). In contrast, 
the size of the colonies formed by these three cell species was severely reduced upon 
niclosamide or calcimycin treatment. Niclosamide treatment further reduced the 
number of colonies to less than 5 % of HCT116 control cells in all three cell species. 
Exposure of HCT116, HCT116/vector and HCT116/S100A4 cells to calcimycin reduced 
even more the number of colonies to less than 3 % of HCT116 control cells (Fig. 4.8B).  
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The inhibition of anchorage-independent cell proliferation was independent on the 
expression level of S100A4, since this effect was also seen in HCT116/S100A4 cells 
that express S100A4 despite the treatment with either of the small molecules. 
 
 
Fig. 4.8 Niclosamide and calcimycin inhibit anchorage-independent cell 
proliferation. Anchorage-independent growth of niclosamide or calcimycin-
treated HCT116, HCT116/vector and HCT116/S100A4 cells was analyzed by 
colony formation assay. (A) Both small molecules reduced the size of HCT116, 
HCT116/vector and HCT116/S100A4 cell colonies. Microphotographs were 
taken on day 7 with 10x and 40x (insets) magnification. Assay was performed 
three times; one representative picture for each condition is presented here. (B) 
Both small molecules were able to reduce the number of HCT116, 
HCT116/vector and HCT116/S100A4 cell colonies. Data represent mean ± SE 
(n>3). Statistical significance was analyzed by two-sided ANOVA and 
Bonferroni post hoc multiple comparison test. 
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4.4. Structural changes on niclosamide reduce its inhibitory efficiency  
The Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, 
NCI, Bethesda, MD, provided niclosamide derivatives which were synthesized by 
adding or removing chemical groups on or from the niclosamide structure as illustrated 
in Fig. 4.9.  
 
Fig. 4.9 Schematic drawing of niclosamide and its derivatives. Schema 
illustrates the comparison of the 2D and 3D structure of niclosamide to the 
structures of its derivatives; added and removed chemical groups were marked 
in red and grey, respectively. Grey clouds surrounding the 3D structure 
represent the van der Waals surface; red and blue indicate negative and 
positive charges, respectively. 
 
The 3D structure prediction for the niclosamide derivatives was different to the 3D 
structure of niclosamide. Moreover, the van der Waals surface energy as predicted by 
MarvinSpace version 5.2.3_1 differed between niclosamide and its derivatives. 
Concluding from these observations, it was questioned how those structural differences 
between niclosamide and its derivatives would influence the inhibition of the S100A4 
expression. To assess this efficiency of niclosamide and its derivates on S100A4 
inhibition, HCT116 cells were treated with either of these compounds at the optimized 
treatment conditions defined for niclosamide. Exposure of HCT116 cells to any of the 
niclosamide derivatives had no significant effect on the S100A4 mRNA expression 
(Fig. 4.10A). In contrast, niclosamide inhibited the S100A4 mRNA level to less than 
50 % of solvent-treated cells. Niclosamide treatment further reduced the S100A4 
protein level, an effect that was not detected when cells were treated with any of the 
niclosamide derivatives. Consistently, cell migration was inhibited only upon 
niclosamide treatment, but not in the presence of any of the six derivatives (Fig. 4.10B). 
In summary, none of the niclosamide derivatives had a stronger inhibitory effect than 
niclosamide on S100A4 expression and S100A4-induced cell motility at the conditions 
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tested. Hence, changes in the structure of niclosamide result in a decrease of its 
efficiency towards S100A4 expression inhibition.  
 
Fig. 4.10 Structural changes on niclosamide abolish its inhibiting function 
on S100A4 expression and S100A4-induced cell motility. HCT116 cells 
were treated with 1 µM niclosamide or with 1 µM of the niclosamide derivatives 
for 24 h and S100A4 expression was analyzed by qRT-PCR and Western blot, 
cell migration was analyzed with the Boyden chamber assay. (A) Niclosamide, 
but not its derivatives, inhibits S100A4 mRNA and protein expression. (B) Cell 
migration is most efficiently inhibited by niclosamide. Data represent mean ± SE 
(n>3). Statistical significance was analyzed by Student’s t-test. 
 
 
4.5. Small molecules interfere with the Wnt pathway 
Both small molecules had a repressing function on the S100A4-promoter activity. 
However, the mechanism by which niclosamide or calcimycin performed this function 
was still to be elucidated. In 2006, Stein et al. described a TCF-binding site in the 
S100A4-promoter and provided evidence that S100A4 is a target gene of the canonical 
Wnt pathway (65). Therefore, it was analyzed if niclosamide or calcimycin might inhibit 
S100A4 expression by interfering with the Wnt pathway. 
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4.5.1. Small molecules inhibit the constitutively active Wnt pathway 
The central player of the Wnt pathway is β-catenin, which is mutated in about 10% 
colon cancers (12, 64). Mutated β-catenin is resistant to proteasomal degradation 
resulting in a constitutively active β-catenin/TCF target gene transcription (38, 47).  
HCT116 cells are heterozygous for a deletion mutation in the β-catenin allele. 
HAB68mut cells are derivatives of HCT116 cells, in which the wildtype allele of β-catenin 
was deleted so that the cells had a constitutively active Wnt pathway (65). On the 
opposite, in HAB92wt cells the mutated β-catenin allele was knocked-out so that the 
cells had wildtype β-catenin only which is not resistant to proteasomal degradation. 
Restriction fragment length polymorphism analysis as described in (65) allowed the 
verification of the β-catenin genotype of HCT116 and its derivative cells (Fig. 4.11) 
 
 
Fig. 4.11 β-catenin genotyping of HCT116 and its derivatives HAB68mut and 
HAB92wt. Restriction fragment length polymorphism analysis was used to 
identify the β-catenin genotype of HCT116, HAB68mut and HAB92wt cells. 
Deletion mutation of the serine 45 added a Bsll restriction site, which was 
absent in the β-catenin wildtype allele. HCT116 are heterozygous bearing a 
wildtype and mutated β-catenin allele, HAB68mut cells were homozygous for 
the deletion mutation. HAB92wt cells were homozygous for the wildtype β-
catenin allele. 
 
Since S100A4 is a β-catenin/TCF target gene, its expression was analyzed in HCT116, 
HAB68mut and HAB92wt cells in the presence of either of the small molecules. 
Treatment of HCT116 and HAB68mut cells with niclosamide reduced the S100A4 mRNA 
level to about 50-60% of solvent-treated HCT116 (Fig 4.12A). Further, niclosamide 
treatment reduced the S100A4 protein expression in these cells. HAB92wt cells 
presented less than 10 % of the S100A4 expression level found in HCT116 cells. This 
weak expression of S100A4 in HAB92wt cells was not significantly changed upon 
niclosamide treatment.  
Consistently, with the S100A4 expression level, cell migration in niclosamide-treated 
HCT116 and HAB68mut cells was significantly reduced to less than 50 % of solvent-
treated HCT116 cells. Interestingly, niclosamide treatment reduced cell migration to the 
level of solvent- or niclosamide treated HAB92wt cells (Fig. 4.12B).  
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Calcimycin reduced the S100A4 mRNA level of HCT116 and HAB68mut cells to about 
30 % of solvent-treated HCT116 cells (Fig 4.12C). S100A4 protein expression in those 
cells was clearly inhibited by calcimycin. Exposure of HCT116, HAB68mut and HAB92wt 
cells to calcimycin inhibited cell migration to less than 30 % of solvent-treated HCT116 
cells (Fig. 4.12D). In summary, both small molecules were able to reduce the S100A4 
expression and S100A4-induced cell migration independent on the β-catenin genotype. 
Thus, niclosamide and calcimycin inhibited β-catenin/TCF target gene transcription 
despite a constitutively active Wnt pathway. 
 
 
Fig. 4.12 Niclosamide and calcimycin inhibit S100A4 expression and 
S100A4-induced cell migration despite a constitutively active Wnt 
pathway. HCT116, HAB68mut and HAB92wt cells were treated with niclosamide 
or calcimycin and S100A4 expression was analyzed by qRT-PCR and Western 
blot. Cell migration was analyzed with the Boyden chamber assay. 
(A) Niclosamide inhibits the S100A4 expression despite mutated β-catenin. 
(B) Cell migration is inhibited in cells with constitutively active Wnt pathway 
upon niclosamide treatment. (C) Calcimycin inhibits S100A4 expression 
independent of the β-catenin genotype. (D) Calcimycin inhibits cell migration 
independent on the β-catenin genotype. Data represent mean ± SE (n=3). 
Statistical significance was analyzed by Student’s t-test. 
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4.5.2. Calcimycin inhibits the β-catenin expression 
To assess the mechanism underlying calcimycin inhibition of S100A4 expression, the 
Wnt pathway activity was analyzed by TOP/FOPflash reporter assay. According to their 
β-catenin genotype, the TOPflash reporter activity was increased in HAB68mut cells and 
reduced in HAB92wt cells to only 30 % of HCT116 cells (Fig. 4.13A). Exposure of 
HCT116 to calcimycin significantly reduced the TOPflash reporter activity to less than 
30 % of solvent-treated HCT116 cells. In HAB68mut and HAB92wt cells calcimycin 
treatment reduced TOPflash reporter activity to less than 15 % of solvent-treated 
HCT116 cells.  
 
Fig 4.13 Calcimycin inhibits the Wnt pathway by interfering with β-catenin 
expression. HCT116, HAB68mut and HAB92wt cells were treated with 1 µM 
calcimycin for 18 h and Wnt pathway activity was determined with 
TOF/FOPflash assay while the expression of β-catenin or β-catenin/TCF target 
genes was analyzed with qRT-PCR and Western blot. (A) Calcimycin inhibited 
Wnt pathway activity in HCT116, HAB68mut andHAB92wt cells. (B) β-catenin 
mRNA and protein expression is reduced upon calcimycin treatment. (C) 
Calcimycin reduced β-catenin/TCF target gene mRNA levels in HCT116 cells. 
Data represent mean ± SE (n=3). Statistical significance was analyzed by 
Student’s t-test. 
 
The extent to which β-catenin/TCF target gene transcription is active is highly 
dependent on the expression level of β-catenin in the cells (47). In solvent-treated 
HCT116, HAB68mut and HAB92wt cells no significant differences in the β-catenin mRNA 
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level were detected (Fig 4.13B). Treatment of those three cell species with calcimycin 
reduced the β-catenin mRNA level to less than 50 % of solvent-treated HCT116 cells. 
Since HAB92wt cells only expressed the wildtype β-catenin protein, which is not 
resistant to proteasomal degradation, the β-catenin protein level in those cells was 
reduced compared to solvent-treated HCT116 and HAB68mut cells. Treatment with 
calcimycin further diminished β-catenin protein expression in all three cell species. 
Reduced β-catenin levels might result in reduced target gene transcription. Thus the 
expression levels of prominent β-catenin/TCF target genes were analyzed such as 
Cyclin D1 (170), c-myc (171) and DKK-1 (60). Consistently, in calcimycin-treated 
HCT116 cells the expression of Cyclin D1, c-myc and DKK-1 was significantly inhibited 
to 35%, 25% and 2% of the solvent-treated control, respectively (Fig 4.13C).  
 
4.5.3. Niclosamide interferes with the β-catenin/TCF-complex 
TOP/FOPflash reporter assay was used to analyze whether niclosamide interfered with 
the Wnt pathway. As it was found for calcimycin, exposure of HCT116, HAB68mut and 
HAB92wt cells to niclosamide reduced the TOPflash reporter activity to less than 50 % 
of solvent-treated HCT116 cells (Fig. 4.14A). Thus, niclosamide inhibited the Wnt 
pathway activity. Consistently, transcription of β-catenin/TCF target genes such as 
Cyclin D1, c-myc and DKK-1 was significantly reduced in niclosamide treated HCT116 
cells (Fig. 4.14B) 
For β-catenin/TCF target gene transcription, β-catenin needs to translocate from the 
cytoplasm to the nucleus (47). Exposure of HCT116 cells to increasing concentrations 
of niclosamide for 18 h did not change the protein level of nuclear β-catenin 
(Fig. 4.14C). Nonetheless, despite the presence of nuclear β-catenin, the TOPflash 
reporter activity was reduced (Fig. 4.14A). To test if niclosamide inhibits the formation 
of the β-catenin/TCF transcription activating complex, electrophoretic mobility shift 
assay (EMSA) was performed. In the same nuclear extract used for determination of 
the β-catenin protein level, biotinylated oligonucleotides which encompassed the T-cell 
factor (TCF)-binding site of the S100A4-promoter were incubated and analyzed by 
EMSA. In solvent-treated HCT116 cells signal shifts were caused by binding of TCF 
and β-catenin/TCF to the oligonucleotides, which is consistent with previous findings 
(65). Exposure of HCT116 cells to increasing concentrations of niclosamide interrupted 
the β-catenin/TCF/oligo complex in a concentration-dependent manner (Fig 4.14C). 
The presence of β-catenin within the complex was verified by complexation with 
monoclonal anti-β-catenin leading to a supershift (Fig 4.14D). No supershift could be 






Fig. 4.14 Niclosamide inhibits the Wnt pathway by interfering with the β-
catenin/TCF-complexation. HCT116, HAB68mut and HAB92wt cells were 
treated with 1 µM niclosamide for 18 h and Wnt pathway activity was analyzed 
by TOP/FOPflash reporter assay. (A) Niclosamide inhibited Wnt pathway 
activity in HCT116, HAB68mut andHAB92wt cells. (B) Niclosamide inhibited β-
catenin/TCF target gene transcription. Data represent mean ± SE (n=3). 
Statistical significance was analyzed by Student’s t-test. Nuclear extracts from 
HCT116 cells treated with indicated niclosamide concentrations for 24 h were 
analyzed with Western blot and EMSA. (C) Increasing concentrations of 
niclosamide had no effect on the nuclear β-catenin protein level, but inhibited 
the β-catenin/TCF complex on biotinylated oligonucleotides which comprised 
the TCF-binding site of the S100A4-promoter. (D) Supershift verified β-catenin 
protein in β-catenin/TCF/oligonucleotide complex. (E) No S100A4-promoter 
fragment could be PCR amplified after treatment of HCT116 cells with 1 µM 
niclosamide for 24 h. For Western blot, EMSA and ChIP data (n>2) one 
representative blot is shown here.  
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Similar results were found with chromatin immunoprecipitation (ChIP) assay 
(Fig. 4.14E). From solvent-treated cell extracts the S100A4-promoter sequence could 
be PCR amplified after β-catenin-immunoprecipitation, as described earlier (65). In 
contrast, no PCR-amplicon was obtained from niclosamide-treated HCT116 cells. 
Further, no PCR product could be detected when control immunoglobulin G was used 
for precipitation or when a fos-promoter sequence was PCR amplified. These results 
indicate that niclosamide treatment inhibited β-catenin/TCF complexation and thereby 
restricted Wnt target gene transcription.   
 
 
4.6. Niclosamide inhibits metastasis formation in colon cancer xenograft mice 
Since niclosamide inhibited the S100A4 expression and S100A4-induced cell migration 
and invasion of colon cancer cells in vitro, the anti-metastatic effects of this small 
molecule inhibitor were determined in xenograft mice. Stein et al. previously described 
that the intrasplenical application of HCT116 cells into xenograft mice was suitable to 
analyze their ability to form liver metastases (65).  
 
4.6.1. Evaluation of an in vivo applicable niclosamide concentration 
For dose-finding experiments in human colon cancer xenograft mice, NODSCID mice 
were intrasplenically injected with HCT116/LUC cells and were intraperitoneally treated 
with daily doses of 6 mg/kg, 12 mg/kg or 24 mg/kg niclosamide or the respective 
amount of solvent in cooperation with PD. Dr. Induna Fichtner (MDC, Berlin, Germany). 
Body weight was measured as a first indicator for toxic adverse effects (172). Body 
weight loss of mice treated with 12 mg/kg or 6 mg/kg niclosamide did not differ from the 
solvent-treated control (Fig. 4.15A).  
In contrast, mice which received daily doses of 24mg/kg niclosamide presented 
increased weight loss until day 24. To evaluate a possible maximum concentration that 
could be applied to mice without toxic adverse effects, niclosamide was 
intraperitoneally applicated at concentrations of 20 mg/kg every 24 h or 15 mg/kg every 
12 h. Analysis of body weight revealed no differences between niclosamide- and 
solvent-treated mice (Fig 4.15B). Thus these concentrations were further used to 






Fig. 4.15 Daily doses of 24 mg/kg niclosamide caused toxic side effects in 
xenograft mice. Indicated concentrations of niclosamide were injected 
intraperitoneally and daily into NODSCID mice bearing an intrasplenal 
HCT116/LUC tumor. Body weight was determined as an indicator for toxic side 
effects. (A) Weight loss in mice treated with 24 mg/kg niclosamide was 
increased compared to solvent-treated control. Data represent mean ± SD (2 
animals/group) (B) No difference in weight loss was observed in solvent or 
niclosamide-treated mice. Data represent mean ± SD (9 animals/group) 
 
 
4.6.2. In vivo metastasis can be visualized by bioluminescence imaging 
Bioluminescence imaging (BLI) presents a non-invasive tool which allows visualizing 
the process of metastasis formation over time (173). To allow tracking of the colon 
cancer cells within the organism, HCT116/LUC cells were used. These cells had an 
endogenously increased level of S100A4 expression as also seen in HCT116 cells, but 
further expressed a CMV-promoter controlled firefly luciferase. This enzyme allows the 
oxidation of D-Luciferin, which leads to the emission of light.  
To monitor the effect of niclosamide on metastasis formation in vivo, HCT116/LUC 
cells were intrasplenically injected into SCID mice and the animals were treated daily 
with 20 mg/kg niclosamide or the respective amount of solvent. A lateral signal became 
visible on day 8 post-transplantation in solvent- and niclosamide-treated mice, which 
was assigned to the spleen (Fig. 4.16A). This spleen tumor signal increased in solvent- 
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and niclosamide-treated mice until it reached a maximum on day 22. In control mice 
ventral imaging revealed a very low signal in the liver region on day 8 indicating that 
liver metastases had formed (Fig. 4.16B). This liver signal became clearly visible until 





Fig. 4.16 Metastasis formation in colon cancer xenograft mice is 
monitored by non-invasive bioluminescence imaging. SCID mice were 
intrasplenically transplanted with HCT116/LUC cells. Bioluminescence was 
measured by intraperitoneal application of 150 mg/kg D-Luciferin and exposure 
for 20 sec in the NightOWL LB 981 system. (A) The lateral signal from the 
spleen tumor is increasing over time in solvent- and niclosamide-treated mice. 
(B) Control mice present a ventral liver metastases signal which is absent in 
niclosamide-treated mice. Data are representative of 4 animals per group. 
 
In situ imaging was performed to confirm the origin of the lateral and ventral signals. 
Dissection of control mice presented liver metastases which were absent in 
niclosamide-treated mice (Fig. 4.17). Since only the HCT116/LUC cells expressed the 
firefly luciferase, bioluminescence imaging could confirm that the expected liver 
metastases were formed by these human colon cancer cells. Imaging of the isolated 
liver and spleen showed that control mice had increased liver metastases. In contrast, 





Fig. 4.17 In situ imaging confirmed the presence or absence of metastasis 
formation in colon cancer xenograft mice. Intrasplenically transplanted 
HCT116/LUC cells SCID xenograft mice were intraperitoneally injected of 
150 mg/kg D-Luciferin, dissected and exposed for 1 sec in the 
NightOWL LB 981 system. In situ imaging and imaging of isolated organs 
confirmed that the signals seen in Fig. 4.16 originated from the spleen tumor 
and liver metastasis. The latter was absent in niclosamide treated mice. Data 
are representative of 4 animals per group. 
 
4.6.3. Niclosamide restricts metastasis formation in mouse xenografts 
Metastasis formation under niclosamide treatment was quantified in cooperation with 
PD. Dr. Induna Fichtner. NODSCID mice bearing an intrasplenical tumor of 
HCT116/LUC cells were treated either daily with 20 mg/kg niclosamide or twice a day 
with 15 mg/kg niclosamide.  
All mice developed a spleen tumor until day 24, which was dissected to analyze the 
S100A4 mRNA levels in the tumor tissues. In niclosamide treated mice the S100A4 
mRNA level in the spleen tumors was significantly reduced to 56-64 % of the S100A4 
expression level found in tumors from solvent-treated mice (Fig. 4.18A). These results 






Fig. 4.18 Niclosamide inhibits metastasis formation in human colon 
cancer xenograft mice. HCT116/LUC cells were intrasplenically transplanted 
into NODSCID mice and mice were treated intraperitoneally with 20 mg/kg 
niclosamide every 24 h or with 15 mg/kg niclosamide every 12 h. The S100A4 
mRNA level in the spleen tumor was determined on day 24 by qRT-PCR. Liver 
metastases were quantified by scoring. (A) Niclosamide treatment inhibited 
S100A4 expression in vivo. Data represent mean ± SE (9 animals/group). 
Statistical significance was analyzed by two-sided ANOVA and Bonferroni post 
hoc multiple comparison test. (B) Niclosamide treatment restricted liver 
metastasis in xenograft mice. (C) Liver metastases were reduced in number 
and size in niclosamide-treated mice. Data represent mean ± SE (9 
animals/group). 
 
In contrast to niclosamide treated mice, in solvent-treated animals large liver 
metastases were found, which were absent in animals from both niclosamide-treated 
groups (Fig. 4.18B). Scoring of the liver metastases including their number and size 
revealed that both niclosamide treatments inhibited liver metastasis formation to less 
than 35 % of solvent-treated mice (Fig. 4.18C). In conclusion, niclosamide inhibited the 






4.7. Relation of the DKK-1 and S100A4 expression in colon cancer cells 
The studies on niclosamide and calcimycin targeting S100A4 expression in colon 
cancer cells emphasized the power of S100A4 to increase cell migration and invasion 
and to drive metastasis formation. Many interaction partners for S100A4 are known 
that explain its metastasis-promoting ability. However, less is known about the 
transcriptional changes that occur upon S100A4 overexpression which might form the 
basis for metastasis formation. Based on microarray data, Stein and colleagues were 
the first to observe that S100A4 overexpression represses the expression of DKK-1, a 
prominent inhibitor of the Wnt pathway. Based on those findings the relation of S100A4 
and DKK-1 expression was analyzed.   
 
4.7.1. DKK-1 and S100A4 expression is inversely correlated in cells with 
mutated or non-mutated β-catenin 
S100A4 and DKK-1 were both described as target genes of the canonical Wnt pathway 
in colon cancer cells (60, 65). Therefore, their expression was analyzed in HCT116 
cells and its derivatives HAB68mut and HAB92wt. The mRNA levels of S100A4 and 
DKK-1 did not significantly differ between HCT116 and HAB68mut cells (Fig. 4.19A). In 
contrast, the S100A4 mRNA level in HAB92wt cells was reduced to about 10% of 
HCT116 cells. Interestingly, HAB92wt cells expressed about 10-fold more DKK-1 mRNA 
compared to HCT116 or HAB68mut cells that expressed mutated β-catenin. Similarly, 
S100A4 protein was high in HCT116 and HAB68mut cells, but clearly lower in HAB92wt 
cells. On the opposite, the amount of secreted DKK-1 protein in HCT116 and HAB68mut 
cells was less than 30% of the amount of secreted DKK-1 found in HAB92wt cells.  
While S100A4 expression was related to the Wnt pathway activity found in HCT116, 





Fig. 4.19 S100A4 and DKK-1 are inversely expressed in cells with mutated 
or wildtype β-catenin. S100A4 and DKK-1 mRNA levels were analyzed by 
qRT-PCR, S100A4 and DKK-1 protein was analyzed by Western blot and 
ELISA, respectively. (A) S100A4 mRNA expression is high in cells with mutated 
β-catenin genotype while DKK-1 mRNA levels are high in cells with wildtype β-
catenin. (C) The S100A4 protein is low in cells with wildtype β-catenin while 
DKK-1 expression is low in cells with mutated β-catenin. Data represent mean ± 
SE (n>3). Statistical significance was analyzed by two-sided ANOVA and 
Bonferroni post hoc multiple comparison test. 
 
4.7.2. DKK-1 and S100A4 expression is negatively correlated in human colon 
cancer cell lines. 
The inverse expression of S100A4 and DKK-1 found in HCT116 and its derivative cells 
was further investigated in a set of 13 colon cancer cell lines. In comparison to HCT116 
cells the S100A4 mRNA levels in SW620, LS174T Colo205 and SW480 cells was at 
least 2.5-fold more than in HCT116 cells. Further these cells presented very low levels 
of DKK-1 mRNA (Fig. 4.20A). In contrast, HCT15, Lovo, HT29, HAB92wt and Caco-2 
cells presented at least 2.5-fold higher levels of DKK-1 and very low levels of S100A4 







Fig. 4.20 S100A4 and DKK-1 are inversely expressed in colon cancer cell 
lines. In a set of 13 colon cancer cell lines the mRNA level of S100A4 and 
DKK-1 were analyzed by qRT-PCR. S100A4 and DKK-1 protein was analyzed 
by Western blot and ELISA, respectively. (A) In the 13 colon cancer cell lines 
that expressed increased S100A4 mRNA levels, DKK-1 mRNA was decreased 
and vice versa. Data represent mean ± SE (n>3). Correlation was analyzed by 
non-parametric Spearman correlation test. (B) On the protein level, cell lines in 
which S100A4 protein was high, only low levels of secreted DKK-1 protein could 




Similar results were found on the protein level (Fig. 4.20B). In SW620, LS174T, 
Colo205 and WiDr cells increased levels of S100A4 protein were found and only low 
levels of secreted DKK-1 were detected in those cell lines. In contrast, in HT29, 
HAB92wt and Caco-2 cells secreted DKK-1 protein levels were increased while the 
S100A4 protein was very low. 
In summary, this set of colon cancer cell lines comprised cells that either expressed 
increased S100A4 or increased DKK-1 or both genes were expressed to a low level. 
Surprisingly, none of the cell lines had both genes upregulated. From this result it was 
hypothesized that the expression of either S100A4 or DKK-1 has a repressing function 
on the respective opponent gene. 
 
 
4.8. S100A4 is a negative regulator of DKK-1 expression 
4.8.1. Exogenous overexpression of S100A4 inhibits DKK-1 expression 
If S100A4 had a repressing function on the DKK-1 expression, its exogenous 
overexpression should reduce the mRNA and protein levels of DKK-1. To assess this, 
HAB92wt cells were used, since they had endogenously increased levels of DKK-1. The 
cells were stably transfected to express a CMV-promoter controlled S100A4 cDNA or 
the empty vector as control. HAB92wt cells and its stable transfected derivatives were 
homozygous for the wildtype β-catenin as was shown by RFLP (Fig. 4.21A).  
Analysis of the S100A4 and DKK-1 expression level showed that no significant 
difference between HAB92wt and empty vector-transfected HAB92wt cells was found 
neither for S100A4 nor DKK-1 (Fig. 4.21B). Hence, the vector backbone itself did not 
interfere. In contrast, the S100A4 mRNA level of S100A4 cDNA-transfected cells was 
15-fold increased compared to the level of HAB92wt cells. Moreover, the DKK-1 mRNA 
level in those cells was more than 2.5-fold decreased compared to non- or vector-
transfected HAB92wt cells. 
S100A4 protein levels were clearly increased in S100A4-transfected HAB92wt cells 
compared to the non- or vector-transfected control (Fig. 4.21C). However, the amount 
of secreted DKK-1 protein was significantly reduced in those cells. In summary 





Fig. 4.21 Exogenous overexpression of S100A4 inhibits DKK-1 
expression. In HAB92wt cells the β-catenin genotype was analyzed by RFLP. 
S100A4 and DKK-1 mRNA levels were analyzed by qRT-PCR. S100A4 and 
DKK-1 protein was analyzed by Western blot and ELISA, respectively. (A) 
HAB92wt cells and its stable transfected derivatives were homozygous for 
wildtype β-catenin. (B) Overexpression of S100A4 cDNA increased S100A4, 
but decreased the DKK-1 mRNA level. (C) Overexpression of S100A4 cDNA 
increased the S100A4 protein amount, but repressed the amount of secreted 
DKK-1 protein. Data represent mean ± SE (n>3). Statistical significance was 




4.8.2. Reduction of S100A4 expression recovers DKK-1 expression 
Since S100A4 overexpression inhibited DKK-1 expression, it was hypothesized that 
reduced S100A4 expression would result in increased DKK-1 mRNA and protein 
levels. To address this, HCT116 cells were used since those cells presented an 
increased endogenous S100A4 expression level. HCT116 cells were either stably 
transfected to express a non-targeting control shRNA or a shRNA targeting the 
S100A4 mRNA. Stable transfection did not interfere with the β-catenin genotype 
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(Fig 4.22A). No significant differences in the expression level of S100A4 and DKK-1 
were detected in HCT116 cells treated with non-targeting control shRNA compared to 
the non-transfected HCT116 cells (Fig. 4.22B). In contrast, transfection with shRNA 
targeting the S100A4 mRNA reduced the latter to less than 50 % of HCT116 cells. 
Furthermore, in those cells, the DKK-1 mRNA level was 2-fold increased compared to 
HCT116 cells.  
 
Fig. 4.22 Inhibition of endogenous S100A4 recovers DKK-1 expression. In 
HCT116 cells the β-catenin genotype was analyzed by RFLP. S100A4 and 
DKK-1 mRNA levels were analyzed by qRT-PCR. S100A4 and DKK-1 protein 
was analyzed by Western blot and ELISA, respectively. (A) HCT116 cells and 
its derivatives were heterozygous for wildtype and mutated β-catenin. (B) 
Transfection of HCT116 cells with non-targeting shRNA (shcon) had no effect 
on S100A4 and DKK-1 expression. Transfection with a shRNA targeting 
S100A4 expression decreased S100A4 and increased DKK-1 mRNA levels. 
Data represent mean ± SE (n>3). Statistical significance was analyzed by two-
sided ANOVA and Bonferroni post hoc multiple comparison test. 
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4.9. DKK-1 inhibits S100A4 expression 
Since S100A4 inhibits DKK-1 expression, the functional consequences of this gene 
regulation were further analyzed. Secreted DKK-1 was found to interact with the 
membranous co-receptor LRP-5/6 and thereby sequesters it from the Wnt-frizzled 
signaling complex (53, 58). Thus, DKK-1 inhibits the Wnt pathway.  
Transfection of HAB92wt cells with shRNA targeting DKK-1 mRNA decreased the DKK-
1 mRNA level to less than 10 % of HAB92wt cells which were transfected with a non-
targeting control shRNA (Fig. 4.23A). Upon decreased DKK-1 expression, the S100A4 
mRNA level was 4-fold increased in those cells compared to control shRNA-transfected 
cells.  
 
Fig. 4.23 DKK-1 is a negative regulator of S100A4 expression. S100A4 and 
DKK-1 mRNA levels were analyzed by qRT-PCR. S100A4 and DKK-1 protein 
was analyzed by Western blot and ELISA, respectively. (A) HAB92wt stably 
transfected with non-targeting (shcon) or DKK-1 targeting shRNA. Upon 
reduction of DKK-1 mRNA levels with DKK-1 targeting shRNA, the S100A4 
expression is increased. (B) Transfection of HAB92wt cells with DKK-1 targeting 
shRNA reduced the amount of secreted DKK-1 protein and increased the 
expression of S100A4 protein. Data represent mean ± SE (n=3). Statistical 
significance was analyzed by Student’s t-test. (C) Treatment of HCT116 cells 
with 25 or 100 ng/ml recombinant DKK-1 (rDKK-1) protein inhibits the S100A4 
mRNA level concentration-dependently. Data represent mean ± SE (n>2). 
Statistical significance was analyzed by two-sided ANOVA and Bonferroni post 





Compared to control-shRNA transfected cells, the amount of secreted DKK-1 protein 
was significantly reduced in HAB92wt cells which were transfected with DKK-1 targeting 
shRNA (Fig. 4.23B). Further, in those cells the S100A4 protein level was clearly 
increased. 
Since DKK-1 is expected to act extracellularly, recombinant DKK-1 protein was added 
onto HCT116 cells and the S100A4 mRNA expression was analyzed. Treatment of 
HCT116 cells with 25 or 100 ng/ml recombinant DKK-1 protein for 24 h reduced the 
S100A4 mRNA level in a concentration-dependent manner (Fig 4.23C). These results 





The multidisciplinary clinical management of metastatic colon cancer has improved the 
five-year survival of patients in recent years (174). However, colon cancer is still the 
second most frequent cause of cancer related death which, in most cases, is provoked 
by the formation of metastases (4, 175, 176). In this respect, the understanding of the 
molecular mechanisms regulating the process of colon cancer metastasis is 
indispensable for the development of anti-metastatic treatments.  
The last two decades of translational research indicated that the calcium-binding 
protein S100A4 is directly involved in cellular processes such as migration, invasion, 
adhesion and angiogenesis, all of which are fundamental to metastasis formation (69, 
71). Many interaction partners of S100A4 were described to promote its function as 
metastasis mediator whereas the knowledge of gene regulation that follows S100A4 
overexpression is very poor. Moreover, there are very few studies on the inhibition of 
S100A4 function. Hence, the inhibition of S100A4 provides a promising therapeutic 
strategy for metastatic intervention (159, 177) while more profound knowledge is 
needed.  
Therefore this study investigated two novel inhibitors for S100A4 transcription in colon 
cancer cells which interfere with a constitutively active Wnt pathway, thereby inhibiting 
S100A4 expression. Reduced S100A4 levels further impaired S100A4-induced cell 
migration and invasion in vitro and metastasis formation in vivo. Moreover, the study 
provides evidence that S100A4 forms a positive feedback loop in the Wnt pathway via 
downregulation of DKK-1 which broadens our understanding for the molecular 
mechanism underlying S100A4-induced colon cancer metastasis. 
 
 
5.1. Inhibition of S100A4 transcription inhibits S100A4-induced cell motility 
5.1.1. Small molecules inhibit S100A4 expression 
Based-on the high throughput screening performed by Walther, Stein and colleagues, 
the anti-helmintic niclosamide and the antibiotic calcimycin inhibited S100A4-promoter 
activity suggesting that both compounds would interfere with S100A4 transcription. 
Consistently, it was shown in this study that both small molecules reduced S100A4 
expression in colon cancer cells dependent on the drug concentration and time of 
treatment. For calcimycin these findings are supported by a study performed in mouse 
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mammary adenocarcinoma cells as well as in human monocytes and lymphocytes in 
which calcimycin was shown to reduce the levels of S100A4 mRNA (178).  
In contrast to the constant S100A4 inhibition observed upon a single dose of 
calcimycin, the inhibition of S100A4 expression by niclosamide was reversible. The 
effect of a single dose of niclosamide to reduce S100A4 mRNA and protein was 
confined to a 12 h time frame, which could be overcome by serial treatment with daily 
doses of niclosamide. Niclosamide is an anti-helmintic drug which can be hydrolytically 
cleaved by cells of the gastrointestinal tract which results in a bioavailability of 10% 
when applied orally (179-181). Metabolism of niclosamide leads to changes in the 
niclosamide structure which might hinder its target binding ability. In this study, 
niclosamide derivatives were analyzed showing that changes on the niclosamide 
structure severely reduced its efficiency on S100A4 expression inhibition. Besides the 
fact that structural changes of niclosamide led to decreased activity, also the loss of 
solubility within aqueous solution rendered some derivatives with no effect on S100A4 
expression.  
In contrast to the endogenous S100A4 expression in colon cancer cells which was 
inhibited by niclosamide or calcimycin, both small molecules did not affect exogenously 
overexpressed S100A4 levels. This finding is consistent with the fact that both small 
molecules repressed the activity of the S100A4-promoter which leads to the reduction 
of S100A4 mRNA and protein. Exogenously overexpressed S100A4 was controlled by 
a CMV-promoter, which was resistant to the inhibitory mechanism induced by either 
niclosamide or calcimycin. Thus, these cells expressed S100A4 mRNA and protein 
despite the presence of either of the small molecules. 
 
5.1.2. Small molecules restrict S100A4-induced cell motility 
Reduction of S100A4 expression in colon cancer cells mediated by niclosamide or 
calcimycin inhibited cell motility including cell migration, wound healing and cell 
invasion. S100A4 is a major regulator of cell migration (65, 69, 98). Knockdown of 
S100A4 mRNA in RNAi experiments was shown to reduce the ability of cells to 
migrate (124, 131). S100A4 protein is found at the leading edge of migrating cells were 
it mobilizes myosin II-A and enhances directed migration (98). Reduced levels of 
S100A4 protein due to treatment with niclosamide or calcimycin might thus, for 
instance, sequester S100A4 protein from its interaction with myosin II-A. Thereby, cell 
migration would be impaired. Being consistent with this expectation, this study showed 
that the overall migration rate as well as directed migration was inhibited by 
niclosamide or calcimycin treatment.  
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In contrast, both small molecules were unable to suppress cell migration in colon 
cancer cells that exogenously overexpressed S100A4. In those cells, S100A4 
expression was still increased despite the treatment with either of the small molecules, 
which allowed S100A4 to interact with its manifold partner proteins and transcriptional 
targets to promote cell migration. Vice versa, these observations provide clear 
evidence that the anti-migratory effect of niclosamide and calcimycin is specific to their 
ability to inhibit S100A4 expression. 
S100A4 protein drives metastasis by interaction with a multitude of partner-proteins. 
This interaction is mostly dependent on calcium ions (160). Calcimycin is an 
ionophorous, polyether antibiotic isolated from Streptomyces chartreusensis. It 
facilitates the transport of divalent cations across the membrane which renders 
calcimycin an useful tool to study calcium-signaling (182). Since calcimycin elevates 
intracellular calcium levels (183), one would expect that it increases the S100A4 
protein activity. In contrast to this, the results presented above did not indicate an 
increased migratory or invasive phenotype in calcimycin-treated cells exogenously 
overexpressing S100A4. However, exogenous overexpression of S100A4 in untreated 
colon cancer cells did also hardly increase cell migration. This implies that the 
endogenous level of S100A4 already triggered migration to a maximum rate which 
could not be further stimulated by more S100A4 protein. Thus, it cannot be completely 
ruled out that calcimycin caused an increased S100A4 protein activity. Nonetheless, 
the results presented here definitely show that reducing the overall expression level of 
S100A4 with calcimycin significantly inhibits cell motility.  
In this study, cell invasion through a layer of Matrigel simulating the extracellular matrix 
was inhibited upon treatment with either of the small molecules. S100A4 is a well 
known inducer of cell invasion (144, 184). S100A4 can access the intercellular space 
from where it interacts with receptors as RAGE or EGFR (114, 119). Receptor binding 
induces the expression of matrix metalloproteinases such as MMP-2, -9 or -13 which 
allows enhanced degradation of the extracellular matrix, and enables cell invasion into 
the neighboring tissue (119, 123, 125). Inhibition of S100A4 expression by RNA 
interference or overexpression of endogenous inhibitors such as PLA2G2A 
phospholipase or interferon-γ (IFN-γ) was shown to reduce cell invasiveness (73, 185, 
186). In consistency to these earlier results, the inhibition of S100A4 transcription with 
niclosamide or calcimycin reduced the amount of overall S100A4 protein, which 
impaired its ability to induce cell invasion. Interestingly, the anti-invasive effect of 
niclosamide or calcimycin could be overcome by ectopic overexpression of S100A4, 
suggesting that the anti-invasive effect of the small molecules was caused by the 
downregulation of S100A4 expression. These observations again emphasize the 
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central role of S100A4 in cell motility which is the basis for the development of colon 
cancer metastasis.  
 
 
5.2. The small molecules inhibit colon cancer cell proliferation 
Treatment of colon cancer cells with niclosamide or calcimycin inhibited anchorage-
dependent and –independent cell proliferation. Knockdown of S100A4 mRNA levels 
with shRNA was shown to inhibit cell proliferation in vitro and to reduce tumor growth 
and metastasis in vivo (187). Moreover, shRNA knockdown of S100A4 increased the 
occurrence of apoptosis in gastric cancer cells and resulted in a G2/M arrest of 
pancreatic cancer cells (131, 188). In fact, the reduction of S100A4 expression in colon 
cancer cells following the treatment with niclosamide or calcimycin was accompanied 
by a simultaneous reduction in cell proliferation and colony formation. However, these 
two effects seemed to be independent of the S100A4 expression level, since ectopic 
overexpression of S100A4 could not rescue cell proliferation.  
Recently, several studies reported anti-proliferative effects of niclosamide in other cell 
systems describing mechanisms that might be applicable to the findings of presented 
by the study at hand (189-191). For instance, in acute myelogenous leukemia cells 
niclosamide inhibits NF-κB signaling which results in the generation of reactive oxygen 
species followed by apoptosis (189). In the present study with colon cancer cells, 
niclosamide and calcimycin were shown to inhibit, besides S100A4, the expression of 
other β-catenin/TCF target genes such as Cyclin D1 and c-myc. Both genes are known 
oncogenes and their overexpression causes increased cell proliferation (170, 171). 
Moreover, inhibition of Cyclin D1 and c-myc expression by shRNA-mediated 
knockdown of β-catenin levels was previously shown to result in reduced cell 
proliferation rates in colon cancer cells (192). Considering that exogenous 
overexpression of S100A4 was ineffective in overcoming the anti-proliferative effect of 
niclosamide or calcimycin, it is plausible to assume that this effect might rather be 
caused by the reduced Cyclin D1 and c-myc levels.  
 
 
5.3. Both small molecules interfere with constitutively active Wnt pathway  
In this study, niclosamide and calcimycin were shown to repress Wnt pathway activity 
in colon cancer cells. S100A4 is a target gene of the canonical Wnt pathway (65). 
Inhibition of this pathway presents, therefore, a basis for the mechanism by which the 
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two small molecules reduce the S100A4-promoter activity. However, the two small 
molecules targeted the Wnt pathway through different mechanisms.  
 
5.3.1. Calcimycin inhibits β-catenin expression 
Calcimycin treatment reduced the expression level of β-catenin which further impaired 
β-catenin/TCF-mediated target gene transcription. Consequently, prominent target 
genes such as Cyclin D1, c-myc or DKK-1 were reduced by calcimycin treatment. 
Calcimycin was previously described to inhibit Wnt pathway activity in HEK293 cells 
that stably expressed the TOPflash reporter plasmid (183). Upon exposure to 
calcimycin the intrinsic Ca2+ level was increased which activated protein 
kinase C (PKC)-mediated phosphorylation of β-catenin and induced β-catenin 
degradation. In this study, calcimycin treatment reduced the β-catenin protein 
expression also in colon cancer cells. Interestingly, β-catenin protein was reduced even 
in cells which were heterozygous or even homozygous for gain-of-function-mutated β-
catenin. Analysis of the β-catenin mRNA level revealed that calcimycin also inhibited β-
catenin transcription, suggesting that calcimycin inhibits the Wnt pathway activity via 
several mechanisms targeting the expression level of β-catenin.  
 
5.3.2. Niclosamide inhibits β-catenin/TCF complexation 
In contrast to calcimycin, niclosamide treatment did not have any effect on the β-
catenin expression level, but also repressed Wnt pathway activity and consequently 
inhibited β-catenin/TCF target gene transcription of Cyclin D1, c-myc, DKK-1 and 
especially S100A4. Niclosamide was previously shown to inhibit the Wnt pathway in 
osteosarcoma cells (191). However, in those cells niclosamide treatment induced the 
internalization of Wnt receptor frizzled-1 which further resulted in proteasomal 
degradation of β-catenin. In this study, no reduction in β-catenin protein was detected 
upon niclosamide treatment suggesting that in colon cancer cells niclosamide targets 
the Wnt pathway via a different mechanism.  
Translocation of β-catenin to the nucleus is a central step in the Wnt pathway. In the 
nucleus β-catenin binds to transcription factors of the TCF/LEF family to activate target 
gene transcription (47). The present study showed that nuclear β-catenin was 
unaffected by niclosamide treatment in colon cancer cells. However, despite high levels 
of β-catenin in the nucleus under niclosamide treatment, β-catenin/TCF target gene 
transcription was impaired in colon cancer cells. Analysis of the β-catenin/TCF complex 
revealed that with increasing concentrations of niclosamide the interaction between β-
catenin and TCF in complex with the S100A4-promoter was disrupted. On the one 
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hand, niclosamide could cause this complex disruption by directly binding to either β-
catenin or TCF, thereby destabilizing the β-catenin/TCF complex. On the other hand, 
niclosamide could activate other negative regulators interfering with the β-catenin/TCF 
complex such as groucho proteins, which are known competitors for β-catenin on their 
binding site to TCF (193, 194). Indeed, within the scope of this study it was 
demonstrated that niclosamide interferes with the β-catenin/TCF complex on the 
S100A4-promoter, thereby impairing S100A4-transcripion in colon cancer cells.  
 
5.3.3. Niclosamide and calcimycin inhibit constitutively active Wnt pathway 
Mutation of the Wnt pathway is a profound step for colon cancer development leading 
to constitutive pathway activity and target gene expression (37). Most mutations in this 
pathway occur either on the destruction complex regulating the cytoplasmic level of β-
catenin or on β-catenin itself (38). With respect to their therapeutic value, Wnt pathway 
inhibitors should preferably target downstream of β-catenin to switch off the 
constitutively active signaling (159, 195). In this study, HCT116 derivative cells were 
used to analyze the capability of niclosamide or calcimycin to reduce Wnt pathway 
activity under mutated or wildtype conditions. Consistently with findings from Kim et al., 
HAB68mut cells presented increased Wnt pathway activity due to the expression of 
mutated β-catenin and HAB92wt cells represented low levels of Wnt pathway activity, 
since these cells expressed wildtype β-catenin which could be targeted for proteasomal 
degradation (164). Interestingly, niclosamide and calcimycin repressed the Wnt 
pathway activity despite the presence of a gain-of-function mutated β-catenin in 
HAB68mut cells to the level found in HAB92wt cells. Deregulated β-catenin action was 
restricted by both small molecules either by reducing the expression of β-catenin as 
described for calcimycin or by interfering with the β-catenin/TCF transcription complex 
as described for niclosamide. Therefore, both small molecules present immense 




5.4. Specificity and potential adverse effects of the small molecules 
Targeting the S100A4-promoter activity with small molecules, implied to interfere within 
a signal transduction pathway and that this targeting will not be solely restricted to the 
inhibition of S100A4 expression, but will have certain side effects. However, there are 
several advantages of targeting the S100A4-promoter instead of the S100A4 protein 
and of using small molecules instead of RNA interference, for instance,. 
88 
DISCUSSION 
5.4.1. Targeting the S100A4-promoter is most efficient 
S100A4 as a mediator of metastasis represents an excellent target to be applied in 
anti-metastatic therapies (159, 196). The design of an inhibitor that would target 
S100A4 function is hampered by the multitude of S100A4-action which occurs intra- 
and extracellular, as homo-, heterodimer or as oligomer and in a calcium-dependent or 
-independent manner (110, 160). 
One approach targeting the Ca2+-binding ability of S100A4 was recently described by 
Bresnick and colleagues (196, 197). They developed a fluorescent S100A4 protein, 
which increased its fluorescence signal upon Ca2+-binding. High throughput screening 
of FDA-approved drugs revealed phenothiazines to inhibit Ca2+-binding on S100A4 and 
consistently the interaction of S100A4 with myosin II-A . However, inhibition of the 
calcium-binding ability of S100A4 does not target all S100A4 functions. For instance, 
S100A4 was described to interact with liprin β1, annexin II or other S100A4 molecules 
in a calcium-independent manner (89, 115, 121). Indeed, phenothiazines were shown 
to provoke the oligomerisation of S100A4 which would promote the S100A4 oligomer-
induced activation of thrombospondin I and MMP expression leading to angiogenesis 
and invasion, respectively (126, 137, 196). 
Targeting extracellular S100A4 protein function with an S100A4-specific antibody was 
shown to inhibit invasive growth of mouse endothelial cells in vitro and cell proliferation 
and vascularisation of the skin in vivo. However, extracellular application of S100A4-
antibody did not target the intracellular functions of S100A4 (122, 198).  
In this study, niclosamide and calcimycin were used to inhibit the Wnt pathway thereby 
repressing the S100A4-promoter activity. Inhibition of S100A4 transcription reduced the 
overall amount of available S100A4 protein in the cell, which targeted its manifold 
interactions with all partner proteins simultaneously. Consequently, the small molecules 
efficiently inhibited S100A4-induced cell migration as well as cell invasion in vitro, and 
further metastasis formation in vivo.  
 
5.4.2. Advantage of using small molecules to inhibit S100A4 expression 
Small molecules are by definition monomeric or short oligomeric organic compounds 
which due to their low molecular weight of less than 800 Dalton can easily transfer the 
plasma membrane to enter the cytoplasm. Using small molecules for targeting the 
expression of S100A4 had several advantages instead of using other expression 
inhibitors such as RNA interference. For instance, the finding of the optimal dose, in 
terms of a maximal degree of S100A4 expression inhibition with the lowest 
concentration possible, was simplified due to the fast inhibitory effect of both small 
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molecules of less than 24 h. In contrast, using RNA interference the depletion of the 
target gene occurs gradually and in most cases takes more than 24 h which hampers 
the finding of the optimal dose (199). Moreover, the therapeutic use and the systemic 
application to organisms is less well explored for RNA interference and challenged by 
the efficient delivery into the cell (200). In contrast, both small molecules were able to 
induce their inhibitory effect, suggesting that they entered the cell without further 
additives. Systemic niclosamide application further inhibited the S100A4 expression in 
vivo providing the basic evidence for its applicability to treat colon cancer metastasis.  
One major concern in the use of inhibitors, independent of what kind, is the potential 
lack of specificity. In this study, the small molecules targeted the S100A4-promoter 
activity, which, of course, implied targeting within a certain pathway and thereby 
affecting the expression of other genes. Therefore, any effect caused by either of the 
small molecules needed to be analyzed for the specificity of their ability to repress 
S100A4 expression. To address this challenge, a cell system was installed which 
expressed S100A4 also despite the treatment with either of the small molecules. All 
effects observed upon niclosamide or calcimycin treatment which were rescued upon 
S100A4 expression were specific to the inhibitor-mediated reduction of S100A4 
expression. For instance, niclosamide and calcimycin were identified as Wnt pathway 
inhibitors. Beside S100A4 also the tyrosine kinase Met is a prominent mediator of 
metastasis and a target gene of Wnt signaling in colon cancer cells (201). Inhibition of 
cell motility by the small molecules could also have been caused by downregulation of 
Met. However, inhibition of cell motility by calcimycin or niclosamide was completely 
rescued by S100A4 overexpression. Thus, the anti-migratory and anti-invasive effects 
of the small molecules were specific to their ability to reduce S100A4 expression. In 
contrast, niclosamide and calcimycin inhibited cell proliferation, which was independent 
on their ability to inhibit S100A4 expression. However, within the scope of an efficient 




5.5. Niclosamide as novel anti-metastatic treatment 
5.5.1. Niclosamide is a favorable inhibitor to be applied in vivo 
The Wnt pathway is the most central pathway in the development of colon cancer. 
However, under non-pathologic conditions it is needed for the homeostasis of the colon 
epithelium (11, 12, 55). Systemic interference with this pathway bears the risk of 
adverse effects for instance on the healthy colon epithelium (195).  
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In this study, both small molecules were active on S100A4 expression inhibition at 
concentrations that did not affect cell viability in general. Moreover, both small 
molecules did not completely switch off the Wnt pathway, but rather reduced its activity 
to a basal level found in HAB-92wt cells. These cells bore no Wnt pathway mutation and 
therefore represented a wildtype level of Wnt pathway activity.  
In contrast to niclosamide, which did not interfere with the β-catenin expression level, 
calcimycin inhibited β-catenin transcription. Beside its function as transcription 
regulator, β-catenin together with E-cadherin plays a role in the formation of cell 
adhesion contacts (49). Deregulation of cell adhesion by calcimycin treatment could 
inhibit the metastatic cell to enter the secondary tumor site. However, also the focal 
contacts in healthy tissue could be destroyed which might also favor metastasis 
formation. Thus, the systemic application of calcimycin might cause adverse effects on 
the colon tissue.  
Niclosamide as a FDA-approved drug is already used in the clinic to treat helmintosis in 
human and veterinary medicine. When taken orally niclosamide proved to have only 
slight adverse effects in humans and mice such as diarrhea or skin rash (202-204). 
Therefore, niclosamide rather than calcimycin was chosen to be further applied in 
xenograft mice to defeat S100A4-induced metastasis. Consistently, daily systemic 
treatment of xenograft mice with niclosamide caused no visible toxic side effects during 
the period of investigation of 24 days.  
 
5.5.2. Non-invasive bioluminescence imaging visualized S100A4-induced 
metastasis 
Experimental metastasis in immune-deficient mice has proven to be suitable to 
evaluate the metastatic potential of a certain population of cells (35, 65, 205). However, 
the problem of this in vivo application is the determination of the optimal endpoint. The 
optimal endpoint should be neither too early, otherwise metastases might not be 
visible, nor too late to reduce the suffering of the animal and avoid tumor burden-
caused death.  
In this study the endpoint decisions were optimized by using non-invasive 
bioluminescence imaging to follow the process of S100A4-induced metastasis of 
human colon cancer cells in vivo. Bioluminescence imaging is based on the detection 
of photons, which are excised as a side product in an enzymatic reaction. In this study, 
firefly luciferase was applied, which stems from the North American firefly Photinus 
pyralis and catalyzes the oxidation of luciferin under ATP consumption and emission of 
light. Monitoring of intrasplenically implanted human colon cancer xenograft mice 
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revealed an increased bioluminescence signal in the spleen region and, until day 24, a 
liver signal in the solvent-treated control mice.  
Many non-invasive imaging modalities besides bioluminescence have been described 
for their use in small animals, such as magnetic resonance imaging, computed 
tomography, positron emission tomography and fluorescence imaging (206). However, 
bioluminescence bears several advantages compared to other modalities such as its 
ease of application and its high-sensitivity. It is free from exposure to radiation and 
provides a relative measure of signal to amount of viable cells. Moreover, mammalian 
tissue has only a very low intrinsic bioluminescence, which therefore generates an 
optimized signal-to-noise ratio (207). The main limitation of bioluminescence is its 
anatomic resolution which is restricted to the organ level. However, bioluminescence 
imaging is useful to detect lung or liver metastases from a multitude of cancer cells, 
such as breast and sarcoma, or prostate, respectively (173, 208-211). In this study, the 
bioluminescence signal from liver metastases formed by colon cancer cells appeared 
already on day 6 as a weak signal in the liver region of solvent-treated control mice. 
Due to its high sensitivity bioluminescence imaging detected even micrometastases 
which may be not visible at that stage. The liver metastasis signal increased over time 
until day 24 and autopsy further confirmed the presence of liver metastases in solvent-
treated xenografts. In conclusion, the non-invasive bioluminescence imaging is a 
helpful tool to monitor the process of S100A4-induced metastasis, and to test potential 
anti-metastatic drugs such as niclosamide.  
 
5.5.3. Intrasplenic xenograft model revealed anti-metastatic function of 
niclosamide  
Niclosamide inhibited the formation of liver metastases in colon cancer xenografts. The 
experimental metastasis model was based on intrasplenic injection of colon cancer 
cells into immune-deficient mice. The spleen is intensively blooded which allows 
intrasplenically injected cells to easily enter the blood circulation (212). Consequently, 
the intrasplenic model does not represent the whole process of metastasis formation 
since it excludes the processes of dissemination from the tumor tissue and invasion of 
the blood circulation (213).  
Metastasis formation starts with the local tumor from which cells invade the vascular 
and lymphatic system, circulate and finally extravasate into the foreign tissue of the 
target organ (28). The entire metastatic cascade is simulated in orthotopic transplanted 
xenograft mice. However, the orthotopic model has several disadvantages, beginning 
with the time-consuming and not always successful surgical set up including a 
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subcutaneous grown tumor which will be sliced and transplanted into the cecum (214). 
Only in 50 % of successful transplanted mice the tumor metastasizes to the lymph 
nodes and very rarely to the liver (213, 214). Further, in most cases the tumor burden 
causes death before liver metastases might become visible (215). 
The appropriate model to study human cancer metastasis needs to fulfill two 
requirements which are based on the ‘seed and soil’ theory (28, 205). Firstly, it must 
include metastatic cells which performed EMT, are able to survive under non-adherent 
conditions and to invade the foreign tissue. Secondly, it must provide tumor growth in 
the targeting organ tissue, which can then be inhibited by potential anti-metastatic 
drugs. In this study, the intrasplenic model used fulfilled both requirements including 
S100A4-overexpressing cells, which presented increased cell motility, and their 
formation of liver metastases. Thus, intrasplenic injection was efficient to analyze the 
anti-metastatic potential of niclosamide, although it only simulated the final processes 
of metastasis formation. 
In xenograft mice, niclosamide treatment reduced the S100A4 expression level in colon 
tumor cells. Furthermore, it restricted the number and size of metastases. However, in 
some niclosamide-treated mice, micrometastases were still found. Reasons for that 
may lie in the concentration of niclosamide or its metabolism. However, a third 
restriction was the time of treatment. The treatment with niclosamide started 24h after 
cells were transplanted, meaning that the cells had at least 24h to circulate in the blood 
and further 24h until niclosamide inhibited S100A4 protein expression. These 
rationales indicate that the micrometastases found could have been an artifact of the 
xenograft model. Nevertheless, the study definitely provides evidence that by inhibiting 
S100A4-expression, niclosamide impaired the metastatic steps of cell extravasation 
and invasion into the foreign tissue as well as restricted the proliferation of metastases 
in vivo.  
 
5.5.4. Niclosamide as anti-metastatic drug for colon cancer patients 
This study provides evidence that niclosamide inhibits S100A4-induced cell motility in 
vitro and metastasis formation and outgrowth in xenograft mice. Based on these 
results, the application of niclosamide is suggested in the management and treatment 
of colon cancer patients. S100A4 expression in tumors from colon cancer patients was 
shown to be prognostic for the development of metastases (34, 65). Moreover, studies 
performed by Stein and colleagues show that the level of free circulating S100A4 
mRNA in the blood of colon cancer patients is specific and sensitive to predict the 
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occurrence of metastases (158). The prognostic value of S100A4 therefore allows 
identifying colon cancer patients which are at high risk to form metastases.  
The majority of colon cancer patients are diagnosed with a colon tumor before 
detectable metastases have formed, and about 20% of those patients will develop 
metachronous metastasis within five years (216, 217). In a treatment scenario, suitable 
patients could be identified for high S100A4 expression either post-tumor-resection via 
immunohistology or RT-PCR or even pre-tumor-resection via blood analysis. In 
patients with increased S100A4 levels, niclosamide treatment could be of immense 
value to restrict colon cancer metastasis.  
To discuss the potential efficiency of niclosamide to successfully treat colon cancer 
patients, the time point of metastatic seed is of particular interest. As discussed in the 
introduction, there are two models for the origin of metastasis: the concurrent model 
and the sequential model. In the sequential model, the metastatic cells stem from the 
late carcinoma, which is based on the observation that mutations of the late carcinoma 
are also found in the respective metastasis (23). In this scenario, patients who might 
develop metachronous metastases could be treated with niclosamide as described 
above. 
In contrast, the concurrent model describes metastatic dissemination to occur early in 
tumor development, planting metastatic seeds which can persist in a dormant state. 
Activation of the latter will give rise to metastasis even after the resection of the primary 
tumor (218, 219). In this scenario, one might think that niclosamide treatment after 
tumor resection might be too late, since metastases could have already formed at the 
time of diagnosis. The model was based on the observation that even years after tumor 
resection metastases can form (32, 218). However, those metastases might not arise 
from dormant cells, but rather from tumor cells that were shedded during surgical 
resection (220). This is in line with the observation that the amount of circulating tumor 
cells increased intraoparatively dependent on the method of surgery (221). 
Nevertheless, 15-25% of colon cancer patients are diagnosed with synchronous 
metastasis (216). These patients might also be eligible for niclosamide treatment, given 
their tumor expressed increased levels of S100A4. In the intrasplenic model 
niclosamide did not only inhibit the extravasation and invasion of cancer metastasis, 
but also the metastatic growth of cells which entered the liver within the first 48 h until 
the niclosamide effect took place. Thus, niclosamide treatment of colon cancer patients 
with synchronous metastasis could reduce their metastatic load and promote their 
eligibility for liver metastasis resection (222).  
Current treatment conditions of colon cancer patients with synchronous or 
metachronous liver metastases are colonic tumor resection along with 
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hepatoectomie (174, 222). In most cases surgical resection is accompanied by 
chemotherapy, such as 5-fluoruracil/leucovorin, irinotecan or oxaliplatin, mostly 
targeting at the increased proliferation rate of cancer cells (223). In the management of 
colon cancer metastasis, however, novel drugs are needed that target at the metastatic 
potential of cells, since metastatic dissemination is the major cause for cancer death. In 
this respect, niclosamide presents substantial potential to be applied as adjuvant 
chemotherapy to tumor and liver metastasis resection. 
 
 
5.6. The inhibitor of the inhibitor – S100A4 and DKK-1 
Negative correlation of gene expression is a first indicator to identify antagonists. In this 
study S100A4 and DKK-1 expression was negatively correlated. In a set of 13 colon 
cancer cell lines both genes were inversely expressed on the mRNA as well as on the 
protein level. Thus, the study presents a novel mechanism of a positive feedback loop 
in the Wnt pathway formed by S100A4 and DKK-1.  
 
5.6.1. S100A4 inhibits DKK-1 expression 
In this study, colon cancer cells with non-mutated β-catenin expressed significantly 
higher levels of DKK-1 mRNA and protein than cells with mutated β-catenin. DKK-1-
promoter reporter assays revealed that promoter activity was inducible by β-catenin 
and TCF-4 leading to the conclusion that in colon cancer cells DKK-1 is a β-
catenin/TCF target gene (60). In this case one would expect DKK-1 to be upregulated 
in cells with mutated β-catenin, which was not the case in this study. However, the 
DKK-1 expression in colon tumor tissue is regulated downwards, but increased in 
normal colon epithelium. This is consistent with the observations obtained from the cell 
system where cells with mutated β-catenin, simulating the tumor tissue, expressed 
reduced levels of DKK-1 and cells with wildtype β-catenin as it is found in normal colon 
epithelium expressed high levels of DKK-1 mRNA and protein (14, 60). These 
observations suggest that DKK-1 expression in colon cells is regulated via a second 
mechanism apart from the β-catenin/TCF complex.  
In colon cancer cells with mutated β-catenin the S100A4 expression was increased 
accompanied by high Wnt pathway activity. In contrast, in colon cancer cells with non-
mutated β-catenin the S100A4 expression was hardly detectable and Wnt pathway 
activity was low. These cell line based observations are consistent with findings in 
tumor tissue of colon cancer patients, in which S100A4 expression and Wnt pathway 
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activity are increased (48, 65). On the opposite, in normal colon epithelium S100A4 
expression is very low accompanied by low Wnt pathway activity (65, 224). 
Exogenous overexpression of S100A4 in cells with increased DKK-1 levels inhibited 
the expression of DKK-1 mRNA and decreased the amount of secreted and thus 
functional DKK-1 protein. These results indicate that S100A4 is an inhibitor for DKK-1 
expression. Consistently, removal of the inhibitor S100A4 rescued the mRNA 
expression of DKK-1 in cells with mutated β-catenin. A similar gene regulation was 
described for S100A4 and E-cadherin. Several independent studies described their 
negative correlation (85, 87, 88, 225). Moreover S100A4 inhibited BNI3 expression 
thereby inducing chemo-resistance in pancreatic cancer (226). However the 
mechanism of expression inhibition was not yet identified in either case. 
S100A4 protein can translocate to the nucleus and nuclear localization of S100A4 was 
found to be of better prognostic value for the formation of metastasis than cytoplasmic 
S100A4 expression (152, 157). These results indicate a considerable role for S100A4 
in gene regulation. A recent study on chrondrocytes described promoter-binding activity 
of S100A4. Upon sumoylation S100A4 translocated to the nucleus were it bound to the 
promoter-region of MMP-13 and induced target gene transcription (227). Similarly, 
S100A4 could function as a repressor on the DKK-1 promoter. In lung and colon 
cancer, downregulation of DKK-1 and other Wnt antagonists is a frequent event which 
is often accompanied by promoter hypermethylation (14, 228, 229). In a set of 54 colon 
tumors expressing low level of DKK-1, 17% presented DKK-1 promoter 
hypermethylation. Therefore, besides direct transcriptional regulation, S100A4 could 
also induce epigenetic inhibition of DKK-1 expression, a hypothesis that will be 
addressed by further investigations.  
 
5.6.2. DKK-1 is an endogenous inhibitor for S100A4 expression 
Colon cancer cells with non-mutated β-catenin presented high levels of DKK-1 
expression and very low levels of S100A4. Inhibition of DKK-1 expression using 
RNA interference rescued the expression of S100A4 indicating that DKK-1 functioned 
as inhibitor for S100A4 expression. DKK-1 belongs to the group of secreted Wnt 
antagonists. It blocks the canonical Wnt pathway by binding to LRP-5/6, the co-
receptors of the Wnt/frizzled signaling complex (51). Binding of DKK-1 to LRP-6 
sequesters the latter from the Wnt/frizzled signaling complex and induces endocytosis 
of the co-receptor together with the transmembrane protein kremen (57, 59). 
Consequently, the Wnt pathway and its target gene transcription are disabled.  
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In cells with non-mutated β-catenin, DKK-1 overexpression caused the inhibition of β-
catenin/TCF target gene transcription such as S100A4. Consistently, in cells with 
endogenously high levels of S100A4, expression of the latter was inhibited when cells 
were treated with recombinant DKK-1 (rDKK-1) protein. The inhibition was 
concentration-dependent. However, the concentrations used were fairly high. Only the 
lower concentration was physiologically found in chronically inflamed colon epithelium 
of Crohn’s cholitis patients (54). The colon cancer cells used in this study were 
heterozygous for mutated β-catenin, which is resistant to upstream signaling 
processes (195). However, these cells also expressed wildtype β-catenin, which 
responds to active Wnt signaling and its inhibition by rDKK-1. Very high concentrations 
of rDKK-1 were thus able to stimulate wildtype β-catenin degradation to a level that 
could not be compensated by mutated β-catenin, leading to a reduction of S100A4 
expression. A recent study on colon cancer cells reported that 100 ng/ml rDKK-1 
inhibited cell migration and wound healing. Moreover, rDKK-1 inhibited the polarization 
of migrating cells at the leading edge (54). All these functions can be induced by 
S100A4 expression. These observations are consistent with the findings of the present 
study showing that rDKK-1 inhibits S100A4 expression. 
 
 
5.7. The new roles for small molecules, S100A4 and DKK-1 in the Wnt pathway 
In colon cancer the Wnt pathway is the most frequently deregulated pathway leading to 
uncontrolled β-catenin levels in the cells and, thus, to constitutively active β-
catenin/TCF target gene transcription (38, 42, 230). The identification of molecular 
mechanisms influencing this pathway is of great interest in the understanding of colon 
cancer and forms the lead for the development of potential therapies (159, 195).This 
study presents several novel interactions that occur in the Wnt pathway which 
systematically enrich our knowledge on its regulation and the possilities of controlling 
it (Fig. 5.1).  
 
This study provides evidence that S100A4 inhibits DKK-1 expression, which by itself is 
a negative regulator of S100A4 expression (Fig. 5.1A). The ubiquitous protein S100A4 
is a target gene of the Wnt pathway and is a central mediator of metastasis, thereby 
promoting one of the leading causes for colon cancer death. During tumorigenesis 
mutations within the Wnt pathway are initial events leading to S100A4 overexpression 
(37, 65, 231). This study entered a new step to the colon cancer cascade, namely that 
S100A4 overexpression leads to inhibition of the Wnt antagonist DKK-1 function by 
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repressing its expression. By inhibition of its endogenous inhibitor, S100A4 induces a 
positive feedback loop which supports the constitutively active Wnt pathway and thus 
ensures its own expression. This novel regulation within the Wnt pathway further 




Fig. 5.1 Novel regulations in the Wnt pathway. Schematic representation of 
the novel regulations of S100A4 and DKK-1 as well as of the small molecules 
niclosamide and calcimycin in the Wnt pathway. (A) S100A4 inhibits the Wnt 
antagonist DKK-1, thereby forming a positive feedback loop. Loss of 
endogenous inhibitor can be compensated by niclosamide and calcimycin. (B) 
Calcimycin inhibits β-catenin expression, thereby reducing intracellular β-
catenin levels. (C) Niclosamide inhibits the complexation of β-catenin and TCF. 
Thus, both small molecules inhibit S100A4 transcription, thereby restricting cell 
migration and invasion as well as metastasis of colon cancer cells.  
 
 
Loss of the endogenous inhibitor for S100A4 was compensated, in this study, by 
niclosamide and calcimycin, two small molecules which inhibit S100A4 expression 
despite a mutated, and thus constitutively active, Wnt pathway. Wnt pathway inhibition 
by niclosamide and calcimycin occurred with different mechanisms. The antibiotic 
calcimycin disabled constitutive β-catenin/TCF target gene expression by inhibition of 
β-catenin transcription (Fig. 5.1B). By decreasing β-catenin overall levels in the cell, 
calcimycin sequestered the most essential regulator for Wnt signaling induced β-
catenin/TCF target gene transcription. In contrast, the anti-helmintic compound 
niclosamide switched off constitutively active β-catenin/TCF target gene transcription 




Wnt pathway, both small molecules restricted S100A4 transcription in colon cancer 
cells and thus inhibited S100A4-induced cell migration, wound healing and cell 
invasion, all fundamental processes in the course of metastasis formation. Moreover, 
niclosamide significantly inhibited the S100A4 expression in vivo resulting in clearly 
reduced liver metastasis. 
Since metastasis is still the major cause for colon cancer death there is an urgent need 
for anti-metastatic treatment and S100A4, as a mediator of this disease progression, 
provides a potential therapeutic target. This study contributes with fundamental 
evidence for the anti-metastatic potential of small molecules targeting S100A4 
expression which could be beneficial for colon cancer patients at high risk for S100A4-
induced metastasis. These inhibitors might provide another strong weapon in the 





The findings of the present study revealed the anti-metastastic potential of niclosamide. 
In a future treatment scenario of colon cancer patients, this drug might be administered 
as adjuvant chemotherapy on a daily basis. In this respect, the long-term effects of 
daily niclosamide administration to xenograft mice are currently investigated. The focus 
lies on the analysis of the long-term drug tolerability and repression of S100A4 
expression. Moreover, it will be analyzed whether growth of metastases reoccurs if the 
niclosamide treatment is discontinued. Further investigation will evaluate the delivery 
mechanism of niclosamide to patients, since its oral bioavailability is limited. Therefore, 
other forms of drug administration, such as intramuscular injection, need to be 
addressed. These investigations will further help to clarify the potential benefits of the 
clinical application of niclosamide to colon cancer patients with high risk of S100A4-
induced metastasis.  
 
The present study revealed a novel mechanism for S100A4 function forming a positive 
feedback loop within the Wnt pathway. The findings are based on expression data, 
leaving the mechanism behind this gene regulation yet unexplored.  
Current investigations concentrate on understanding if S100A4 inhibits DKK-1 
expression by targeting DKK-1 mRNA through the activation of miRNA mechanisms, or 
by targeting the DKK-1 transcription through inhibiting DKK-1-promoter activity. DKK-1-
promoter reporter assays followed by EMSA and ChIP analysis will evaluate if S100A4 
directly interferes with the DKK-1-promoter. In parallel, research in bioinformatics on 
the DKK-1 mRNA revealed two potential miRNAs which were already shown to act on 
DKK-1 expression. Their impact in this gene regulation will be analyzed.  
Wnt pathway activity and S100A4-induced cell motility in rDKK-1-treated colon cancer 
cells will be analyzed to investigate the power of antibodies mimicking DKK-1 function 
on LRP-5/-6 receptors as potential anti-metastatic drugs.  
The prognostic value of high levels of S100A4 along with low levels of DKK-1 is 
currently investigated in well-characterized colon cancer tissues with 5-year follow-up 
data to predict metastasis formation of colon cancer patients and to allow the early 





1. Garcia M, Jema lA, Ward E, et al. Global Cancer Facts & Figures.  American 
Cancer Society. Atlanta, GA: American Cancer Society; 2007. 
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and 
mortality in Europe in 2008. Eur J Cancer 2010 Mar;46(4):765-81. 
3. Husmann G, Kaatsch P, Katalinic A, et al. Krebs in Deutschland 2005/2006 
Häufigkeiten und Trends. Robert Koch-Institut, Gesellschaft der 
epidemiologischen Krebsregister in Deutschland eV 2010;7:1-120. 
4. Stein U, Schlag PM. Clinical, biological, and molecular aspects of metastasis in 
colorectal cancer. Recent Results Cancer Res 2007;176:61-80. 
5. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. 
Lancet 2005 Jan 8-14;365(9454):153-65. 
6. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon 
cancer. Gastroenterology 2010 Jun;138(6):2044-58. 
7. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare 
Dis 2009;4:22. 
8. Boland CR, Goel A. Microsatellite instability in colorectal cancer. 
Gastroenterology 2010 Jun;138(6):2073-87 e3. 
9. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. 
Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 
2008 Jan 15;27(2):104-19. 
10. de Santa Barbara P, van den Brink GR, Roberts DJ. Development and 
differentiation of the intestinal epithelium. Cell Mol Life Sci 2003 Jul;60(7):1322-
32. 
11. de Lau W, Barker N, Clevers H. WNT signaling in the normal intestine and 
colorectal cancer. Front Biosci 2007;12:471-91. 
12. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. 
Science 2005 Mar 25;307(5717):1904-9. 
13. Humphries A, Wright NA. Colonic crypt organization and tumorigenesis. Nat Rev 
Cancer 2008 Jun;8(6):415-24. 
14. Aguilera O, Fraga MF, Ballestar E, et al. Epigenetic inactivation of the Wnt 
antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 
2006 Jul 6;25(29):4116-21. 
15. Shih IM, Wang TL, Traverso G, et al. Top-down morphogenesis of colorectal 
tumors. Proc Natl Acad Sci U S A 2001 Feb 27;98(5):2640-5. 
16. Wright NA, Poulsom R. Top down or bottom up? Competing management 
structures in the morphogenesis of colorectal neoplasms. Gut 2002 
Sep;51(3):306-8. 
17. Preston SL, Wong WM, Chan AO, et al. Bottom-up histogenesis of colorectal 
adenomas: origin in the monocryptal adenoma and initial expansion by crypt 
fission. Cancer Res 2003 Jul 1;63(13):3819-25. 
18. Smith AJ, Stern HS, Penner M, et al. Somatic APC and K-ras codon 12 mutations 




19. Wasan HS, Park HS, Liu KC, et al. APC in the regulation of intestinal crypt 
fission. J Pathol 1998 Jul;185(3):246-55. 
20. Siu IM, Robinson DR, Schwartz S, et al. The identification of monoclonality in 
human aberrant crypt foci. Cancer Res 1999 Jan 1;59(1):63-6. 
21. Raica M, Cimpean AM, Ribatti D. Angiogenesis in pre-malignant conditions. Eur J 
Cancer 2009 Jul;45(11):1924-34. 
22. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of 
colorectal cancer. N Engl J Med 2009 Dec 17;361(25):2449-60. 
23. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides 
insights into tumor evolution. Proc Natl Acad Sci U S A 2008 Mar 
18;105(11):4283-8. 
24. Shinagawa K, Kitadai Y, Tanaka M, et al. Mesenchymal stem cells enhance 
growth and metastasis of colon cancer. Int J Cancer 2010 May 6. 
25. Weinberg RA. Mechanisms of malignant progression. Carcinogenesis 2008 
Jun;29(6):1092-5. 
26. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of 
development and tumor metastasis. Dev Cell 2008 Jun;14(6):818-29. 
27. Zeidman I, Mc CM, Coman DR. Factors affecting the number of tumor 
metastases; experiments with a transplantable mouse tumor. Cancer Res 1950 
Jun;10(6):357-9. 
28. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis 
revisited. Nat Rev Cancer 2003 Jun;3(6):453-8. 
29. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 
2004 Jun;4(6):448-56. 
30. Riethdorf S, Pantel K. Clinical relevance and current challenges of research on 
disseminating tumor cells in cancer patients. Breast Cancer Res 2009;11 Suppl 
3:S10. 
31. Vincan E, Barker N. The upstream components of the Wnt signalling pathway in 
the dynamic EMT and MET associated with colorectal cancer progression. Clin 
Exp Metastasis 2008;25(6):657-63. 
32. Barkan D, Kleinman H, Simmons JL, et al. Inhibition of metastatic outgrowth from 
single dormant tumor cells by targeting the cytoskeleton. Cancer Res 2008 Aug 
1;68(15):6241-50. 
33. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific 
biological properties of disseminating tumour cells. Nat Rev Cancer 2008 
May;8(5):329-40. 
34. Gongoll S, Peters G, Mengel M, et al. Prognostic significance of calcium-binding 
protein S100A4 in colorectal cancer. Gastroenterology 2002 Nov;123(5):1478-84. 
35. Stein U, Walther W, Arlt F, et al. MACC1, a newly identified key regulator of HGF-
MET signaling, predicts colon cancer metastasis. Nat Med 2009 Jan;15(1):59-67. 
36. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 Jan 7;100(1):57-
70. 
37. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990 
Jun 1;61(5):759-67. 
38. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in 
cancer. Biochim Biophys Acta 2003 Jun 5;1653(1):1-24. 
102 
REFERENCES 
39. Kemp Z, Rowan A, Chambers W, et al. CDC4 mutations occur in a subset of 
colorectal cancers but are not predicted to cause loss of function and are not 
associated with chromosomal instability. Cancer Res 2005 Dec 15;65(24):11361-
6. 
40. Barber TD, McManus K, Yuen KW, et al. Chromatid cohesion defects may 
underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci 
U S A 2008 Mar 4;105(9):3443-8. 
41. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a 
signalling pathway. Nature 2005 Aug 11;436(7052):792. 
42. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005 Apr 
14;434(7035):843-50. 
43. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. 
Nat Rev Cancer 2008 May;8(5):387-98. 
44. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008 
Apr;4(2):68-75. 
45. Amit S, Hatzubai A, Birman Y, et al. Axin-mediated CKI phosphorylation of beta-
catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 2002 May 
1;16(9):1066-76. 
46. Wang Z, Vogelstein B, Kinzler KW. Phosphorylation of beta-catenin at S33, S37, 
or T41 can occur in the absence of phosphorylation at T45 in colon cancer cells. 
Cancer Res 2003 Sep 1;63(17):5234-5. 
47. Barker N. The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol 
2008;468:5-15. 
48. Brabletz T, Jung A, Hermann K, Gunther K, Hohenberger W, Kirchner T. Nuclear 
overexpression of the oncoprotein beta-catenin in colorectal cancer is localized 
predominantly at the invasion front. Pathol Res Pract 1998;194(10):701-4. 
49. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin 
dysfunction promote tumor progression? Oncogene 2008 Nov 24;27(55):6920-9. 
50. Alves-Guerra MC, Ronchini C, Capobianco AJ. Mastermind-like 1 Is a specific 
coactivator of beta-catenin transcription activation and is essential for colon 
carcinoma cell survival. Cancer Res 2007 Sep 15;67(18):8690-8. 
51. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell 
Sci 2003 Jul 1;116(Pt 13):2627-34. 
52. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. 
Oncogene 2006 Dec 4;25(57):7469-81. 
53. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 
is a member of a new family of secreted proteins and functions in head induction. 
Nature 1998 Jan 22;391(6665):357-62. 
54. Koch S, Capaldo CT, Samarin S, et al. Dkk-1 inhibits intestinal epithelial cell 
migration by attenuating directional polarization of leading edge cells. Mol Biol 
Cell 2009 Nov;20(22):4816-25. 
55. Pinto D, Gregorieff A, Begthel H, Clevers H. Canonical Wnt signals are essential 
for homeostasis of the intestinal epithelium. Genes Dev 2003 Jul 15;17(14):1709-
13. 
56. Bafico A, Liu G, Yaniv A, Gazit A, Aaronson SA. Novel mechanism of Wnt 
signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell 
Biol 2001 Jul;3(7):683-6. 
103 
REFERENCES 
57. Mao B, Wu W, Li Y, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf 
proteins. Nature 2001 May 17;411(6835):321-5. 
58. Semenov MV, Tamai K, Brott BK, Kuhl M, Sokol S, He X. Head inducer Dickkopf-
1 is a ligand for Wnt coreceptor LRP6. Curr Biol 2001 Jun 26;11(12):951-61. 
59. Mao B, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that 
regulate Wnt/beta-catenin signalling. Nature 2002 Jun 6;417(6889):664-7. 
60. Gonzalez-Sancho JM, Aguilera O, Garcia JM, et al. The Wnt antagonist 
DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is 
downregulated in human colon cancer. Oncogene 2005 Feb 3;24(6):1098-103. 
61. Aguilera O, Pena C, Garcia JM, et al. The Wnt antagonist DICKKOPF-1 gene is 
induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of 
human colon cancer cells. Carcinogenesis 2007 Sep;28(9):1877-84. 
62. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996 
Oct 18;87(2):159-70. 
63. Liu W, Dong X, Mai M, et al. Mutations in AXIN2 cause colorectal cancer with 
defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet 
2000 Oct;26(2):146-7. 
64. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in 
colon cancer by mutations in beta-catenin or APC. Science 1997 Mar 
21;275(5307):1787-90. 
65. Stein U, Arlt F, Walther W, et al. The metastasis-associated gene S100A4 is a 
novel target of beta-catenin/T-cell factor signaling in colon cancer. 
Gastroenterology 2006 Nov;131(5):1486-500. 
66. Garrett SC, Varney KM, Weber DJ, Bresnick AR. S100A4, a mediator of 
metastasis. J Biol Chem 2006 Jan 13;281(2):677-80. 
67. Marenholz I, Lovering RC, Heizmann CW. An update of the S100 nomenclature. 
Biochim Biophys Acta 2006 Nov;1763(11):1282-3. 
68. Schneider M, Hansen JL, Sheikh SP. S100A4: a common mediator of epithelial-
mesenchymal transition, fibrosis and regeneration in diseases? J Mol Med 2008 
May;86(5):507-22. 
69. Boye K, Maelandsmo GM. S100A4 and metastasis: a small actor playing many 
roles. Am J Pathol 2010 Feb;176(2):528-35. 
70. Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Proteins of the S100 
family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci U 
S A 2005 Mar 29;102(13):4735-40. 
71. Helfman DM, Kim EJ, Lukanidin E, Grigorian M. The metastasis associated 
protein S100A4: role in tumour progression and metastasis. Br J Cancer 2005 
Jun 6;92(11):1955-8. 
72. Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and 
several other prometastatic genes in medulloblastoma. Cancer Res 2003 Jan 
1;63(1):140-8. 
73. Kim TH, Kim HI, Soung YH, Shaw LA, Chung J. Integrin (alpha6beta4) signals 
through Src to increase expression of S100A4, a metastasis-promoting factor: 
implications for cancer cell invasion. Mol Cancer Res 2009 Oct;7(10):1605-12. 
74. Cohn MA, Hjelmso I, Wu LC, Guldberg P, Lukanidin EM, Tulchinsky EM. 
Characterization of Sp1, AP-1, CBF and KRC binding sites and minisatellite DNA 
104 
REFERENCES 
as functional elements of the metastasis-associated mts1/S100A4 gene intronic 
enhancer. Nucleic Acids Res 2001 Aug 15;29(16):3335-46. 
75. Hjelmsoe I, Allen CE, Cohn MA, Tulchinsky EM, Wu LC. The kappaB and V(D)J 
recombination signal sequence binding protein KRC regulates transcription of the 
mouse metastasis-associated gene S100A4/mts1. J Biol Chem 2000 Jan 
14;275(2):913-20. 
76. Tulchinsky E, Kramerov D, Ford HL, Reshetnyak E, Lukanidin E, Zain S. 
Characterization of a positive regulatory element in the mts1 gene. Oncogene 
1993 Jan;8(1):79-86. 
77. Zhang R, Fu H, Chen D, et al. Subcellular distribution of S100A4 and its 
transcriptional regulation under hypoxic conditions in gastric cancer cell line 
BGC823. Cancer Sci 2010 Feb 15. 
78. Tulchinsky E, Ford HL, Kramerov D, et al. Transcriptional analysis of the mts1 
gene with specific reference to 5' flanking sequences. Proc Natl Acad Sci U S A 
1992 Oct 1;89(19):9146-50. 
79. Ambartsumian N, Tarabykina S, Grigorian M, et al. Characterization of two splice 
variants of metastasis-associated human mts1 gene. Gene 1995 Jun 
14;159(1):125-30. 
80. Gingras AR, Basran J, Prescott A, Kriajevska M, Bagshaw CR, Barsukov IL. 
Crystal structure of the Ca(2+)-form and Ca(2+)-binding kinetics of metastasis-
associated protein, S100A4. FEBS Lett 2008 May 28;582(12):1651-6. 
81. Dutta K, Cox CJ, Huang H, Basavappa R, Pascal SM. Calcium coordination 
studies of the metastatic Mts1 protein. Biochemistry 2002 Apr 2;41(13):4239-45. 
82. Pathuri P, Vogeley L, Luecke H. Crystal structure of metastasis-associated 
protein S100A4 in the active calcium-bound form. J Mol Biol 2008 Oct 
31;383(1):62-77. 
83. Vallely KM, Rustandi RR, Ellis KC, Varlamova O, Bresnick AR, Weber DJ. 
Solution structure of human Mts1 (S100A4) as determined by NMR spectroscopy. 
Biochemistry 2002 Oct 22;41(42):12670-80. 
84. Kohya N, Kitajima Y, Jiao W, Miyazaki K. Effects of E-cadherin transfection on 
gene expression of a gallbladder carcinoma cell line: repression of MTS1/S100A4 
gene expression. Int J Cancer 2003 Mar 10;104(1):44-53. 
85. Moriyama-Kita M, Endo Y, Yonemura Y, et al. S100A4 regulates E-cadherin 
expression in oral squamous cell carcinoma. Cancer Lett 2005 Dec 
18;230(2):211-8. 
86. Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM. 
Expression of S100A4 combined with reduced E-cadherin expression predicts 
patient outcome in malignant melanoma. Mod Pathol 2004 Aug;17(8):990-7. 
87. Kimura K, Endo Y, Yonemura Y, et al. Clinical significance of S100A4 and E-
cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 
2000 Jun;16(6):1125-31. 
88. Yonemura Y, Endou Y, Kimura K, et al. Inverse expression of S100A4 and E-
cadherin is associated with metastatic potential in gastric cancer. Clin Cancer 
Res 2000 Nov;6(11):4234-42. 
89. Kriajevska M, Fischer-Larsen M, Moertz E, et al. Liprin beta 1, a member of the 
family of LAR transmembrane tyrosine phosphatase-interacting proteins, is a new 




90. Serra-Pages C, Streuli M, Medley QG. Liprin phosphorylation regulates binding to 
LAR: evidence for liprin autophosphorylation. Biochemistry 2005 Dec 
6;44(48):15715-24. 
91. Watanabe Y, Usada N, Minami H, et al. Calvasculin, as a factor affecting the 
microfilament assemblies in rat fibroblasts transfected by src gene. FEBS Lett 
1993 Jun 7;324(1):51-5. 
92. Takenaga K, Nakamura Y, Sakiyama S, Hasegawa Y, Sato K, Endo H. Binding of 
pEL98 protein, an S100-related calcium-binding protein, to nonmuscle 
tropomyosin. J Cell Biol 1994 Mar;124(5):757-68. 
93. Kriajevska MV, Cardenas MN, Grigorian MS, Ambartsumian NS, Georgiev GP, 
Lukanidin EM. Non-muscle myosin heavy chain as a possible target for protein 
encoded by metastasis-related mts-1 gene. J Biol Chem 1994 Aug 
5;269(31):19679-82. 
94. Ford HL, Zain SB. Interaction of metastasis associated Mts1 protein with 
nonmuscle myosin. Oncogene 1995 Apr 20;10(8):1597-605. 
95. Li ZH, Spektor A, Varlamova O, Bresnick AR. Mts1 regulates the assembly of 
nonmuscle myosin-IIA. Biochemistry 2003 Dec 9;42(48):14258-66. 
96. Ford HL, Silver DL, Kachar B, Sellers JR, Zain SB. Effect of Mts1 on the structure 
and activity of nonmuscle myosin II. Biochemistry 1997 Dec 23;36(51):16321-7. 
97. Kim EJ, Helfman DM. Characterization of the metastasis-associated protein, 
S100A4. Roles of calcium binding and dimerization in cellular localization and 
interaction with myosin. J Biol Chem 2003 Aug 8;278(32):30063-73. 
98. Li ZH, Bresnick AR. The S100A4 metastasis factor regulates cellular motility via a 
direct interaction with myosin-IIA. Cancer Res 2006 May 15;66(10):5173-80. 
99. Wang G, Rudland PS, White MR, Barraclough R. Interaction in vivo and in vitro of 
the metastasis-inducing S100 protein, S100A4 (p9Ka) with S100A1. J Biol Chem 
2000 Apr 14;275(15):11141-6. 
100. Tarabykina S, Kriajevska M, Scott DJ, et al. Heterocomplex formation between 
metastasis-related protein S100A4 (Mts1) and S100A1 as revealed by the yeast 
two-hybrid system. FEBS Lett 2000 Jun 23;475(3):187-91. 
101. Wang G, Zhang S, Fernig DG, Martin-Fernandez M, Rudland PS, Barraclough R. 
Mutually antagonistic actions of S100A4 and S100A1 on normal and metastatic 
phenotypes. Oncogene 2005 Feb 17;24(8):1445-54. 
102. Bronckart Y, Decaestecker C, Nagy N, et al. Development and progression of 
malignancy in human colon tissues are correlated with expression of specific 
Ca(2+)-binding S100 proteins. Histol Histopathol 2001 Jul;16(3):707-12. 
103. Koshelev YA, Kiselev SL, Georgiev GP. Interaction of the S100A4 (Mts1) protein 
with septins Sept2, Sept6, and Sept7 in vitro. Dokl Biochem Biophys 2003 Jul-
Aug;391:195-7. 
104. Hall PA, Russell SE. The pathobiology of the septin gene family. J Pathol 2004 
Nov;204(4):489-505. 
105. Li CL, Martinez V, He B, Lombet A, Perbal B. A role for CCN3 (NOV) in calcium 
signalling. Mol Pathol 2002 Aug;55(4):250-61. 
106. Endo H, Takenaga K, Kanno T, Satoh H, Mori S. Methionine aminopeptidase 2 is 




107. Dulyaninova NG, Malashkevich VN, Almo SC, Bresnick AR. Regulation of 
myosin-IIA assembly and Mts1 binding by heavy chain phosphorylation. 
Biochemistry 2005 May 10;44(18):6867-76. 
108. Dukhanina EA, Dukhanin AS, Lomonosov MY, Lukanidin EM, Georgiev GP. 
Spectral studies on the calcium-binding properties of Mts1 protein and its 
interaction with target protein. FEBS Lett 1997 Jun 30;410(2-3):403-6. 
109. Grigorian M, Andresen S, Tulchinsky E, et al. Tumor suppressor p53 protein is a 
new target for the metastasis-associated Mts1/S100A4 protein: functional 
consequences of their interaction. J Biol Chem 2001 Jun 22;276(25):22699-708. 
110. Ismail TM, Zhang S, Fernig DG, et al. Self-association of calcium-binding protein 
S100A4 and metastasis. J Biol Chem 2010 Jan 8;285(2):914-22. 
111. van Dieck J, Brandt T, Teufel DP, Veprintsev DB, Joerger AC, Fersht AR. 
Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73. 
Oncogene 2010 Apr 8;29(14):2024-35. 
112. van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR. Modulation of 
the oligomerization state of p53 by differential binding of proteins of the S100 
family to p53 monomers and tetramers. J Biol Chem 2009 May 
15;284(20):13804-11. 
113. van Dieck J, Teufel DP, Jaulent AM, et al. Posttranslational modifications affect 
the interaction of S100 proteins with tumor suppressor p53. J Mol Biol 2009 Dec 
18;394(5):922-30. 
114. Klingelhofer J, Moller HD, Sumer EU, et al. Epidermal growth factor receptor 
ligands as new extracellular targets for the metastasis-promoting S100A4 protein. 
FEBS J 2009 Oct;276(20):5936-48. 
115. Semov A, Moreno MJ, Onichtchenko A, et al. Metastasis-associated protein 
S100A4 induces angiogenesis through interaction with Annexin II and accelerated 
plasmin formation. J Biol Chem 2005 May 27;280(21):20833-41. 
116. Watanabe Y, Usuda N, Tsugane S, Kobayashi R, Hidaka H. Calvasculin, an 
encoded protein from mRNA termed pEL-98, 18A2, 42A, or p9Ka, is secreted by 
smooth muscle cells in culture and exhibits Ca(2+)-dependent binding to 36-kDa 
microfibril-associated glycoprotein. J Biol Chem 1992 Aug 25;267(24):17136-40. 
117. Kiryushko D, Novitskaya V, Soroka V, et al. Molecular mechanisms of Ca(2+) 
signaling in neurons induced by the S100A4 protein. Mol Cell Biol 2006 
May;26(9):3625-38. 
118. Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: 
an update. Biochim Biophys Acta 2009 Jun;1793(6):993-1007. 
119. Yammani RR, Carlson CS, Bresnick AR, Loeser RF. Increase in production of 
matrix metalloproteinase 13 by human articular chondrocytes due to stimulation 
with S100A4: Role of the receptor for advanced glycation end products. Arthritis 
Rheum 2006 Sep;54(9):2901-11. 
120. Ambartsumian N, Klingelhofer J, Grigorian M, et al. The metastasis-associated 
Mts1(S100A4) protein could act as an angiogenic factor. Oncogene 2001 Aug 
2;20(34):4685-95. 
121. Burkitt WI, Derrick PJ, Lafitte D, Bronstein I. Protein-ligand and protein-protein 
interactions studied by electrospray ionization and mass spectrometry. Biochem 
Soc Trans 2003 Oct;31(Pt 5):985-9. 
107 
REFERENCES 
122. Schmidt-Hansen B, Ornas D, Grigorian M, et al. Extracellular S100A4(mts1) 
stimulates invasive growth of mouse endothelial cells and modulates MMP-13 
matrix metalloproteinase activity. Oncogene 2004 Jul 15;23(32):5487-95. 
123. Mathisen B, Lindstad RI, Hansen J, et al. S100A4 regulates membrane induced 
activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp 
Metastasis 2003;20(8):701-11. 
124. Gao XN, Tang SQ, Zhang XF. S100A4 antisense oligodeoxynucleotide 
suppresses invasive potential of neuroblastoma cells. J Pediatr Surg 2005 
Apr;40(4):648-52. 
125. Saleem M, Kweon MH, Johnson JJ, et al. S100A4 accelerates tumorigenesis and 
invasion of human prostate cancer through the transcriptional regulation of matrix 
metalloproteinase 9. Proc Natl Acad Sci U S A 2006 Oct 3;103(40):14825-30. 
126. Senolt L, Grigorian M, Lukanidin E, et al. S100A4 is expressed at site of invasion 
in rheumatoid arthritis synovium and modulates production of matrix 
metalloproteinases. Ann Rheum Dis 2006 Dec;65(12):1645-8. 
127. Hsieh HL, Schafer BW, Weigle B, Heizmann CW. S100 protein translocation in 
response to extracellular S100 is mediated by receptor for advanced glycation 
endproducts in human endothelial cells. Biochem Biophys Res Commun 2004 
Apr 9;316(3):949-59. 
128. Chuong C, Katz J, Pauley KM, Bulosan M, Cha S. RAGE expression and NF-
kappaB activation attenuated by extracellular domain of RAGE in human salivary 
gland cell line. J Cell Physiol 2009 Nov;221(2):430-4. 
129. Belot N, Pochet R, Heizmann CW, Kiss R, Decaestecker C. Extracellular S100A4 
stimulates the migration rate of astrocytic tumor cells by modifying the 
organization of their actin cytoskeleton. Biochim Biophys Acta 2002 Nov 
4;1600(1-2):74-83. 
130. Rakic JM, Maillard C, Jost M, et al. Role of plasminogen activator-plasmin system 
in tumor angiogenesis. Cell Mol Life Sci 2003 Mar;60(3):463-73. 
131. Tabata T, Tsukamoto N, Fooladi AA, et al. RNA interference targeting against 
S100A4 suppresses cell growth and motility and induces apoptosis in human 
pancreatic cancer cells. Biochem Biophys Res Commun 2009 Dec 
18;390(3):475-80. 
132. Berge G, Maelandsmo GM. Evaluation of potential interactions between the 
metastasis-associated protein S100A4 and the tumor suppressor protein p53. 
Amino Acids 2010 Feb 24. 
133. Berge G, Costea DE, Berg M, et al. Coexpression and nuclear colocalization of 
metastasis-promoting protein S100A4 and p53 without mutual regulation in 
colorectal carcinoma. Amino Acids 2010 Feb 27. 
134. Liang SH, Clarke MF. Regulation of p53 localization. Eur J Biochem 2001 
May;268(10):2779-83. 
135. Ebralidze A, Tulchinsky E, Grigorian M, et al. Isolation and characterization of a 
gene specifically expressed in different metastatic cells and whose deduced gene 
product has a high degree of homology to a Ca2+-binding protein family. Genes 
Dev 1989 Jul;3(7):1086-93. 
136. Grigorian M, Ambartsumian N, Lykkesfeldt AE, et al. Effect of mts1 (S100A4) 




137. Schmidt-Hansen B, Klingelhofer J, Grum-Schwensen B, et al. Functional 
significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay. J 
Biol Chem 2004 Jun 4;279(23):24498-504. 
138. Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N, Nakamura M. Identification 
of a key molecular regulator of liver metastasis in human pancreatic carcinoma 
using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) 
mice. Int J Oncol 2007 Oct;31(4):741-51. 
139. Ambartsumian NS, Grigorian MS, Larsen IF, et al. Metastasis of mammary 
carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 1996 
Oct 17;13(8):1621-30. 
140. Davies MP, Rudland PS, Robertson L, Parry EW, Jolicoeur P, Barraclough R. 
Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu 
transgenic mice induces metastasis of mammary tumours. Oncogene 1996 Oct 
17;13(8):1631-7. 
141. Grum-Schwensen B, Klingelhofer J, Grigorian M, et al. Lung metastasis fails in 
MMTV-PyMT oncomice lacking S100A4 due to a T-cell deficiency in primary 
tumors. Cancer Res 2010 Feb 1;70(3):936-47. 
142. Li ZH, Dulyaninova NG, House RP, Almo SC, Bresnick AR. S100A4 regulates 
macrophage chemotaxis. Mol Biol Cell 2010 Aug 1;21(15):2598-610. 
143. Grum-Schwensen B, Klingelhofer J, Berg CH, et al. Suppression of tumor 
development and metastasis formation in mice lacking the S100A4(mts1) gene. 
Cancer Res 2005 May 1;65(9):3772-80. 
144. Olsen CJ, Moreira J, Lukanidin EM, Ambartsumian NS. Human mammary 
fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture 
and increase stroma development in mouse xenografts. BMC Cancer 
2010;10:444. 
145. Platt-Higgins AM, Renshaw CA, West CR, et al. Comparison of the metastasis-
inducing protein S100A4 (p9ka) with other prognostic markers in human breast 
cancer. Int J Cancer 2000 Mar 20;89(2):198-208. 
146. Ninomiya I, Ohta T, Fushida S, et al. Increased expression of S100A4 and its 
prognostic significance in esophageal squamous cell carcinoma. Int J Oncol 2001 
Apr;18(4):715-20. 
147. Nakamura T, Ajiki T, Murao S, et al. Prognostic significance of S100A4 
expression in gallbladder cancer. Int J Oncol 2002 May;20(5):937-41. 
148. Saleem M, Adhami VM, Ahmad N, Gupta S, Mukhtar H. Prognostic significance 
of metastasis-associated protein S100A4 (Mts1) in prostate cancer progression 
and chemoprevention regimens in an autochthonous mouse model. Clin Cancer 
Res 2005 Jan 1;11(1):147-53. 
149. Ai KX, Lu LY, Huang XY, Chen W, Zhang HZ. Prognostic significance of S100A4 
and vascular endothelial growth factor expression in pancreatic cancer. World J 
Gastroenterol 2008 Mar 28;14(12):1931-5. 
150. Tsuna M, Kageyama S, Fukuoka J, et al. Significance of S100A4 as a prognostic 
marker of lung squamous cell carcinoma. Anticancer Res 2009 Jul;29(7):2547-54. 
151. Bandiera A, Melloni G, Freschi M, et al. Prognostic factors and analysis of 
S100a4 protein in resected pulmonary metastases from renal cell carcinoma. 
World J Surg 2009 Jul;33(7):1414-20. 
109 
REFERENCES 
152. Cho YG, Kim CJ, Nam SW, et al. Overexpression of S100A4 is closely 
associated with progression of colorectal cancer. World J Gastroenterol 2005 Aug 
21;11(31):4852-6. 
153. Takenaga K, Nakanishi H, Wada K, et al. Increased expression of S100A4, a 
metastasis-associated gene, in human colorectal adenocarcinomas. Clin Cancer 
Res 1997 Dec;3(12 Pt 1):2309-16. 
154. Taylor S, Herrington S, Prime W, Rudland PS, Barraclough R. S100A4 (p9Ka) 
protein in colon carcinoma and liver metastases: association with carcinoma cells 
and T-lymphocytes. Br J Cancer 2002 Feb 1;86(3):409-16. 
155. Hemandas AK, Salto-Tellez M, Maricar SH, Leong AF, Leow CK. Metastasis-
associated protein S100A4--a potential prognostic marker for colorectal cancer. J 
Surg Oncol 2006 May 1;93(6):498-503. 
156. Flatmark K, Pedersen KB, Nesland JM, et al. Nuclear localization of the 
metastasis-related protein S100A4 correlates with tumour stage in colorectal 
cancer. J Pathol 2003 Aug;200(5):589-95. 
157. Boye K, Nesland JM, Sandstad B, Maelandsmo GM, Flatmark K. Nuclear S100A4 
is a novel prognostic marker in colorectal cancer. Eur J Cancer 2010 Aug 16. 
158. Stein U, Burock S, Herrmann P, et al. Diagnostic and prognostic value of 
metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric 
cancer patients. J Mol Diagn 2010. 
159. Sack U, Stein U. Wnt up your mind - intervention strategies for S100A4-induced 
metastasis in colon cancer. Gen Physiol Biophys 2009;28(Focus Issue):F55-F64. 
160. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS. Calcium-dependent and -
independent interactions of the S100 protein family. Biochem J 2006 Jun 
1;396(2):201-14. 
161. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to 
the ionizing radiation response. Proc Natl Acad Sci U S A 2001 Apr 
24;98(9):5116-21. 
162. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types 
by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002 May 
14;99(10):6567-72. 
163. Hosack DA, Dennis G, Jr., Sherman BT, Lane HC, Lempicki RA. Identifying 
biological themes within lists of genes with EASE. Genome Biol 2003;4(10):R70. 
164. Kim JS, Crooks H, Dracheva T, et al. Oncogenic beta-catenin is required for bone 
morphogenetic protein 4 expression in human cancer cells. Cancer Res 2002 
May 15;62(10):2744-8. 
165. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid 
guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987 
Apr;162(1):156-9. 
166. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using 
bicinchoninic acid. Anal Biochem 1985 Oct;150(1):76-85. 
167. Boyden S. The chemotactic effect of mixtures of antibody and antigen on 
polymorphonuclear leucocytes. J Exp Med 1962 Mar 1;115:453-66. 
168. Spencer VA, Sun JM, Li L, Davie JR. Chromatin immunoprecipitation: a tool for 




169. Rodriguez LG, Wu X, Guan JL. Wound-healing assay. Methods Mol Biol 
2005;294:23-9. 
170. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the 
beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999 May 
11;96(10):5522-7. 
171. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC 
pathway. Science 1998 Sep 4;281(5382):1509-12. 
172. Workman P, Balmain A, Hickman JA, et al. United Kingdom Co-ordinating 
Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of 
Animals in Experimental Neoplasia (Second Edition). Br J Cancer 1998;77(1):1-
10. 
173. O'Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT. Bioluminescent 
imaging: a critical tool in pre-clinical oncology research. J Pathol 2010 
Feb;220(3):317-27. 
174. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to 
potential cure. Oncology 2010;78(3-4):237-48. 
175. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008 
Mar-Apr;58(2):71-96. 
176. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev 
Med 2009;60:207-19. 
177. Sherbet GV. Metastasis promoter S100A4 is a potentially valuable molecular 
target for cancer therapy. Cancer Lett 2009 Jul 18;280(1):15-30. 
178. Grigorian M, Tulchinsky E, Burrone O, Tarabykina S, Georgiev G, Lukanidin E. 
Modulation of mts1 expression in mouse and human normal and tumor cells. 
Electrophoresis 1994 Mar-Apr;15(3-4):463-8. 
179. Campbell WC. The chemotherapy of parasitic infections. J Parasitol 1986 
Feb;72(1):45-61. 
180. Chang Y, Yeh T, Lin K, et al. Pharmacokineticts of Anti-SARS-CoV Agent 
Niclosamdie and Its Analogs in Rats. Journal of Food and Drug Analysis 
2006;14(4):329-33. 
181. Espinosa-Aguirre JJ, Reyes RE, Cortinas de Nava C. Mutagenic activity of 2-
chloro-4-nitroaniline and 5-chlorosalicylic acid in Salmonella typhimurium: two 
possible metabolites of niclosamide. Mutat Res 1991 Nov;264(3):139-45. 
182. Pressman BC. Biological applications of ionophores. Annu Rev Biochem 
1976;45:501-30. 
183. Gwak J, Cho M, Gong SJ, et al. Protein-kinase-C-mediated beta-catenin 
phosphorylation negatively regulates the Wnt/beta-catenin pathway. J Cell Sci 
2006 Nov 15;119(Pt 22):4702-9. 
184. Moriyama-Kita M, Endo Y, Yonemura Y, et al. Correlation of S100A4 expression 
with invasion and metastasis in oral squamous cell carcinoma. Oral Oncol 2004 
May;40(5):496-500. 
185. Ganesan K, Ivanova T, Wu Y, et al. Inhibition of gastric cancer invasion and 
metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res 
2008 Jun 1;68(11):4277-86. 
186. Andersen K, Smith-Sorensen B, Pedersen KB, et al. Interferon-gamma 
suppresses S100A4 transcription independently of apoptosis or cell cycle arrest. 
Br J Cancer 2003 Jun 16;88(12):1995-2001. 
111 
REFERENCES 
187. Shi Y, Zou M, Collison K, et al. Ribonucleic acid interference targeting S100A4 
(Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma 
in a mouse model. J Clin Endocrinol Metab 2006 Jun;91(6):2373-9. 
188. Hua J, Chen D, Fu H, et al. Short hairpin RNA-mediated inhibition of S100A4 
promotes apoptosis and suppresses proliferation of BGC823 gastric cancer cells 
in vitro and in vivo. Cancer Lett 2009 Nov 27. 
189. Jin Y, Lu Z, Ding K, et al. Antineoplastic Mechanisms of Niclosamide in Acute 
Myelogenous Leukemia Stem Cells: Inactivation of the NF-{kappa}B Pathway and 
Generation of Reactive Oxygen Species. Cancer Res 2010 Mar 15;70(6):2516-
27. 
190. Balgi AD, Fonseca BD, Donohue E, et al. Screen for chemical modulators of 
autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 
2009;4(9):e7124. 
191. Chen M, Wang J, Lu J, et al. The anti-helminthic niclosamide inhibits 
Wnt/Frizzled1 signaling. Biochemistry 2009 Nov 3;48(43):10267-74. 
192. Huang WS, Wang JP, Wang T, Fang JY, Lan P, Ma JP. ShRNA-mediated gene 
silencing of beta-catenin inhibits growth of human colon cancer cells. World J 
Gastroenterol 2007 Dec 28;13(48):6581-7. 
193. Brantjes H, Roose J, van De Wetering M, Clevers H. All Tcf HMG box 
transcription factors interact with Groucho-related co-repressors. Nucleic Acids 
Res 2001 Apr 1;29(7):1410-9. 
194. Daniels DL, Weis WI. Beta-catenin directly displaces Groucho/TLE repressors 
from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 2005 
Apr;12(4):364-71. 
195. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev 
Drug Discov 2006 Dec;5(12):997-1014. 
196. Malashkevich VN, Dulyaninova NG, Ramagopal UA, et al. Phenothiazines inhibit 
S100A4 function by inducing protein oligomerization. Proc Natl Acad Sci U S A 
2010 May 11;107(19):8605-10. 
197. Garrett SC, Hodgson L, Rybin A, et al. A biosensor of S100A4 metastasis factor 
activation: inhibitor screening and cellular activation dynamics. Biochemistry 2008 
Jan 22;47(3):986-96. 
198. Zibert JR, Skov L, Thyssen JP, Jacobsen GK, Grigorian M. Significance of the 
S100A4 protein in psoriasis. J Invest Dermatol 2010 Jan;130(1):150-60. 
199. Eggert US, Field CM, Mitchison TJ. Small molecules in an RNAi world. Mol 
Biosyst 2006 Feb;2(2):93-6. 
200. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: 
recent progress. BioDrugs 2010 Jun;24(3):195-205. 
201. Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST. Wnt signaling 
regulates expression of the receptor tyrosine kinase met in colorectal cancer. 
Cancer Res 2002 Sep 15;62(18):5126-8. 
202. Jones WE. Niclosamide as a treatment for Hymenolepis diminuta and Dipylidium 
caninum infection in man. Am J Trop Med Hyg 1979 Mar;28(2):300-2. 
203. Merschjohann K, Steverding D. In vitro trypanocidal activity of the anti-helminthic 
drug niclosamide. Exp Parasitol 2008 Apr;118(4):637-40. 
204. Pearson RD, Hewlett EL. Niclosamide therapy for tapeworm infections. Ann 
Intern Med 1985 Apr;102(4):550-1. 
112 
REFERENCES 
205. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth 
G.H.A. Clowes memorial award lecture. Cancer Res 1990 Oct 1;50(19):6130-8. 
206. Koo V, Hamilton PW, Williamson K. Non-invasive in vivo imaging in small animal 
research. Cell Oncol 2006;28(4):127-39. 
207. Sadikot RT, Blackwell TS. Bioluminescence imaging. Proc Am Thorac Soc 
2005;2(6):537-40, 11-2. 
208. Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces 
a metastatic switch in primary breast cancer. Cancer Res 2010 Sep 
15;70(18):7042-52. 
209. Vikis HG, Jackson EN, Krupnick AS, et al. Strain-specific susceptibility for 
pulmonary metastasis of sarcoma 180 cells in inbred mice. Cancer Res 2010 Jun 
15;70(12):4859-67. 
210. Drake JM, Gabriel CL, Henry MD. Assessing tumor growth and distribution in a 
model of prostate cancer metastasis using bioluminescence imaging. Clin Exp 
Metastasis 2005;22(8):674-84. 
211. Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and 
refine traditional murine models of tumor growth and metastasis. Clin Exp 
Metastasis 2003;20(8):733-44. 
212. Giavazzi R, Jessup JM, Campbell DE, Walker SM, Fidler IJ. Experimental nude 
mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst 
1986 Dec;77(6):1303-8. 
213. Kubota T. Metastatic models of human cancer xenografted in the nude mouse: 
the importance of orthotopic transplantation. J Cell Biochem 1994 Sep;56(1):4-8. 
214. Tan MH, Holyoke ED, Goldrosen MH. Murine colon adenocarcinoma: syngeneic 
orthotopic transplantation and subsequent hepatic metastases. J Natl Cancer Inst 
1977 Nov;59(5):1537-44. 
215. Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: 
advantages and disadvantages. Eur J Cancer 2004 Apr;40(6):852-7. 
216. Adam R. Colorectal cancer with synchronous liver metastases. Br J Surg 2007 
Feb;94(2):129-31. 
217. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. 
Epidemiology and management of liver metastases from colorectal cancer. Ann 
Surg 2006 Aug;244(2):254-9. 
218. Hedley BD, Chambers AF. Tumor dormancy and metastasis. Adv Cancer Res 
2009;102:67-101. 
219. Ossowski L, Aguirre-Ghiso JA. Dormancy of metastatic melanoma. Pigment Cell 
Melanoma Res 2010 Feb;23(1):41-56. 
220. Taniguchi T, Makino M, Suzuki K, Kaibara N. Prognostic significance of reverse 
transcriptase-polymerase chain reaction measurement of carcinoembryonic 
antigen mRNA levels in tumor drainage blood and peripheral blood of patients 
with colorectal carcinoma. Cancer 2000 Sep 1;89(5):970-6. 
221. Papavasiliou P, Fisher T, Kuhn J, Nemunaitis J, Lamont J. Circulating tumor cells 
in patients undergoing surgery for hepatic metastases from colorectal cancer. 
Proc (Bayl Univ Med Cent) 2010 Jan;23(1):11-4. 
222. Kemeny N. The management of resectable and unresectable liver metastases 




223. Kim R, Yamaguchi Y, Toge T. Adjuvant therapy for colorectal carcinoma. 
Anticancer Res 2002 Jul-Aug;22(4):2413-8. 
224. Iwamoto M, Hoffenberg EJ, Carethers JM, et al. Nuclear accumulation of beta-
catenin occurs commonly in the epithelial cells of juvenile polyps. Pediatr Res 
2005 Jan;57(1):4-9; discussion 1-3. 
225. Keirsebilck A, Bonne S, Bruyneel E, et al. E-cadherin and metastasin (mts-
1/S100A4) expression levels are inversely regulated in two tumor cell families. 
Cancer Res 1998 Oct 15;58(20):4587-91. 
226. Mahon PC, Baril P, Bhakta V, et al. S100A4 contributes to the suppression of 
BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic 
cancer. Cancer Res 2007 Jul 15;67(14):6786-95. 
227. Miranda KJ, Loeser RF, Yammani RR. Sumoylation and nuclear translocation of 
S100A4 regulates IL-1 {beta} mediated production of matrix metalloprotinase-13. 
J Biol Chem 2010 Aug 4. 
228. Licchesi JD, Westra WH, Hooker CM, Machida EO, Baylin SB, Herman JG. 
Epigenetic alteration of Wnt pathway antagonists in progressive glandular 
neoplasia of the lung. Carcinogenesis 2008 May;29(5):895-904. 
229. Hussain M, Rao M, Humphries AE, et al. Tobacco smoke induces polycomb-
mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res 2009 Apr 
15;69(8):3570-8. 
230. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin 
Invest 2009 Jun;119(6):1420-8. 






Ich versichere hiermit, dass die von mir vorgelegte Dissertation eigenständig und ohne 
Benutzung anderer als der angegebenen Hilfsmittel angefertigt wurde. Ich versichere, 
dass alle aus anderen Quellen übernommenen Daten und Konzepte, sowie Ergebnisse 
aus Kooperationsprojekten unter Angabe der Referenz gekennzeichnet sind. 
Außerdem versichere ich, dass mir die aktuelle Promotionsordnung bekannt ist und ich 
mich nicht anderwärts um einen Doktorgrad bewerbe, bzw. noch keinen 
entsprechenden Doktorgrad besitze. Diese Arbeit wurde in gleicher oder ähnlicher 



















Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, Fichtner I, Schlag PM, 
Shoemaker RH, Stein U. Novel effect of anti-helmintic niclosamide on S100A4-induced 
metastasis in colon cancer. In revision at JNCI, Sep 2010. 
Sack U, Walther W, Scudiero D, Selby M, Schlag PM, Shoemaker RH, Stein U. 
Calcimycin inhibits the canonical Wnt/β-catenin pathway and blocks S100A4-induced 
cell invasion in colon cancer cells. In revision at MBoC, Sep 2010. 
Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, Lemm M, Fichtner I, 
Shoemaker RH, Schlag PM. Intervening in β-catenin signaling by sulindac inhibits 
S100A4-dependent colon cancer metastasis. In revision at Neoplasia, Sep 2010. 
Weiller M, Weiland T, Dunstl G, Sack U, Kunstle G, Wendel A. Differential 
immunotoxicity of histone deacetylase inhibitors on malignant and naive hepatocytes. 
Exp Toxicol Pathol 2010 May 25. 
Sack U, Stein U. Wnt up your mind - intervention strategies for S100A4-induced 
metastasis in colon cancer. Gen Physiol Biophys 2009;28(Focus Issue):F55-F64. 
 
CONFERENCES 
“Niclosamide, a newly identified inhibitor that restricts S100A4-induced metastasis 
formation in colon cancer” (Poster), Sack U, Walther W, Shoemaker RH, Fichtner I, 
Schlag PM, Stein U; Deutscher Krebskongress 2010; Berlin, Germany; Feb 24-27, 
2010, honored with poster award 
“Identification of a small molecule inhibitor to restrict S100A4-induced metastasis 
formation in colon cancer” (Talk), Sack U and Stein U; MDC/FMP PhD Retreat 2009; 
Kremmen, Germany; Sep 3-5, 2009 
 “Knockdown of S100A4 expression by small molecules restricts metastasis formation 
in colon cancer” (Poster), Sack U, Walther W, Shoemaker RH, Fichtner I, Schlag PM, 
Stein U; ECS Workshop on Annexins, Targets and Calcium-binding Proteins in 




 “Small Molecules restrict S100A4 induced metastasis formation in Colon Carcinoma” 
(Poster), Sack U, Walther W, Scudiero D, Selby M, Shoemaker RH, Schlag PM, Stein 
U; International AEK Cancer Congress; Berlin, Germany; Mar 18-20, 2009 
 “S100A4-Suppression: A prospective intervention against metastasis formation in 
colon carcinoma” (Poster), Sack U, Walther W, Herrmann P, Scudiero D, Selby M, 
Shoemaker RH, Schlag PM, Stein U; MDC/FMP PhD Retreat 2008, Berlin Döllnsee, 
Germany, Sep 10-13, 2008  
 
“A novel assay for improving the identification of internal ribosome entry sequences” 
(Poster), Sack U, Willet M, Morley SJ, Coldwell MJ; 2nd EMBO Conference on Protein 
synthesis and translational control, Heidelberg, Germany, Sep 12-16 2007 
 
 “A novel assay for improving the identification of internal ribosome entry sequences” 
(Poster), Sack U, Sivakumaran K, Morley SJ, Coldwell MJ; Conference Translation UK, 
















I would like to thank Prof. Dr. Peter M. Schlag and Prof. Dr. Ulrike Stein for giving me 
the opportunity to research in their lab, providing me with all I needed to contribute to 
their impressive research in the field of metastasis formation in colon cancer. I am 
thankful to Prof. Dr. Thomas Börner for taking over my supervision for the Humboldt-
University Berlin enabling me to fulfill my degree. I would like to thank the PhD 
Programme for Molecule Cell Biology of the MDC for their financial and scientific 
support, for giving me the opportunity to organize a scientific meeting and for supplying 
me with lectures and courses. 
I am deeply grateful to Prof. Dr. Ulrike Stein for taking over my supervision, for sharing 
her time with me, for financially support all my ideas on that project and giving me the 
chance to work and publish self-determined. Without her patience, her endurance and 
her unlimited help this work would not have been possible.  
I would like to thank PD Dr. Wolfgang Walther, Dr. Robert H Shoemaker, Dr. Dominic 
Scudiero and Mike Selby for their great cooperation on the small molecule project. I 
further like to thank Dr. Robert H Shoemaker for supporting this work with niclosamide 
derivatives and PD Dr. Wolfgang Walther for his scientific support and his helpful 
comments on the small molecule project.  
I am thankful to PD Dr. Iduna Fichtner and Margit Lemm for their fruitful cooperation on 
all the animal work. Without their help and scientific advice concerning in vivo 
experiments, this work would have not been possible. 
I am very thankful to Dennis Kobelt and Dr. Franziska Siegel who got me started in the 
lab and with their patients for my questions made this time most enjoyable. My very 
warm gratitude goes to Pia Hermann, Janice Smith and Jutta Aumann for their great 
and unlimited technical assistance and their work to keep the labs going. I am very 
thankful to Dr. Clara Lemos who, despite her short time in the Stein lab, essentially 
helped me by sharing her experience on publishing papers and by proof-reading my 
thesis. I am deeply thankful to all the members of the Stein and Walther Lab. Our team 
spirit and our exceptionally nice and relaxed atmosphere full of helping hands and 
ideas was the best motivation to go through the ups and downs of research.  
Last but not least, I want to thank my family and friends. Their unlimited support, 
understanding, tolerance and love were the best motivation to keep me going. 
118 
